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Abstract	
Introduction:	
Despite	 its	prevalence	and	associated	morbidity	and	mortality,	 there	are	still	 significant	drawbacks	
to	 the	diagnosis	 and	management	of	patent	ductus	 arteriosus	 (PDA).	 There	 is	 a	 lack	of	 consensus	
about	when	a	PDA	is	haemodynamically	significant,	the	nature	and	timing	of	intervention	and	even	
whether	 or	 not	 it	 is	 pathological	 or	 a	 mere	 innocent	 bystander	 of	 prematurity.	 Furthermore,	
drawbacks	 in	 PDA	 research	 such	 as	 a	 lack	 of	 core	 data	 sets,	 lack	 of	 consistency	 in	 applying	
treatments	 during	 clinical	 trials	 and	 lack	 of	 robust	 long-term	 outcome	 measures	 have	 hindered	
advancement	 of	 clinical	 management.	 Utilisation	 of	 novel	 biomarkers	 has	 improved	 the	 research	
quality	and	clinical	care	of	a	number	of	paediatric	conditions.	Despite	a	number	of	studies	assessing	
possible	novel	biomarkers	in	the	management	of	PDA,	none	have	been	deemed	suitable	for	clinical	
application.	Pulse	Wave	Velocity	(PWV)	is	haemodynamic	biomarker	used	in	adult	populations	as	a	
marker	of	 cardiovascular	morbidity	 that	may	be	 relevant	 to	PDA.	 Evidence	of	 its	 use	 in	paediatric	
populations	is	minimal	and	a	process	of	validation	is	yet	to	be	undertaken	in	neonatal	populations.		
Aim:	
The	 aims	 of	 this	 study	 are	 to	 highlight	 the	 current	 benefits	 and	 drawbacks	 in	 the	 diagnosis	 and	
monitoring	 of	 PDA,	 begin	 a	 process	 of	 validation	 for	 PWV	 and	 its	 expression	 in	 terms	 of	 phase	
difference	 as	 novel	 biomarkers	 in	 neonatal	 populations,	 and	 to	 assess	 the	 relationship	 between	
these	 biomarkers	 and	 echocardiographic	 markers	 of	 PDA	 to	 evaluate	 its	 potential	 future	 role	 in	
clinical	practice.		
Methods:	
A	 systematic	 review	 was	 conducted	 to	 assess	 current	 practices	 in	 defining	 haemodynamically	
significant	PDA	(hs-PDA).	A	subsequent	prospective	observational	study	was	conducted	to	assess	the	
measurement	of	PWV/phase	difference	in	neonatal	populations,	the	effects	of	various	demographic	
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and	 clinical	 parameters	 on	 their	 measurement	 and	 their	 relationship	 with	 echocardiographic	
parameters	used	in	the	diagnosis	of	PDA.		
Results:	
Our	 systematic	 review	 highlighted	 significant	 variation	 in	 what	 clinical	 and	 echocardiographic	
parameters	 were	 used	 to	 define	 hs-PDA	 in	 randomised	 controlled	 trials.	 The	 prospective	
observational	 study	 found	weak	associations	between	 the	measurement	of	PWV/phase	difference	
and	most	demographic/clinical	variables.	The	study	also	highlighted	poor	correlations	between	their	
measurement	and	 the	presence	of	PDA.	However,	 the	 small	 sample	 size	means	 future	 research	 is	
required	 before	 firm	 conclusions	 can	 be	 drawn	 about	 the	 relationship	 between	 PWV/phase	
difference	and	 the	demographic,	 clinical	 and	echocardiographic	 variables	encountered	 in	neonatal	
care.		
Conclusion:	
Current	 research	 about	PDA	 in	neonates	 is	 suboptimal	 and	 could	benefit	 from	 the	 formation	of	 a	
core	 data	 set	 to	 improve	 meta-analysis.	 The	 identification	 of	 novel	 biomarkers	 to	 aid	
echocardiography	as	a	diagnostic	 tool	 could	also	be	beneficial.	PWV/phase	difference	have	shown	
potential	 as	 useful	 novel	 biomarkers	 in	 neonatal	 haemodynamics,	 however	 further	 research	 is	
required	to	fully	evaluate	their	relationship	with	PDA.	
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Chapter	1:	Introduction	
1.1 Background	
Preterm	birth,	defined	as	birth	at	 less	 than	37	weeks	gestational	age	 (1),	occurs	 in	5-
10%	of	births	in	resource-rich	countries	such	as	the	UK	and	USA	(2).	Although	evidence	
is	limited,	the	prevalence	of	preterm	birth	in	developing	countries	has	been	estimated	
at	approximately	25%	 (3).	Preterm	neonates	are	a	population	vulnerable	 to	a	unique	
set	 of	 pathologies	 that	 are	 associated	 with	 high	 rates	 of	 mortality	 and	 long-term	
morbidity.	 It	 is	 encouraging	 that	 from	 the	 development	 of	 antepartum	 steroid	 and	
surfactant	therapy	for	neonatal	respiratory	distress	syndrome	(RDS)	(4,	5),	to	the	use	of	
therapeutic	 hypothermia	 in	 the	 management	 of	 hypoxic	 ischaemic	 encephalopathy	
(HIE)	 (6),	survival	rates	 in	both	preterm	and	term	neonates	have	 improved	drastically	
across	 the	globe	 (7,	8).	However,	 in	2014	there	were	still	2.9	million	neonatal	deaths	
worldwide	 (9)	 and	 the	Office	 for	National	 Statistics	 reported	 that	between	2014	and	
2015,	 immaturity-related	 conditions	 were	 responsible	 for	 between	 49.3-50.3%	 of	
neonatal	 deaths	 in	 England	 and	 Wales	 (10).	 This	 demonstrates	 that	 there	 remains	
considerable	scope	to	improve	outcomes	for	these	children.	
Holistic	 care	 in	 neonatology	 involves	 much	 more	 than	 just	 the	 treatment	 of	 illness.	
Patients	are	often	subjected	to	constant	monitoring	and	repeated	investigations	which	
can	 have	 a	 number	 of	 adverse	 effects	 on	 the	 neonate.	Not	 only	 are	 procedures	 and	
investigations	distressing	to	both	the	patient	and	their	parents,	disruption	of	the	baby	
and	their	environment	whilst	being	treated	in	neonatal	intensive	care	units	(NICU)	can	
also	hinder	their	development	(11-13).	There	is	therefore	a	need	for	research	into	the	
development	of	non-invasive	methods	of	monitoring	 to	help	provide	optimal	 care	 to	
patients	 and	 give	 an	 already	 vulnerable	 population	 the	 best	 chance	 to	 thrive	 and	
survive.	
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One	 of	 the	 commonest	 conditions	 to	 affect	 preterm	 infants	 is	 the	 patent	 ductus	
arteriosus	 (PDA).	 This	 condition	 affects	 between	 30-50%	 of	 all	 preterm	 neonates	
depending	on	gestation	(14).	Although	necessary	for	survival	of	the	fetus	in	utero	and	
normal	for	the	first	24-48	hours	of	life,	persistence	of	the	ductus	arteriosus	after	birth	
is	 associated	 with	 a	 number	 of	 serious	 adverse	 outcomes.	 These	 include	 the	
development	 of	 intraventricular	 haemorrhage	 (IVH),	 bronchopulmonary	 dysplasia	
(BPD)	 and	 necrotizing	 enterocolitis	 (NEC)	 (15-18).	 The	 current	 gold	 standard	
investigation	 for	 the	 diagnosis	 of	 PDA	 is	 the	 echocardiogram.	 Although	 this	 can	
accurately	measure	 the	size	of	 the	PDA	as	well	as	a	number	of	other	haemodynamic	
characteristics	 of	 the	 neonate,	 it	 has	 a	 number	 of	 drawbacks.	 Echocardiograms	 are	
disruptive	 to	 the	neonate	 and	only	provide	 a	one-off	 reading	 at	 a	 particular	 point	 in	
time.	 This	 means	 that	 in	 the	 process	 of	 investigating	 patients	 and	 monitoring	 their	
response	 to	 treatment,	 neonates	 are	 often	 subjected	 to	 multiple	 echocardiograms.	
This	can	cause	disruption	to	their	sleep	cycle,	increased	noise	around	the	incubator	and	
temperature	 changes,	 all	 of	 which	 can	 be	 detrimental	 to	 the	 patient	 (11-13).	 This	
chapter	 aims	 to	 review	 the	 fetal	 and	 neonatal	 cardiovascular	 systems,	 the	
pathophysiology,	 diagnosis	 and	management	 of	 PDA,	 the	 use	 of	 novel	 biomarkers	 in	
neonatology	and	 finally,	 the	current	and	potential	uses	of	pulse	wave	velocity	 (PWV)	
and	phase	difference	as	novel	biomarkers	in	neonatal	care.		
1.2 Fetal	and	Transitional	Circulation	
1.2.1 Vascular	Physiology	
With	 each	 beat	 of	 the	 heart,	 blood	 passes	 from	 the	 ventricles	 through	 the	 arterial	
system	and	around	the	body.	The	flow	of	blood	around	the	body	is	achieved	through	a	
combination	 of	 mass	 flow	 of	 blood	 (i.e.	 blood	 that	 is	 ejected	 from	 the	 ventricles	
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pushing	along	any	residual	blood	in	the	arteries)	supplemented	by	recoil	of	the	blood	
vessel	walls	that	relates	to	the	vascular	tone	of	the	arteries.	Vascular	tone	refers	to	a	
vessels	 ability	 to	 constrict	 relative	 to	 its	maximally	 dilated	 state.	 A	 vessels	 ability	 to	
constrict	 or	 dilate	 contributes	 to	 vascular	 resistance,	 and	 can	 therefore	 increase	 or	
decrease	 blood	 flow	 to	 the	 target	 organs	 based	 on	 metabolic	 demand.	 Tone	 is	
modulated	through	contraction	or	relaxation	of	the	vascular	smooth	muscle	cells	under	
the	influence	of	a	number	of	intrinsic	and	extrinsic	factors.	Intrinsic	factors	(e.g.	nitric	
oxide	 (NO),	 prostacyclin,	 thromboxane	 A2	 etc)	 (19)	 derive	 from	 within	 the	 vascular	
endothelium,	 whereas	 extrinsic	 factors	 (e.g.	 angiotensin	 II,	 atrial	 natriuretic	 peptide	
(ANP))	 derive	 from	 a	 source	 outside	 of	 the	 vessel	 or	 the	 organ	 or	 tissue	 where	 the	
vessel	is	located.	Another	important	extrinsic	factor	which	plays	a	significant	role	in	the	
control	 of	 haemodynamics	 within	 the	 body	 is	 input	 from	 the	 autonomic	 nervous	
system	(ANS).	The	ANS	is	part	of	the	peripheral	nervous	system	which	controls	multiple	
physiological	 processes	 such	 as	 maintenance	 of	 blood	 pressure,	 regulation	 of	 heart	
rate,	pupillary	dilatation	and	constriction	and	control	of	secretions	such	as	sweat	and	
saliva	 (20).	There	are	 two	branches	of	 the	ANS,	 the	parasympathetic	nervous	 system	
(PNS)	 and	 the	 sympathetic	 nervous	 system	 (SNS).	 Activation	 of	 the	 SNS	 causes	 an	
increase	in	heart	rate,	cardiac	contractility	and	peripheral	resistance	via	post-ganglionic	
nerve	fibres	(20-22).	Activation	of	the	PNS	causes	a	decrease	 in	these	haemodynamic	
properties	 of	 the	 cardiovascular	 system,	 predominantly	 via	 the	 action	 of	 the	 vagus	
nerve	 (20-22).	 Any	 alteration	 to	 the	 development	 or	 functioning	 of	 the	 ANS	 can	
therefore	 have	 significant	 consequences	 to	 the	 haemodynamic	 control	 within	 the	
neonate.		
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1.2.2	Fetal	Circulation	
There	are	a	number	of	differences	between	the	circulatory	system	of	a	fetus	(Figure	1)	
(23)	 and	 that	of	 a	newborn.	 The	 circulatory	 system	 in	utero	 is	different	 to	 that	 after	
birth	 as	 the	 right	 ventricle	 is	 involved	 in	 the	 ejection	 of	 oxygenated	 blood.	Whilst	 in	
utero,	 the	 fetus	 relies	 on	 the	 delivery	 of	 oxygenated	 blood	 from	 the	mother	 via	 the	
umbilical	 vein	 (24).	 Blood	 from	 the	 umbilical	 vein	 either	 travels	 through	 the	 liver	
microcirculation	or	bypasses	it	entirely	by	entering	the	inferior	vena	cava	(IVC)	via	the	
ductus	venosus	(DV).	The	IVC	then	allows	the	oxygen-rich	blood	to	enter	the	right	side	
of	the	heart.	The	Eustachian	valve	helps	direct	the	flow	of	blood	from	the	right	atrium	
(RA)	to	the	left	atrium	(LA)	via	an	intra-cardiac	shunt	known	as	the	foramen	ovale	(24).	
The	patency	of	the	foramen	ovale	is	maintained	in	utero	by	a	combination	of	factors.	
The	collapsed	and	fluid-filled	fetal	lungs	cause	increased	resistance	to	the	right	outflow	
tract	due	to	high	pulmonary	vascular	resistance	(PVR).	This	results	in	decreased	venous	
return	to	the	LA	via	the	pulmonary	veins.	The	combination	of	raised	PVR	and	reduced	
venous	return	to	the	LA	causes	a	pressure	gradient	across	the	atria,	allowing	blood	to	
shunt	 from	 right	 to	 left.	 An	 additional	 embryological	 adaptation	 that	 aids	 the	
distribution	of	maternal	blood	around	the	fetus	is	the	ductus	arteriosus	(DA).	The	DA	is	
an	extra-cardiac	shunt	that	allows	communication	between	the	 left	pulmonary	artery	
and	 the	 descending	 aorta.	 High	 pulmonary	 vascular	 resistance	 causes	 a	 right-to-left	
shunt,	allowing	between	75-90%	of	 right	ventricular	output	 to	bypass	 the	pulmonary	
circulation	and	enter	the	systemic	circulation	(24).	During	fetal	life,	the	DA’s	patency	is	
maintained	by	a	combination	of	low	partial	pressure	of	oxygen	in	the	non-functioning	
fetal	 lungs,	 vasodilatory	 prostaglandins	 (e.g.	 PGE2)	 secreted	 by	 the	 placenta	 and	 the	
secretion	of	NO	by	ductal	endothelial	cells	(25).	Together,	this	system	of	shunts	allows	
optimal	distribution	of	oxygenated	maternal	blood	around	the	fetal	body	in	an	attempt	
to	ensure	favourable	growth	and	development.	 	
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	 	Figure	1	The	fetal	circulation.	Adapted	from	the	American	Heart	Association	(23)	
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1.2.3	Transitional	Circulation	of	the	Newborn	
Prior	to	birth,	the	fetal	circulation	is	maintained	by	two	main	factors.	The	placenta	acts	
as	 a	 low	 pressure	 vascular	 bed	 which	 allows	 deoxygenated	 blood	 from	 the	 fetus	 to	
return	to	the	mother	via	the	placenta	through	the	umbilical	arteries	(24).	Secondly,	the	
high	 vascular	 resistance	 of	 the	 pulmonary	 circulation	 caused	 by	 the	 non-functioning	
fetal	 lungs	 maintains	 a	 right-to-left	 cardiac	 shunt,	 thus	 ensuring	 the	 distribution	 of	
oxygenated	 maternal	 blood	 throughout	 the	 systemic	 circulation.	 Although	 these	
factors	are	key	to	the	survival	of	the	fetus	in	utero,	a	number	of	changes	must	occur	for	
the	 fetus	 to	 successfully	 transition	 to	 life	 outside	 the	 womb.	 The	 term	 “transitional	
circulation”	 refers	 to	 cardiopulmonary	 changes	 that	 occur	 as	 the	 baby	 is	 born	 that	
allows	 them	 to	 adapt	 to	 post-natal	 life.	During	 labour,	 pressure	 from	 the	birth	 canal	
aids	the	removal	of	some	of	the	fluid	that	occupies	the	fetal	lungs.	This	in	combination	
with	a	number	of	thermal,	chemical	and	tactile	stimuli	at	birth	initiates	breathing	(26).	
As	the	baby	takes	their	first	breath,	inflation	of	the	lungs	causes	a	significant	reduction	
in	pulmonary	vascular	resistance.	The	mechanism	of	this	reduction	is	thought	to	be	due	
to	a	combination	of	factors.	The	stimulation	of	pulmonary	stretch	receptors	stimulates	
vasodilatation	 of	 the	 pulmonary	 vasculature	 and	 the	 improved	 oxygenation	 of	 blood	
reduces	 vasoconstriction	 secondary	 to	 hypoxia	 (27).	 The	 reduction	 in	 pulmonary	
vascular	resistance	results	in	increased	pulmonary	blood	flow	and	therefore	increased	
venous	 return	 to	 the	 LA.	 This	 causes	 a	 subsequent	 rise	 in	 left	 atrial	 pressure.	 In	
combination	with	this,	the	removal	of	the	placental	circulation	through	clamping	of	the	
umbilical	 cord	 causes	 an	 increase	 in	 systemic	 vascular	 resistance	 and	 a	 significant	
reduction	 in	the	venous	return	to	the	right	side	of	 the	heart	via	 the	DV	and	 IVC	(27).	
The	 resulting	 increased	 left	 atrial	 pressure	 and	 decreased	 right	 atrial	 pressure	
culminate	in	the	closure	of	the	foramen	ovale,	causing	a	cessation	of	shunting	between	
the	 atria.	 The	 DA	 is	 closed	 by	 a	 combination	 of	 decreased	 pulmonary	 vascular	
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resistance	 along	 with	 a	 reduction	 in	 vasodilatory	 prostaglandins.	 This	 is	 achieved	
through	 cessation	 of	 placental	 blood	 flow	 and	 pulmonary	 metabolism	 of	 PGE2.	
“Functional”	 closure	 of	 the	 DA,	 whereby	 there	 is	 complete	 cessation	 of	 left-to-right	
shunting,	typically	occurs	within	24	hours;	however,	there	is	still	the	possibility	of	the	
DA	 becoming	 patent	 again	 (25).	 “Anatomical”	 closure	 of	 the	 DA,	 characterised	 by	
fibrous	 proliferation	 of	 the	 intima	 and	 thus	 an	 inability	 to	 reopen,	 typically	 occurs	
within	2-3	weeks	after	birth	(25).	Anatomical	closure	of	the	DA	results	in	the	formation	
of	the	ligamentum	arteriosum,	allowing	the	infant	to	develop	a	normal	dual	circulatory	
system.	
1.2.4	 Factors	 affecting	 the	Transitional	 Circulation	 in	Term	
Infants	
Although	almost	all	term	neonates	adapt	well	to	post-natal	life,	the	persistence	of	the	
fetal	 circulation	 can	 be	 extremely	 detrimental	 to	 their	 health.	 The	 presence	 of	
abnormal	physiological	states	such	as	hypoxia,	hypercarbia	and	hypothermia	caused	by	
birth	 complications	 can	 result	 in	 vasoconstriction	 of	 sensitive	 neonatal	 pulmonary	
arterioles	 (27).	This	 results	 in	an	 increase	 in	pulmonary	vascular	 resistance,	causing	a	
persistence	 of	 right-to-left	 shunting	which	 inhibits	 the	 natural	 closure	 of	 the	DA	 and	
foramen	ovale	(Figure	2)	(27).	
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Figure	2	The	"Vicious	Cycle"	of	Persistent	Fetal	Circulation	(PFC)	-	Adapted	from	Fetal	Circulation	by	Murphy	(27)	
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1.2.5	Factors	affecting	the	Transitional	Circulation	in	
Preterm	Infants	
Preterm	 infants	 are	 particularly	 susceptible	 to	 disruptions	 to	 the	 development	 of	 a	
functional	 post-natal	 circulatory	 system.	 Although	 they	 too	 are	 susceptible	 to	 the	
effects	 of	 the	 “vicious	 cycle”	 of	 PFC,	 the	 incomplete	 development	 of	 key	 organs	 can	
lead	to	abnormal	physiological	functioning.	
Cardiovascular	System:	
Preterm	infants	are	particularly	susceptible	to	the	persistence	of	a	PDA,	which	will	be	
discussed	in	detail	later	in	the	chapter.	Immature	cardiac	myocytes	present	in	preterm	
infants	may	result	in	reduced	cardiac	contractility	(24).	Their	increased	heart	rate	also	
impairs	 diastolic	 filling,	which	 in	 combination	with	 reduced	 contractility,	 significantly	
reduces	their	cardiac	output	(CO)	(24).	
Central	Nervous	System:	
Preterm	 infants	with	 reduced	CO	may	be	at	 increased	 risk	of	 cerebral	hypoperfusion	
due	to	altered	cerebral	autoregulation.	Although	its	mechanism	is	poorly	understood,	
cerebral	autoregulation	refers	to	the	process	by	which	the	vasculature	within	the	brain	
rapidly	 responds	 to	 alterations	 in	 blood	 pressure	 in	 order	 to	 maintain	 cerebral	
perfusion	and	prevent	hypoxic	injury	(28,	29).	The	“autoregulatory	plateau”	shows	the	
maintenance	 of	 stable	 cerebral	 blood	 flow	 (CBF)	 at	 varying	 mean	 arterial	 blood	
pressures	 (Figure	 3)	 (30).	 It	 has	 been	 suggested	 that	 extremely	 premature	 neonates	
have	a	much	narrower	autoregulatory	plateau	(31),	resulting	in	increased	fluctuations	
in	 CBF	 (32).	 Failure	 of	 cerebral	 autoregulation	 (commonly	 referred	 to	 as	 “pressure	
passivity”)	whereby	the	infant	is	unable	to	maintain	their	CBF	even	with	minor	falls	in	
arterial	blood	pressure,	is	associated	with	cerebral	ischaemia	(33).		
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Figure	3	The	"Autoregulatory	Plateau"	of	cerebral	autoregulation	–	adapted	from	Autoregulation	of	cerebral	blood	flow	in	newborn	babies	by	Greisen	(30).	CrCp	=	
Critical	Closing	Pressure	
“Autoregulatory	Plateau”	
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It	 is	 thought	 that	 this	 may	 be	 associated	 with	 the	 absence	 of	 muscle	 in	 premature	
penetrating	 cerebral	 arterioles	 (34).	 Neurological	 insults	 such	 as	 cerebral	 ischaemia	
may	affect	the	transitional	circulation	through	their	effect	on	the	development	of	the	
ANS.	As	previously	mentioned,	 the	ANS	plays	a	 key	 role	 in	 the	 regulation	of	 vascular	
tone	 and	 thus	 haemodynamic	 control	 of	 the	 newborn.	 It	 has	 been	 suggested	 that	
perinatal	 neurological	 damage	 can	 cause	 alterations	 to	 the	 development	 of	 the	 ANS	
(35).	A	recent	study	outlined	the	effects	of	hypoxic-ischaemic	encephalopathy	(HIE)	on	
the	 development	 of	 the	 ANS	 in	 the	 new-born.	 HIE	 is	 a	 perinatal	 neurological	 injury	
associated	with	hypoxia	and	reduced	CBF.	It	was	found	that	although	injury	to	different	
parts	of	the	cerebral	cortex	and	cerebellum	had	differing	effects	on	the	development	
of	the	ANS,	hypoxic-ischaemic	 injury	of	the	brain	causes	alterations	to	the	sympatho-
vagal	balance	of	 the	ANS	 (22).	 This	alteration	 in	 the	 functioning	of	 the	neonatal	ANS	
may	 affect	 their	 ability	 to	 adjust	 their	 pulmonary	 and	 systemic	 vascular	 resistance	
which	are	key	aspects	of	the	transitional	circulation.	
Endocrine	System:	
Preterm	 infants	may	 be	 susceptible	 to	 endocrine	 dysfunction	 which	 can	 affect	 their	
ability	to	adapt	to	life	outside	the	womb.	A	cortisol	“surge”	occurs	after	the	placental	
circulation	is	disrupted.	Cortisol	stimulates	a	number	of	key	physiological	processes	in	
the	 neonate.	 It	 is	 involved	 in	 the	 increase	 in	 beta-adrenergic	 receptor	 density	 in	 the	
heart	 and	 lungs,	 the	 induction	 of	 the	 maturation	 of	 the	 surfactant	 system	 and	
stimulating	the	release	of	catecholamines	which	are	responsible	for	thermogenesis	and	
increasing	blood	pressure	after	birth	 (36,	37).	Cortisol	also	aids	the	conversion	of	 the	
thyroid	hormone	 thyroxine	 (T4)	 to	 its	active	metabolite	 triiodothyronine	 (T3).	T3	and	
cortisol	 are	 associated	with	 the	 activation	 of	 the	Na+K+ATPase	 responsible	 for	 aiding	
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the	clearance	of	fluid	from	the	fetal	lungs	(37).	Preterm	infants	may	be	susceptible	to	a	
reduction	in	cortisol	due	to	immature	adrenal	glands	at	the	time	of	birth	(37).		
1.3	The	Patent	Ductus	Arteriosus	
1.3.1	The	Pathophysiology	of	the	Patent	Ductus	Arteriosus	
A	PDA	is	a	common	condition	within	neonatology.	It	occurs	in	approximately	1	in	2000	
term	 neonates	 (38)	 and	 is	 inversely	 proportional	 to	 gestational	 age	 in	 premature	
neonates,	 with	 the	 incidence	 ranging	 from	 30-50%	 (14).	 Combined	 data	 from	 five	
studies	showed	that	spontaneous	closure	of	a	PDA	after	7	days	of	life	occurred	in	only	
36%	of	patients	born	at	27-28	weeks	gestational	age	(GA),	in	32%	of	those	born	at	25-
26	weeks	GA,	and	in	just	13%	of	those	born	at	24	weeks	GA	(15).	There	are	a	number	
of	factors	that	contribute	to	the	persistence	of	a	PDA	in	preterm	neonates.	It	is	thought	
that	as	term	babies	approach	birth,	there	is	a	decrease	in	the	sensitivity	of	ductal	cells	
to	 the	 vasodilatory	 prostaglandins	 that	 help	 maintain	 the	 patency	 of	 the	 DA	 (39).	
Ductal	 cells	 in	 the	 preterm	 infant	 are	 therefore	 thought	 to	 be	 more	 sensitive	 to	
vasodilatory	 prostaglandins.	 This	 in	 combination	 with	 the	 immature	 fetal	 lungs’	
reduced	 ability	 to	 metabolise	 prostaglandins	 contribute	 to	 the	 failure	 of	 the	 DA	 to	
close	(40,	41).		
PDA	 is	 associated	with	a	number	of	 life-threatening	 conditions	 such	as	 IVH,	NEC	and	
BPD	(15-18).	Adverse	outcomes	secondary	to	PDA,	particularly	BPD,	can	be	attributed	
to	the	so	called	“steal	phenomenon”.	A	left-to-right	shunt	caused	by	the	lower	vascular	
resistance	of	the	pulmonary	vessels	results	in	pulmonary	hyperperfusion	and	systemic	
hypoperfusion	(42).	This	has	a	particularly	significant	effect	on	the	cerebral,	renal	and	
mesenteric	 systems	 (15,	 43).	 It	 is	 hypothesised	 that	 this	may	 be	 exacerbated	 by	 the	
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effect	of	a	PDA	on	the	ANS.	One	study	showed	that	preterm	infants	with	a	PDA	had	an	
association	with	predominance	of	the	PNS	(44).	It	was	hypothesised	that	a	PDA	caused	
an	 increased	 end	 diastolic	 pressure	 (secondary	 to	 the	 persistent	 shunting	 of	 blood)	
which	 subsequently	 caused	 a	 release	 of	 atrial	 natriuretic	 peptide	 (ANP),	 resulting	 in	
widespread	 hypotension	 and	 systemic	 hypoperfusion.	 It	 was	 suggested	 that	 the	
systemic	 hypoperfusion	 results	 in	 decreased	 cerebral	 oxygenation	 which	 further	
disrupts	the	normal	development	of	the	ANS,	impairing	the	sympatho-vagal	balance.	
1.3.2	Investigating	the	Patent	Ductus	Arteriosus	
Although	 investigations	 such	 as	 electrocardiogram	 (ECG)	 and	 chest	 radiographs	 can	
provide	additional	information	when	assessing	an	infant	with	a	PDA,	the	gold	standard	
investigation	is	the	echocardiogram	(43).	Echocardiograms	in	the	investigation	of	a	PDA	
are	 transthoracic	 ultrasound	 scans	 of	 the	 cardiovascular	 anatomy.	 Ultrasound	
composes	of	high	frequency	sound	waves	beyond	the	human	auditory	range	travelling	
through	 tissues	 of	 various	 densities.	 A	 transducer	 emits	 the	 waves	 through	 a	
conductive	medium	which	eliminates	power	 loss	at	the	air-tissue	interface.	Tissues	of	
different	densities	 then	 reflect	different	quantities	of	 the	ultrasound	wave	which	are	
collected	by	 the	 transducer	before	being	 converted	 into	 an	 image	on	 the	ultrasound	
screen.	The	resistance	of	a	tissue	to	the	passing	of	ultrasound	waves	 is	known	as	the	
“acoustic	 impedance”	(45).	Fluid	allows	greater	transmission	of	ultrasound	waves	and	
in	 doing	 so	 reflect	 little	 of	 the	 ultrasound	 waves	 back	 to	 the	 transducer	 (45).	 This	
produces	a	“hypoechoic”	or	dark	image	(45).	Denser	tissues	such	as	bone	reflect	much	
more	of	the	ultrasound	waves	and	in	doing	so	produce	a	“hyperechoic”	or	light	image	
(45).	This	allows	the	practitioner	to	differentiate	between	different	structures	based	on	
the	density	of	tissue.	Doppler	ultrasonography	provides	additional	 information	on	the	
velocity	and	direction	of	the	flow	of	fluid.		
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PDA	is	diagnosed	by	using	echocardiography	to	demonstrate	evidence	of	blood	flow	of	
abnormal	origin	along	the	pulmonary	artery.	Once	visualised,	the	diameter	of	the	PDA	
can	 be	 measured,	 along	 with	 a	 number	 of	 other	 parameters	 to	 assess	 its	
haemodynamic	 significance.	 Echocardiography	 is	 considered	 the	 gold-standard	
investigation	of	PDA	as	it	provides	the	clinician	with	direct	visualisation	of	the	duct,	as	
well	as	measurement	of	its	severity	from	a	haemodynamic	standpoint.	
Despite	 its	widespread	use	 in	 the	 diagnosis	 of	 PDA,	 there	 are	 a	 number	 of	 potential	
drawbacks	to	the	use	of	echocardiography	 in	neonatal	care.	Concerns	surrounding	 its	
repeatability	 and	 accessibility	 have	 been	 raised	 in	 literature,	 whilst	 the	 need	 for	
repeated	 measurements	 may	 make	 it	 inappropriate	 for	 monitoring	 a	 dynamic	
condition	 such	 as	 a	 PDA.	 The	 current	 uses,	 benefits	 and	 drawbacks	 of	
echocardiography	in	neonatal	care	will	be	discussed	in	more	detail	in	chapter	2.	
1.3.3	Management	of	Patent	Ductus	Arteriosus	
Management	 of	 PDA	 remains	 controversial.	 Not	 only	 are	 there	 multiple	 treatment	
options,	 but	 there	 are	 also	 conflicting	 opinions	 on	 whether	 or	 not	 a	 PDA	 requires	
intervention	 due	 to	 the	 lack	 of	 evidence	 for	 improvement	 in	 long	 term	 outcomes	
associated	 with	 treatment	 (46,	 47).	 Current	 established	 treatment	 options	 typically	
include	 medical	 management	 with	 indomethacin	 or	 ibuprofen,	 or	 surgical	 ligation.	
Indomethacin	and	ibuprofen	are	non-steroidal	anti-inflammatory	drugs	(NSAIDs)	which	
act	by	inhibiting	vasodilatory	prostaglandins	such	as	PGE2	which	maintain	the	patency	
of	the	DA.	Although	treatment	with	NSAIDs	is	successful	 in	treating	PDA	in	70-80%	of	
cases,	 they	are	associated	with	a	number	of	adverse	side	effects	 including	decreased	
renal	 function	 and	 gastrointestinal	 bleeding	 (48,	 49).	 Surgical	 ligation	 is	 typically	
reserved	 for	 PDA	 that	 is	 refractory	 to	 medical	 treatment	 or	 when	 NSAIDs	 are	
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contraindicated	 (50).	 Although	 it	 has	 been	 shown	 to	 reduce	mortality,	management	
with	 surgical	 ligation	 has	 been	 associated	 with	 a	 number	 of	 complications	 including	
hypotension,	 adverse	 neurodevelopmental	 outcomes	 and	 increased	 rates	 of	
pneumothorax	 and	 infection	 (48,	 49).	 Paracetamol	 has	 recently	 been	 studied	 as	 a	
possible	alternative	to	medical	management	with	NSAIDs	that	is	associated	with	lower	
rates	of	toxicity.	It	is	thought	that	this	is	due	to	paracetamol’s	different	mechanism	of	
action.	 Like	 traditional	 NSAIDs,	 it	 reduces	 synthesis	 of	 prostaglandins	 through	 the	
inhibition	of	prostaglandin	synthetase	(PGHS),	however,	 it	acts	on	a	different	enzyme	
binding	site	known	as	the	peroxidase	region	(POX)	(51).		A	recent	review	found	it	was	
equally	 as	 efficacious,	 but	 that	 further	 evidence	 was	 required	 to	 assess	 long-term	
effects	 and	 potential	 adverse	 reactions	 before	 it	 should	 be	 considered	 a	 first-choice	
drug	in	the	management	of	PDA	(52).	
1.4	Novel	Biomarkers	in	Neonatology	
1.4.1	Background	
Biomarkers	are	defined	as	“a	characteristic	that	is	objectively	measured	and	evaluated	
as	 an	 indicator	 of	 normal	 biological	 processes,	 pathogenic	 processes,	 or	
pharmacological	 response	 to	 a	 therapeutic	 intervention”	 (53).	 Neonatology	 has	 seen	
an	increase	in	research	in	biomarkers	to	help	improve	the	diagnosis	and	management	
of	 life-threatening	 conditions.	 For	 example,	 conventional	 biomarkers	 such	 as	
interleukins	 and	 cytokines	 involved	 in	 the	 immune	 cascade	 have	 been	 extensively	
researched	 in	 relation	to	neonatal	 sepsis	 (54-56).	However,	 these	biomarkers	are	not	
specific	to	a	particular	disease	or	organ	system.	There	has	thus	been	a	call	for	further	
investigation	into	“novel”	biomarkers	to	help	improve	diagnostic	capabilities	and	drug	
development	in	neonatology	and	paediatrics	(57,	58).	Disease-specific	biomarkers	have	
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been	 used	 to	 great	 effect	 in	 paediatric	 populations.	 Examples	 of	 established	
biomarkers	 include	 haemoglobin	 A1C	 in	 the	 diagnosis	 and	 monitoring	 of	 diabetes	
mellitus,	 and	 the	 MYCN	 oncogene	 in	 the	 assessment	 of	 risk	 of	 developing	
neuroblastoma	 (58).	 The	 use	 of	 established	 biomarkers	 such	 as	 these	 in	 everyday	
paediatric	practice	highlights	their	clinical	potential.	
1.4.2	Desirable	Traits	of	a	Biomarker	
The	 desirable	 traits	 of	 a	 biomarker	 have	 been	 well	 documented	 (59).	 Ultimately,	 a	
biomarker	should	consist	of	a	sample	that	is	acceptable	and	accessible	combined	with	
an	appropriate	and	accurate	assay.	However,	when	investigating	a	novel	biomarker	for	
its	 association	 with	 a	 specific	 clinical	 outcome,	 the	 importance	 of	 considering	 the	
following	has	been	outlined:	
I. Assay	performance	–	 is	 the	assay	accurate,	reliable	and	responsive	to	the	
condition	under	investigation?	
II. Qualification	 –	 does	 the	 biomarker	 have	 a	 robust	 relationship	 with	 the	
current	gold	standard	investigation	for	the	proposed	clinical	outcome?	
III. Utility	–	can	the	biomarker	improve	care	beyond	what	is	already	available?	
(59)	
The	importance	of	considering	the	effects	of	normal	growth	and	development	before	a	
biomarker	is	 implemented	in	clinical	practice	has	also	been	outlined	(58).	 In	order	for	
biomarkers	to	be	considered	useful,	there	therefore	needs	to	be	a	rigorous	process	of	
validation	before	they	can	be	considered	for	application	in	clinical	practice	(60-62).		
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1.4.3	Drawbacks	in	Biomarker	Research	
Researching	 novel	 biomarkers	 in	 paediatric	 populations	 is	 subject	 to	 a	 number	 of	
unique	 drawbacks	 (59).	 The	 first	 of	 which	 is	 the	 incidence	 and	 prevalence	 rates	 of	
morbidity	 in	 children.	 In	 general,	 there	 are	 lower	 incidence	 and	 prevalence	 rates	 of	
disease	in	children.	This	often	results	in	a	significantly	smaller	sample	size	for	analysis,	
affecting	 the	validity	of	 results.	Even	 in	conditions	 that	 typically	predominantly	affect	
children	 such	 as	 congenital	 conditions	 and	 chromosomal	 abnormalities,	 the	 sample	
sizes	 are	 still	 significantly	 smaller	 than	 other	 conditions	 that	 are	 well	 researched	 in	
adults.	 As	 well	 as	 this,	 due	 to	 reluctance	 to	 perform	 unnecessary	
investigations/interventions	 on	 healthy	 children,	 it	 is	 often	 more	 difficult	 to	 obtain	
control	 groups	 to	 use	 as	 comparison	 when	 investigating	 biomarkers.	 Another	
important	aspect	to	consider	with	research	in	paediatrics	is	the	changes	in	physiology	
and	 pathophysiology	 between	 differing	 age	 groups.	 Considerable	 changes	 to	 normal	
physiology	occur	as	children	grow,	with	different	organ	systems	developing	at	different	
rates.	 This	 further	 hinders	 researchers’	 ability	 to	 gather	 large,	 reliable	 sample	 sizes.	
Furthermore,	 when	 considering	 conditions	 that	 are	 common	 in	 adults	 and	 children	
(e.g.	diabetes	mellitus),	comparisons	cannot	be	made	between	the	two	groups	due	to	
significant	 differences	 in	 pathophysiology.	 Although	 novel	 biomarkers	 have	 the	
potential	 to	 make	 a	 significant	 impact	 to	 patient	 care	 in	 neonatology,	 performing	
quality	research	into	their	clinical	application	can	be	challenging.	
1.4.4	Biomarker	Method	Validation	
Before	implementation	in	clinical	practice,	biomarkers	should	be	subject	to	a	rigorous	
process	of	method	validation.	Method	validation	can	be	defined	as	“the	confirmation	
by	 examination	 and	 the	 provision	 of	 objective	 evidence	 that	 the	 particular	
requirements	for	a	specific	intended	use	are	fulfilled”	(62).	When	seeking	to	validate	a	
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novel	 biomarker,	 it	 has	 been	 suggested	 that	 first	 the	 purpose,	 target	 values	 and	
acceptance	 limits	 of	 the	 method	 should	 be	 agreed	 upon	 before	 assessing	 the	
biomarkers	performance	by	experimentation	(62).		
1.4.5	Novel	Biomarkers	in	the	Investigation	of	Patent	Ductus	
Arteriosus	
The	 use	 of	 alternative	 biomarkers	 in	 the	 monitoring	 of	 PDA	 has	 been	 investigated,	
most	notably	the	use	of	brain	natriuretic	peptide	(BNP)	and	amino-terminal	pro-B-type	
natriuretic	 peptide	 (NT-proBNP).	 BNP	 and	 NT-proBNP	 are	 released	 in	 response	 to	
cardiac	 wall	 stress	 and	 act	 by	 inducing	 naturesis/diuresis	 and	 vasodilatation,	 whilst	
concurrently	inhibiting	the	renin-angiotensin-aldosterone	system	(RAAS)	and	SNS	(63).	
Although	some	studies	showed	promising	results	for	the	use	of	BNP	and	NT-proBNP	in	
the	diagnosis	and	monitoring	of	haemodynamically	significant	PDA	(hs-PDA)	(64-66),	a	
recent	systematic	 review	reported	 that	 results	varied	widely	depending	on	assay	and	
patient	 characteristics	 (67).	 This	 outlines	 the	 need	 for	 further	 research	 into	 specific	
biomarkers	for	PDA.	Novel	biomarkers	in	PDA	can	help	avoid	unnecessary	investigation	
and	treatment,	whilst	also	monitoring	progress	and	response	to	 treatment,	however,	
taking	a	consistent	approach	to	testing	each	biomarker	is	imperative.	
A	 recent	 unpublished	 pilot	 study	 performed	 at	 the	 Liverpool	 Women’s	 Hospital	
assessed	the	use	of	phase	difference	and	pulse	wave	velocity	(PWV)	as	potential	novel	
biomarkers	 in	 the	 haemodynamic	 assessment	 of	 extremely	 preterm	 neonates.	
Although	it	was	a	small	pilot	study	consisting	of	 just	14	patients,	 it	showed	promising	
results	with	phase	difference	showing	significant	correlation	to	the	PDA	diameter	(P	=	
<0.001;	 r	 =	 0.820).	 Another	 recent	 study	 also	 assessed	 the	 measurement	 of	 PWV	
expressed	 as	 phase	difference	 as	 a	 non-invasive	method	of	 detecting	PDA.	Data	was	
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collected	 on	 those	 aged	 <32	 weeks	 GA	 and	 using	 arterial	 photoplethysmography	
collected	 from	 a	 pulse	 oximeter,	 they	 found	 that	 phase	 difference	 was	 strongly	
associated	with	 PDA	 (optimal	 pulse	 phase	 difference	 (PPD)	 cut-off	 of	 ≥1.65	 deg/cm,	
with	 an	 area	 under	 the	 receiver	 operating	 characteristics	 (ROC)	 curve	 of	 0.98	 (95%	
confidence	 interval,	 0.96-1),	 sensitivity	 =	 94.2%;	 specificity	 =	 98.3%)	 and	 should	 be	
considered	as	a	non-invasive	method	of	detection	(68).	Oishi	et	al	reviewed	the	same	
technique	as	a	method	of	evaluating	neonatal	peripheral	circulation.	Within	their	study	
they	 included	 a	 case	 study	 of	 a	 patient	 who	was	 diagnosed	with	 symptomatic	 PDA.	
They	noted	a	decrease	in	PPD	whilst	the	PDA	was	symptomatic	and	an	increase	in	PPD	
following	treatment	with	anti-prostaglandin	therapy	(69).	The	results	of	these	studies	
highlight	 the	potential	 uses	of	PWV	and	phase	difference	as	novel	biomarkers	 in	 the	
diagnosis	and	management	of	PDA.		
1.5	Pulse	Wave	Velocity	and	Phase	Difference	
1.5.1	Background	
The	speed	at	which	blood	is	propagated	around	the	body	can	be	used	as	a	method	of	
analysing	vascular	compliance.	PWV	is	a	method	of	measuring	arterial	compliance	that	
is	 calculated	 from	 measurements	 of	 the	 time	 it	 takes	 the	 impulse	 arising	 from	 a	
contraction	 of	 the	 heart’s	 ventricles	 to	 travel	 between	 two	 recording	 sites	 –	 the	 so-
called	 “pulse	 transit	 time”	 (70).	 The	 measurement	 of	 arterial	 stiffness,	 which	 is	
inversely	proportional	to	PWV,	helps	us	understand	the	mechanics	of	large	vessels	and	
thus	circulatory	physiology	and	disease	(70).	The	factors	affecting	PWV	can	be	shown	
by	the	Moens-Korteweg	equation	(Figure	4):	
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PWV	can	also	be	expressed	in	terms	of	phase	difference.	Phase	difference	refers	to	the	
difference	between	two	waves	of	the	same	frequency	that	are	referenced	to	the	same	
point	(71).	The	speed	of	pulse	wave	propagation	can	be	measured	as	the	difference	in	
time	 between	 the	 R	 wave	 of	 an	 electrocardiogram	 (ECG)	 wave	 (corresponding	 to	
ventricular	contraction)	and	the	peak	of	the	systolic	blood	pressure	wave	measured	at	
a	known	point.	The	phase	difference	can	be	expressed	in	time	or	as	a	proportion	of	a	
total	wave	(in	degrees).	
1.5.2	 Practical	 considerations	 of	 measuring	 Pulse	 Wave	
Velocity	
There	 are	 a	 number	 of	 different	methods	 of	 measuring	 PWV	 including	 intra-arterial	
transducers,	 arterial	 tonometry,	 Doppler	 ultrasound	 and	 oscillometry	 (72,	 73).	 The	
waves	need	to	be	detected	at	two	set	points	in	order	to	calculate	a	value	for	PWV.	The	
most	 common	 is	 the	 aortic	 PWV,	 whereby	 measuring	 points	 used	 are	 either	 at	 the	
aortic	 arch	or	 the	 common	 carotid	 artery	 and	 the	 femoral	 artery	 (72).	Once	 the	 two	
measurement	 points	 have	 been	 set,	 the	 distance	 between	 them	 in	 calculated.	 This	
then	allows	the	PWV	to	be	calculated	using	the	equation:	
PWV	=	d	(metres)	/	t	(seconds)	
Measurements	 of	 this	 value	 in	 neonates	 are	 met	 with	 a	 number	 of	 potential	
drawbacks.	Methods	such	as	oscillometry	require	cuffs	to	be	applied	over	the	carotid	
artery	in	the	neck	and	the	femoral	artery	in	the	leg	(73).	Applying	a	cuff	to	the	neck	of	a	
Figure	4	Moens	Korteweg	equation	–	E	=	incremental	elastic	modulus	of	the	vessel	wall;	h	=	wall	thickness;	r	=	
vessel	radius;	p	=	blood	density.	
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neonate	has	the	potential	to	be	not	only	practically	difficult	but	also	distressing	for	the	
patient	and	their	 family.	Other	methods	such	as	Doppler	ultrasound	require	accurate	
measurement	of	 the	pulse	wave	 at	 two	determined	points	which	may	be	difficult	 to	
achieve	and	maintain	in	a	moving	neonate.	We	postulate	that	for	the	measurement	of	
this	value	in	patients	admitted	to	the	NICU,	the	most	reliable	and	minimally	disruptive	
method	 is	 through	measurement	 via	 an	 intra-arterial	 line;	more	 specifically,	 through	
the	use	of	an	umbilical	arterial	catheter	(UAC).	
UAC	 insertion	 is	 common	 practice	 in	 neonates	 who	 require	 invasive	 haemodynamic	
monitoring	or	frequent	arterial	blood	tests	(74).	The	UAC	is	connected	to	a	transducer	
which	 provides	 real-time	 information	 to	 the	 patients	 monitor,	 allowing	 the	 arterial	
waveform	to	be	observed.	In	order	to	use	the	data	from	the	UAC	to	calculate	the	PWV,	
a	number	of	steps	must	be	taken.	First,	as	per	common	practice,	all	patients	fitted	with	
a	UAC	must	have	an	appropriate	x-ray	to	ensure	the	 line	 is	adequately	placed.	Based	
on	 this	 radiograph,	 a	 calculation	 of	 the	 distance	 of	 the	 tip	 of	 the	 catheter	 from	 the	
aortic	 valve	 can	be	 calculated	 to	provide	 the	distance	 the	pulse	wave	 is	 travelling.	 If	
compared	to	the	patient’s	ECG	data,	we	can	calculate	the	PWV	through	measuring	the	
time	 difference	 between	 the	 R	 wave	 of	 the	 ECG	 (corresponding	 to	 ventricular	
contraction	 and	 the	 ejection	 of	 blood	 from	 the	 heart)	 and	 the	 peak	 of	 the	 systolic	
waveform	as	measured	by	the	UAC.	This	provides	a	time	measurement	to	how	fast	the	
pulse	wave	is	travelling	between	the	two	set	measurement	points.	This	value	may	also	
be	 expressed	 in	 the	 form	 of	 “phase	 difference”.	 The	 proportion	 of	 the	 cardiac	 cycle	
whereby	the	pulse	wave	is	being	transmitted	can	therefore	be	represented	as	a	phase	
difference	in	degrees	(°)	whereby	the	total	cardiac	cycle	represents	360°.	
There	are	benefits	 and	drawbacks	of	 expressing	haemodynamics	 in	 terms	of	PWV	or	
phase	difference	which	are	outlined	in	Table	1.	
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	 Pulse	Wave	Velocity	(PWV)	 Phase	Difference	
Benefits	 Calculation	is	based	on	a	more	
scientifically	 familiar	 concept	
of	 calculating	 speed	 from	
distance	and	time.	
Calculation	 is	 based	 purely	 on	 ECG	
and	 arterial	 waveforms,	 eliminating	
the	 measurement	 error	 associated	
with	expression	of	PWV.	
Drawbacks	 Relies	on	the	measurement	of	
distance	 from	 Aortic	 Valve	 to	
UAC	 tip	 –	 subject	 to	
potentially	 significant	 error	 of	
measurement.	
Expression	 of	 phase	 difference	 is	
uncommon	 practice	 in	 medicine	 and	
therefore	 is	 a	 more	 abstract	 concept	
than	measurement	of	PWV.	
Table	1	Benefits	and	Drawbacks	of	PWV	and	Phase	Difference	
1.5.3	Current	and	Potential	Uses	of	Pulse	Wave	Velocity	and	
Phase	 Difference	 in	 the	 measurement	 of	 haemodynamic	
function	
PWV	is	a	well-established	biomarker	used	in	the	investigation	of	cardiovascular	disease	
in	adults.	It	is	considered	to	be	a	very	accurate	method	of	investigating	arterial	stiffness	
(75),	 but	 it	 has	 also	 been	 shown	 to	 be	 associated	 with	 variation	 in	 left	 ventricular	
systolic	function	as	well	(76).	Although	it	is	typically	used	to	measure	arterial	stiffening	
in	 a	 clinical	 setting,	 it	 has	 been	 suggested	 that	 the	 concurrent	 analysis	 of	 heart	 rate	
variability	and	PWV	can	be	used	to	assess	peripheral	vascular	sympathetic	functions	as	
well	(77).	Due	to	its	accuracy	and	repeatability	as	a	cardiovascular	biomarker	in	adults,	
PWV	has	been	investigated	for	its	potential	uses	in	paediatric	populations.	It	has	been	
shown	 that	 PWV	 can	 be	 accurately	measured	 and	 easily	 reproduced	when	 assessing	
the	 vasculature	 of	 the	 neonate	 (78)	 and	 although	 predominantly	 an	 illness	 of	 older	
populations,	 arterial	 stiffening	 has	 been	 noted	 in	 paediatric	 populations	 with	
conditions	associated	with	cardiovascular	disease	such	as	diabetes	mellitus	and	chronic	
kidney	 disease	 (79,	 80).	 Phase	 difference	 is	 not	 currently	 used	 as	 a	 method	 of	
expressing	 variations	 in	 haemodynamic	 function.	We	 hypothesise	 that	 based	 on	 the	
factors	 affecting	 the	 Moens-Korteweg	 equation	 (see	 Figure	 4	 above)	 there	 are	 a	
number	of	other	potential	conditions	which	may	cause	variations	in	the	measurement	
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of	 PWV.	 These	 include	 conditions	 which	may	 cause	 variation	 to	 the	 radius	 of	 blood	
vessels,	namely	patent	ductus	arteriosus	(PDA)	and	hypotension.	Based	on	the	existing	
evidence	 regarding	 the	 accuracy	 and	 repeatability	 of	 measuring	 PWV	 in	 paediatric	
populations,	 we	 believe	 the	 research	 into	 the	 use	 of	 PWV	 and	 phase	 difference	 as	
potential	biomarkers	in	neonatal	haemodynamics	is	warranted.	
1.6	Aims	and	Objectives	
This	study	aims	to	challenge	current	practices	in	the	field	of	neonatal	haemodynamics.	
Current	 practices	 regarding	 the	 investigation	 and	 management	 of	 PDA	 will	 be	
reviewed.	 We	 will	 also	 seek	 to	 improve	 the	 current	 understanding	 of	 the	 factors	
affecting	 the	measurement	of	PWV	 in	neonatal	populations.	 It	 is	hoped	 that	 this	will	
stimulate	 a	 process	 of	 validation	 for	 the	 use	 of	 PWV/phase	 difference	 as	 a	 novel	
biomarker	in	the	field	of	neonatal	haemodynamics.	With	the	vascular	tone	of	arteries	
being	 controlled	 by	 a	 careful	 balance	 between	 the	 SNS	 and	 PNS,	 and	 PDA	 being	
associated	with	PNS	predominance	and	hypotension,	we	postulate	that	the	association	
between	PDA	and	PWV/phase	difference	may	be	related	to	 increased	radius	of	blood	
vessels,	thus	altering	the	Moens-Korteweg	equation.		
Chapter	 two	will	 review	 the	use	 of	 echocardiography	 as	 an	 investigation	 in	 neonatal	
care,	 specifically	 reviewing	 its	 current	 uses	 in	 the	 haemodynamic	 assessment	 of	 the	
neonate,	its	accuracy,	reliability	and	accessibility,	as	well	as	potential	alternatives	to	its	
use.	
Chapter	three	will	consist	of	a	systematic	review	of	the	clinical	and	echocardiographic	
markers	 of	 haemodynamic	 significance	 used	 in	 the	 assessment	 of	 the	 neonate	 with	
suspected	hs-PDA.	
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Chapter	 four	 describes	 a	 prospective	 observational	 study	 analysing	 the	 factors	
affecting	the	measurement	of	PWV	and	phase	difference	in	the	first	three	days	of	life.	
The	impact	of	numerous	continuous	and	dichotomous	variables	that	frequently	occur	
in	neonatal	care	will	be	reviewed.	
Chapter	five	describes	the	relationship	between	pulse	wave	velocity,	phase	difference	
and	echocardiographic	markers	of	PDA.		
Chapter	 six	 discusses	 the	 findings	 from	 the	 previous	 chapters	 and	 outlines	 their	
relevance	 to	 clinical	 practice.	 This	 chapter	will	 critically	 evaluate	 the	potential	 use	of	
PWV/phase	 difference	 as	 continuous	 non-invasive	 biomarkers	 in	 neonatal	
haemodynamics.	
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Chapter	2:	Echocardiography	–	A	Review	
2.1	Introduction	
Echocardiography	 has	 been	 considered	 the	 “gold	 standard”	 investigation	 for	 the	
diagnosis	of	PDA	for	decades.	Hailed	for	its	ease	of	use	and	accuracy,	it	has	become	a	
mainstay	of	investigation	in	neonatal	units	across	the	UK.	However,	there	are	a	number	
of	 potential	 drawbacks	 which	 reduce	 the	 value	 of	 echocardiography.	 Furthermore,	
there	 are	 a	 number	 of	 areas	 where	 the	 use	 of	 echocardiography	 could	 be	
supplemented	by	additional	investigations.	This	chapter	aims	to	critically	evaluate	the	
pros	 and	 cons	of	 the	use	of	 echocardiography	as	part	 of	 the	management	of	 PDA	 in	
patients	that	are	treated	in	NICU.	
2.2	 Current	 Uses	 of	 Echocardiography	 in	 Neonatal	
Haemodynamics	
Echocardiography	allows	the	clinician	to	directly	view	and	measure	the	size	of	the	PDA.	
This	allows	the	investigator	to	make	a	bedside	diagnosis	as	well	as	a	prediction	of	the	
severity	 of	 disease	 based	 on	 the	 PDA	 diameter.	 The	 development	 of	 Doppler	
ultrasound	 has	 since	 provided	 the	 clinician	 with	 a	 means	 of	 assessing	 a	 number	 of	
additional	 parameters	which	 aid	 in	 the	 diagnosis	 of	 an	 hs-PDA.	 The	 ability	 to	 assess	
direction	 and	 velocity	 of	 blood	 flow	 adds	 further	 value	 to	 the	 echocardiographic	
evaluation	of	a	patient	as	it	allows	the	clinician	to	assess	the	direction	of	the	shunting	
as	well	as	the	rate	of	flow	through	the	ductus.	Although	the	assessment	of	numerous	
haemodynamic	parameters	is	useful	in	theory,	their	application	to	a	clinical	scenario	is	
somewhat	 limited	by	the	 lack	of	a	universally	accepted	grading	criteria	to	confidently	
declare	 haemodynamic	 significance.	 McNamara	 et	 al	 stated	 that	 “the	 lack	 of	 a	
standardised	 approach	 in	 assigning	 echocardiographic	 significance	 is	 a	 major	 barrier	
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towards	 better	 understanding	 the	 clinical	 impact	 of	 the	 ductus	 arteriosus”	 (81).	
Although	 they	 subsequently	 proposed	 a	 system	 for	 determining	 haemodynamic	
significance,	 the	 authors	 of	 more	 recent	 literature	 still	 note	 that	 there	 is	 no	 clear	
clinical	 definition	 (82,	 83).	 This	 lack	 of	 clinical	 clarity	 has	 the	 potential	 to	 result	 in	
significant	 variation	 in	 the	 use	 of	 echocardiography	 as	 a	 means	 of	 investigating	 the	
haemodynamic	status	of	the	neonate.	
2.3	The	Accuracy	of	Echocardiography	in	the	Haemodynamic	
Assessment	of	the	Neonate	
In	 the	 hands	 of	 an	 experienced	 clinician,	 echocardiography	 is	 deemed	 to	 be	 an	
accurate	 method	 of	 investigating	 cardiovascular	 anatomy.	 A	 number	 of	 studies	
conducted	 in	 the	 1980s	 showed	 echocardiography’s	 potential	 as	 a	 useful	 bedside	
investigation	 in	 the	 detection	 of	 PDA.	 Smallhorn	 et	 al	 assessed	 94	 patients	 ranging	
from	 28	 weeks’	 gestation	 to	 8	 years	 of	 age	 using	 suprasternal	 cross-sectional	
echocardiography	and	compared	them	to	a	group	of	37	patients	without	a	diagnosis	of	
PDA.	 In	all	patients,	angiographic,	surgical	or	necropsy	confirmation	was	available.	Of	
the	94	patients	with	PDA,	87	were	correctly	identified	with	7	false	negatives	where	the	
PDA	 was	 <2mm	 (84).	 This	 highlighted	 the	 reliability	 of	 echocardiography	 to	 identify	
moderate-to-large	PDAs	whilst	also	exposing	its	inaccuracy	when	assessing	small	PDAs.	
The	authors	 felt,	however,	 that	 this	was	not	a	major	drawback	as	a	PDA	of	diameter	
<2mm	 was	 unlikely	 to	 have	 any	 haemodynamic	 significance	 (84).	 Rigby	 et	 al	
investigated	 35	 preterm	 infants	 ranging	 from	 26	 to	 30	 weeks’	 gestational	 age	 using	
cross-sectional	 echocardiography.	 Although	 they	 did	 not	 specifically	 measure	 PDA	
diameter	 as	 part	 of	 their	 study,	 they	were	 able	 to	 identify	 the	 presence	of	 a	 PDA	 in	
100%	of	patients	in	their	study	population	(85).	The	authors	agreed	with	the	findings	of	
Smallhorn	et	al,	deducing	that	it	was	possible	for	small	ductuses	<2mm	to	be	missed	on	
[40]	
	
echocardiography	 (85).	 Vick	 et	 al	 used	 a	 combination	 of	 2D	 echocardiography	 and	
Doppler	ultrasound	to	assess	preterm	infants	who	were	suspected	of	having	PDA	based	
on	clinical	findings	(auscultation	of	a	murmur,	ventilator	dependence,	and	chest	x-ray	
findings)	(86).	They	found	satisfactory	detection	of	PDA	in	33	of	36	examinations	(92%)	
(86).	 These	 early	 studies	 showed	 a	 high	 degree	 of	 accuracy	 in	 the	 detection	 of	 PDA	
using	echocardiography.		
Whilst	drawbacks	 in	 the	detection	of	 small	PDAs	were	 identified,	modern	 technology	
has	 improved	 the	 accuracy	 of	 echocardiography	 in	 the	 30	 years	 since	 these	 studies.	
Hiraishi	 et	 al	 compared	 two-dimensional	 and	 Doppler	 echocardiography	 data	 to	
angiographic,	 surgical	 and	post-mortem	data	 of	 213	patients	 ranging	 from	birth	 to	 4	
years	old	with	a	diagnosis	of	congenital	heart	disease.	Of	the	79	patients	observed	to	
have	 PDA	 via	 invasive	 methods,	 76	 (96.2%)	 were	 correctly	 identified	 by	
echocardiography	 (sensitivity	 =	 96%;	 specificity	 =	 100%)	 (87).	 Lee	 et	 al	 looked	 at	 the	
ability	 of	 both	 a	 neonatologist	 and	 cardiologist	 to	 diagnose	 PDA	 using	 a	 portable	
ultrasound	machine.	Of	the	24	examinations,	15	were	ultimately	deemed	to	be	positive	
for	PDA.	Neonatologist	examinations	had	a	sensitivity	of	69%	and	a	specificity	of	88%,	
compared	 to	 the	 cardiologist’s	 examinations	 which	 had	 a	 sensitivity	 of	 87%	 and	
specificity	of	 71%	 (88).	On	5	occasions,	 a	neonatologist	 believed	 there	 to	be	no	PDA	
present	when	 a	 cardiologist	 evaluation	was	 positive	 for	 PDA,	 however,	 in	 3	 of	 these	
cases,	 the	 PDA	was	 considered	 “small”	 or	 “tiny”	 based	 on	 pre-set	 criteria	 (88).	 This	
study	highlighted	the	ability	of	both	cardiologists	and	neonatologists	(who	had	limited	
training	 in	 the	 diagnosis	 of	 PDA	 using	 echocardiography)	 to	 detect	 patency	 with	 a	
moderate	 degree	 of	 accuracy	 and	 certainty.	 Furthermore,	 this	 study	 was	 conducted	
using	a	portable	ultrasound	machine.	 It	was	 suggested	 that	 rates	of	detection	would	
therefore	 likely	 improve	 if	 more	 sophisticated	 equipment	 was	 used.	 Sohn	 et	 al	
compared	preoperative	echocardiographic	findings	to	surgical	findings	in	patients	with	
[41]	
	
congenital	heart	disease.	26	of	the	patients	reviewed	as	part	of	their	study	were	found	
to	have	PDA,	22	of	whom	were	<1	year-old.	100%	of	the	children	with	PDA	in	this	study	
were	correctly	diagnosed	with	pre-operative	echocardiography	(89).		
Literature	 spanning	 the	 last	 30	 years	 is	 in	 agreement	 that	 echocardiography	 is	 an	
accurate	 method	 of	 diagnosing	 PDA	 in	 infants.	 Galante	 et	 al	 reported	 that	 all	
ultrasound	 measurements	 have	 an	 error	 range	 of	 10-20%	 (90),	 however,	 this	 value	
seems	 to	 be	 greatly	 overestimated	 in	 the	 case	 of	 diagnosing	 PDA	 in	 new-borns.	
Nonetheless,	the	studies	presented	highlight	the	fact	that	there	is	still	a	small	degree	of	
error	in	echocardiography’s	diagnostic	capabilities.	
One	 particular	 area	 where	 the	 diagnostic	 capabilities	 of	 echocardiography	 may	 be	
limited	 further	 is	 in	 patients	 suffering	 from	 lung	 disease.	Hiraishi	 et	 al	 reported	 that	
respiratory	 problems	 such	 as	 hyperinflation	 and	 pneumothorax	 resulted	 in	 a	 “poor	
parasternal	window”,	 causing	 suboptimal	 imaging	of	 the	PDA	 (87).	 Furthermore,	 in	5	
cases	 in	 the	Smallhorn	et	al	study,	an	 inadequate	suprasternal	window	was	observed	
due	to	secondary	hyperinflation	of	the	chest	(84).	Hyperinflation	can	occur	in	a	number	
of	conditions	likely	to	coexist	with	PDA	such	as	BPD,	transient	tachypnoea	of	the	new-
born	(TTN)	and	meconium	aspiration	syndrome	(MAS).	BPD	affects	at	least	a	quarter	of	
those	born	with	 a	birth	weight	of	 less	 than	1500g,	with	 its	 incidence	 increasing	with	
reduced	 gestational	 age	 and	 birth	weight	 (91).	 TTN	 is	 the	most	 common	 respiratory	
disease	of	new-borns	occurring	in	approximately	5.7	per	100	term	births	in	the	UK	(92,	
93).	 Although	 predominantly	 a	 condition	 affecting	 babies	with	 increasing	 gestational	
age,	MAS	is	still	a	highly	prevalent	condition	in	neonatology,	occurring	in	0.43	per	1000	
births	 in	a	 recent	 study	conducted	 in	Australia	and	New	Zealand	 (94).	Often	patients	
with	 severe	 lung	 disease	 will	 require	 high-frequency	 oscillatory	 ventilation	 (HFOV)	
which	may	 further	 limit	 the	diagnostic	abilities	of	echocardiography	due	 to	 increased	
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thoracic	movement.	The	high	rates	of	incidence	of	these	conditions	with	the	potential	
to	 affect	 the	 accuracy	 of	 PDA	 diagnosis	 highlight	 a	 potential	 pitfall	 in	 the	 use	 of	
echocardiography	in	NICU.	
2.4	Repeatability	of	Echocardiography	
In	order	 for	an	 investigation	to	be	considered	useful,	 there	must	be	a	high	degree	of	
repeatability	in	its	measurement	to	ensure	consistency	of	diagnosis.	Echocardiography	
is	highly	dependent	on	both	the	practical	and	interpretive	skills	of	the	user,	resulting	in	
the	 potential	 for	 misdiagnosis	 in	 inexperienced	 hands.	 The	 repeatability	 of	
echocardiographic	 parameters	 has	 been	 described	 as	 “far	 from	 optimal”	 (83),	 with	
another	 review	 claiming	 left-atrium-to-aortic-root	 ratio	 (LA:Ao)	 is	 “subject	 to	
considerable	 operator	 variability”	 (81).	 An	 overview	 of	 the	 literature	 reviewing	
repeatability	 of	 echocardiographic	 parameters	 is	 presented	 in	 Table	 2.	 This	 lack	 of	
repeatability	may	 result	 in	misdiagnosis,	over-	or	underestimation	of	disease	 severity	
and	conflicting	clinical	pictures	produced	by	different	examiners.	
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Author	
(Year):	
Echocardiographic	
Parameters	
Assessed:	
Results:	
Within-Observer	Repeatability:	 Between-User	Repeatability	
RepC	 95%	CI	 RepI	 95%	CI	 Rep	C	 95%	CI	 RepI	 95%	CI	
Schwarz	et	
al	
(2016)(83)	
RI_CA	 	 	 	 	 0.09	 0.07-0.13	 11	 9-17*	
RI_ACA	 	 	 	 	 0.11	 0.08-0.16	 14	 11-20*	
LA:Ao	 	 	 	 	 0.23	 0.17-0.33	 16	 12-23	
LVPEP/LVET	 	 	 	 	 0.08	 0.06-0.11	 23	 18-32	
VTI_Ao/VTI_Pa	 	 	 	 	 0.28	 0.21-0.40	 26	 20-38	
PDA	Diameter	 	 	 	 	 0.28	 0.15-1.47	 21	 12-112	
Groves	et	
al	
(2008)(95)	
SVC	Flow	 30**	 17-43**	 	 	 85**	 35-136**	 	 	
DAo	Flow	 60**	 34-86**	 	 	 80**	 33-127**	 	 	
Skinner	et	
al	
(1996)(96)	
PDA	max	 0.48	 0.33-0.88	 39	 27-71	 0.56	 0.40-0.92	 28	 20-47	
PDA	mean	 0.39	 0.27-0.71	 47	 32-85	 0.58	 0.41-0.95	 36	 26-60	
Moorthy	et	
al	
(1990)(97)	
Cerebral	Artery	
Pulsatility	Index	
	 	 17	 	 	 	 20	 	
Table	2	Repeatability	of	Echocardiographic	Parameters;	RepC	=	Repeatability	Coefficient;	95%CI	=	95%	Confidence	Interval;	RepI	=	Repeatability	Index;	RI_CA/ACA	=	Resistance	Index	in	
Coeliac	Artery/Anterior	Cerebral	Artery;	LA:Ao	=	Left	Atrium:Aoric	Root	Ratio;	LVPEP/LVET	=	Left-ventricular-preejection-period-to-ejection-time-ratio;	VTI_Ao/VTI_Pa	=	ratio	of	the	
velocity	time	integrals	in	the	large	vessels;	SVC	=	Superior	Vena	Cava;	Dao	=	Descending	Aorta;	*indicates	statistically	significant	result;	**values	stated	in	ml/kg/min.	
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2.5	Accessibility	of	Neonatologist-performed	Echocardiography	
In	 order	 to	 ensure	 optimal	 accuracy	 and	 repeatability	 of	 diagnosis	 whilst	 using	
echocardiography,	 users	 require	 thorough	 training	 and	 sophisticated	 technology	 (98).	
Echocardiograms	are	often	performed	by	paediatric	 cardiologists	who	are	attending	 the	NICU,	
with	 many	 neonatologists	 lacking	 the	 expertise	 to	 perform	 these	 examinations	 themselves.	
Although	 in	 some	 large	 centres	 there	 is	no	 shortage	of	paediatric	 cardiologists,	 this	 is	 not	 the	
case	for	many	smaller	centres	and	there	have	therefore	been	calls	for	more	neonatologists	to	be	
trained	in	echocardiography	(88,	90).	Despite	increasing	prevalence	of	neonatologist-performed	
echocardiography,	 the	 number	 of	 neonatal	 physicians	 with	 adequate	 training	 is	 still	 limited.	
Schachinger	 et	 al	 conducted	 a	 survey	 in	 2014	 covering	 95%	 of	 neonatal-perinatal	 training	
programs	 in	 the	 US.	 They	 found	 that	 just	 9%	 of	 neonatal	 units	 had	 a	 functional	
echocardiography-trained	 neonatologist,	 whilst	 only	 8%	 of	 centres	 offered	 echocardiography	
training	 as	 part	 of	 their	 neonatal-perinatal	 training	 pathways	 (99).	 In	 the	 UK,	 only	 56%	 of	
neonatal	 training	 programs	 offer	 training	 in	 echocardiography	 (100).	 Additionally,	 78%	 of	
neonatal	 consultants	 reportedly	 expressed	 an	 interest	 in	 achieving	 formal	 accreditation	 in	
neonatal	echocardiography	(100).	These	statistics	highlight	the	lack	of	neonatologists	adequately	
trained	in	the	use	of	echocardiography	in	countries	which	are	deemed	to	be	at	the	forefront	of	
medical	care.	In	the	wake	of	these	studies,	the	need	for	structured	echocardiography	training	for	
neonatologists	 has	 been	 highlighted	 in	 a	 number	 of	 expert	 consensuses	 from	 the	UK,	US	 and	
Europe	(100-102).		
Some	potential	 barriers	 remain	 to	 the	widespread	 use	 of	 echocardiography	 in	 neonatal	 units.	
Aside	 from	 the	 lack	 of	 established	 training	 programs	 highlighted	 by	 numerous	 expert	
consensuses,	 they	 suggested	 other	 pitfalls	 included	 the	 difficulty	 in	 recruiting	 experienced	
cardiologists	to	teach	the	technique	to	neonatologists	and	a	lack	of	equipment	(90).	It	has	been	
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suggested	that	technological	solutions,	such	as	telemedicine,	may	help	alleviate	some	of	these	
barriers	 for	 those	practicing	 in	rural	areas	with	 limited	access	 to	expertly	 trained	physicians	or	
substandard	equipment.	A	2010	study	performed	between	a	tertiary	care	hospital	in	Lisbon	and	
three	rural	hospitals	 in	Portugal	and	the	Azores	reviewed	the	used	of	teleconsultations	for	the	
assessment	 of	 echocardiograms	 performed	 on	 foetuses,	 newborns	 and	 children	 (103).	 They	
concluded	 that	 it	was	not	only	diagnostically	beneficial,	 but	 also	aided	 the	 training	of	medical	
staff	and	provided	socio-economic	benefit	to	centres	operating	in	remote	conditions	(103).	The	
risk	of	misdiagnosis	and	unnecessary	intervention	has	also	been	reported	to	affect	the	decision	
of	neonatologists	to	train	in	echocardiography.	This	suggestion	is	somewhat	validated	by	Lee	et	
al	finding	a	number	of	neonatologists	performing	echocardiography	missed	PDAs	that	paediatric	
cardiologists	were	 able	 to	detect.	 Furthermore,	 one	 study	 investigated	 the	 rates	 of	 treatment	
between	disclosure	 and	non-disclosure	 groups	who	 received	 echocardiographic	 assessment	 of	
suspected	 PDA.	 Although	 the	 statistical	 differences	 between	 their	 two	 groups	 were	 deemed	
insignificant,	 it	was	suggested	 that	avoiding	 routine	echocardiography	could	 reduce	 the	use	of	
drug	therapy	in	very	preterm	neonates	(104).	
Overall,	 it	 is	 evident	 that	 there	 are	 inadequacies	 in	 the	 current	 training	 of	 neonatologists	 in	
echocardiography.	Current	expert	consensuses	have	somewhat	addressed	the	issue	by	providing	
guidance	on	prospective	training	programs,	however,	until	widespread	application	occurs,	these	
inadequacies	are	likely	to	continue.	Furthermore,	the	economic	impact	of	the	introduction	of	a	
training	 program	 such	 as	 this	 cannot	 be	 ignored.	 Although	 the	 use	 of	 technologies	 such	 as	
telemedicine	can	help	improve	care	in	rural	areas	or	low-income	countries,	this	has	the	potential	
to	 add	 to	 the	 already	 significant	 workload	 of	 those	 trained	 in	 neonatal	 echocardiography	
elsewhere.	We	believe	that	improving	echocardiography	training	for	neonatologists	would	help	
improve	accessibility	to	this	valuable	investigation.		
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2.6	Echocardiography	as	a	non-continuous	method	of	Investigating	
PDA	
Despite	 its	accuracy	and	non-invasiveness,	one	of	 the	major	drawbacks	of	echocardiography	 is	
the	need	for	repeated	measurements.	Echocardiography	shows	a	snapshot	of	the	cardiovascular	
anatomy	 and	 haemodynamic	 status	 of	 the	 patient	 at	 a	 particular	 point	 in	 time.	 Therefore	
patients	 with	 persistent	 PDA	 are	 often	 subject	 to	 multiple	 echocardiograms.	 Although	 it	 has	
been	suggested	serial	echocardiography	can	help	 improve	diagnostic	accuracy	(83),	this	can	be	
disruptive	 to	 the	neonate.	 There	have	 thus	been	 calls	 for	 a	 continuous	method	of	monitoring	
(84)	which	would	not	only	be	beneficial	in	identifying	those	suitable	for	diagnostic	scanning,	but	
would	 also	 aid	 in	 the	 monitoring	 of	 response	 to	 pharmacological	 or	 surgical	 management.	
Further	 research	 into	 non-invasive	 continuous	 methods	 of	 monitoring	 PDA	 is	 believed	 to	 be	
beneficial	 for	 a	 number	 of	 reasons.	 Firstly,	 many	 units	 employ	 routine	 echocardiography	 for	
preterm	neonates,	many	of	whom	will	 not	have	pathological	PDAs.	 This	 subjects	newborns	 to	
unnecessary	 scanning	 which,	 as	 previously	 mentioned,	 can	 be	 distressing	 to	 the	 patient.	 The	
ability	 to	 identify	 a	 continuous	 monitoring	 system	 could	 potentially	 highlight	 those	 requiring	
further	 investigation	 with	 echocardiography,	 thus	 reducing	 the	 number	 of	 unnecessary	
investigations.	This	would	not	only	be	beneficial	for	patients,	but	could	also	reduce	the	workload	
of	 those	 trained	 in	 neonatal	 echocardiography.	 This	 could	 be	 beneficial	 for	 those	 working	 in	
smaller	health	care	centres.	As	well	as	this,	a	continuous	monitoring	method	could	be	utilised	to	
monitor	response	to	treatment,	to	identify	those	with	PDAs	refractory	to	medical	management	
and	who	may	benefit	from	surgical	treatment.	
2.7	Conclusion	
Despite	its	reported	accuracy	in	the	measurement	of	PDA	diameter	and	certain	haemodynamic	
parameters,	 there	 are	 a	 number	 of	 inadequacies	 in	 echocardiography	 as	 a	 method	 of	
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investigating	 PDA.	 These	 include	 issues	 surrounding	 repeatability	 and	 the	 lack	 of	 structured	
training	 programs	 for	 neonatologists	 affecting	 accessibility	 to	 echocardiography	 on	 certain	
neonatal	 units.	 Furthermore,	 we	 believe	 the	 non-continuous	 nature	 of	 echocardiography	 is	 a	
major	 drawback	 in	 the	 measurement	 of	 haemodynamic	 and	 PDA	 status	 as	 they	 are	 highly	
variable	 states	 that	 change	 frequently	 and	 rapidly.	 Research	 into	 the	 development	 of	 a	
continuous,	 non-invasive	 method	 of	 monitoring	 PDA	 in	 neonates	 is	 therefore	 deemed	 to	 be	
appropriate.	
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Chapter	3:	Clinical	and	Echocardiographic	Markers	of	
Haemodynamically	Significant	PDA	in	Neonatology:	A	Systematic	
Review	
3.1	Introduction	
Despite	its	prevalence	in	neonatology,	there	are	currently	no	widely	accepted	criteria	for	the	
diagnosis	of	a	haemodynamically	significant	PDA	(hs-PDA)	(82,	83).	Although	suggestions	as	to	
what	defines	a	hs-PDA	have	been	made	in	the	literature	(101),	different	centres	will	use	
different	parameters	and	cut-offs	resulting	in	greatly	varying	thresholds	for	treatment	across	the	
globe.	This	variation	is	just	one	of	a	number	of	drawbacks	prevalent	in	PDA	research,	which	also	
includes	high	contamination	rates	between	treatments	during	clinical	trials,	and	the	lack	of	
validated	long-term	outcome	measures.	These	factors	have	limited	the	implementation	of	
evidence	based	treatment	strategies	for	the	management	of	PDA	(81).		
The	decision	to	initiate	or	withhold	treatment	is	often	based	on	the	results	of	clinical	trials	and	
meta-analysis.	Evidence-based	medicine	relies	on	the	production	of	robust	evidence	that	is	free	
from	significant	bias.	Core	data	sets	refer	to	an	agreed	standardised	collection	of	measurements	
and	outcomes	which	should	be	reported	on	when	conducting	research	on	a	clinical	topic	(105).	
These	help	facilitate	meta-analysis	by	reducing	heterogeneity,	reducing	the	risk	of	bias,	and	
ensuring	clinically	relevant	outcomes	are	identified	and	reported	on	(106).	It	is	important	to	
ensure	that	meta-analyses	of	studies	of	PDA	therapy	are	not	based	on	different	definitions	of	a	
hs-PDA.	Development	of	consensus	is	required	before	any	core	data	sets	for	PDA	can	be	
determined.	Throughout	this	review,	when	discussing	the	formation	of	a	“core	data	set”,	the	
authors	refer	to	the	process	of	standardising	the	clinical	and/or	echocardiographic	biomarkers	of	
haemodynamic	significance	used	in	PDA	research.	
The	aim	of	this	study	was	to	conduct	a	systematic	review	of	the	randomised	controlled	trials	
(RCTs)	of	the	medical	management	of	PDA	in	neonates.	The	primary	outcome	was	the	clinical	
and	echocardiographic	parameters	used	for	determining	haemodynamic	significance	to	assess	
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the	extent	of	variation	in	clinical	practice.	This	represents	the	first	step	towards	development	of	
a	core	data	set	for	PDA	disease.		
3.2	Methods	
A	literature	search	of	relevant	studies	was	performed	using	the	PubMed,	Scopus	and	Web	of	
Science	databases.	Boolean	operators	and	MeSH	terms	were	used	to	help	eliminate	irrelevant	
studies.	Two	investigators	(BR	and	DH)	independently	performed	the	initial	screening	of	titles	
and	abstracts,	before	BR	reviewed	full	text	reports	for	appropriateness.	All	papers	deemed	
suitable	by	either	BR	or	DH	were	subject	to	full	text	review.	Any	uncertainty	regarding	the	
appropriateness	of	including	a	study	was	discussed	between	researchers	BR	and	DH	before	a	
consensus	was	reached.		A	full	search	strategy	is	shown	in	Appendix	1.	The	terms	
“haemodynamically	significant	PDA”	and	“symptomatic	PDA	(s-PDA)”	were	deemed	
interchangeable,	and	so	studies	using	either	term	were	included	for	review.	
Inclusion	Criteria:	
Publications	evaluating	medical	management	of	PDA	in	neonates	of	all	gestations	were	searched	
for	using	appropriate	search	terms	(see	Appendix	1).	Only	RCTs	were	included,	as	the	authors	
were	aware	that	there	are	a	considerable	number	in	this	area.	Only	studies	which	specifically	
outlined	their	criteria	for	determining	haemodynamic	significance	via	clinical	and/or	
echocardiographic	means	were	included	for	review.		
Exclusion	Criteria:	
Studies	on	animal	models;	surgical	trials;	non-RCT;	no	definition	of	haemodynamic	significance.	
Primary	Outcomes:	
Specific	clinical	or	echocardiographic	parameters	used	as	part	of	a	study’s	definition	of	hs-PDA.		
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Secondary	Outcomes:	
- To	review	literature	regarding	the	repeatability	of	echocardiographic	parameters	to	
evaluate	echocardiography’s	usefulness	as	a	means	of	measuring	markers	of	
haemodynamic	significance.	
Data	Extraction:	
Data	extraction	was	performed	by	researcher	BR	with	the	help	of	authors	DH,	AG,	FB,	GJ	and	PD	
for	studies	published	in	languages	other	than	English.	Trials	were	studied	for	their	inclusion	of	
criteria	for	defining	a	hs-PDA.	Studies	that	specifically	stated	their	criteria	for	determining	
haemodynamic	significance	were	included	for	review.	The	clinical/echocardiographic	parameters	
used	as	part	of	their	definition	were	extracted,	as	well	as	interventions	studied	and	the	number	
of	study	participants.		
Data	Presentation:	
Data	was	presented	in	tables	and	diagrams	intended	to	highlight	the	variation	and	relationship	
between	the	clinical	and	echocardiographic	parameters	used	to	define	hs-PDA.	
Quality	Assessment:	
A	critique	of	the	methodological	quality	of	the	included	studies	was	deemed	unnecessary,	as	this	
research	did	not	involve	the	synthesis	of	outcome	data.	
3.3	Results	
A	total	of	40	studies	were	found	to	meet	the	inclusion	and	exclusion	criteria.	The	review	
flowchart	is	shown	in	Figure	5,	with	the	reasons	individual	studies	were	excluded	summarised	in	
Appendix	2.	Table	3	contains	details	of	the	studies	included	for	review.	A	total	of	3,723	
participants	were	included	across	the	40	studies.		
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PubMed:	
n	=	126	
Scopus:	
n	=	245	
Web	of	Science	
n	=	53		
Total	Number	of	Records	from	Searches:	
n	=	424	
Number	of	Titles	and	Abstracts	Reviewed:	
n	=	318	
Number	of	Studies	Included	in	Review:	
n	=	40	
Number	of	Full	Text	Articles	Reviewed	for	Inclusion:	
n	=	64	
Duplicates	Removed:	
n	=	106	
Studies	Excluded:	
n	=	254	
Studies	Excluded:	
n	=	24	
Reasons	for	Exclusion:	
Ø Unable	to	Obtain	
Translation	=	1;	
Ø Not	RCT	=	2;	
Ø Did	not	outline	criteria	for	
diagnosis	of	hs-PDA	=	19;	
Ø Did	not	use	clinical	or	
echocardiographic	means	
of	diagnosing	hs-PDA	=	1	
Ø Study	was	a	follow-up	of	
another	RCT	included	in	
the	review	=	1	
Figure	5	Review	Flowchart	
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Author	(Year):	 n:	 Interventions:	 Clinical	Markers	of	Haemodynamic	
Significance	Used:	
Echocardiographic	Markers	of	
Haemodynamic	Significance	Used:	
El-Mashad	et	al	(2017)(107)	 300	 IV	PARA	vs	IV	IBU	vs	IV	INDO	 N/A	 • LA:Ao	>1.6:1	
• Pulmonary	artery	backflow	
• Duct	Diameter	>1.5mm	
• Reverse	end-diastolic	flow	in	the	
descending	aorta/mesenteric	
artery	
Lin	et	al	(2017)	(108)		 144	 IV	INDO	vs	IV	IBU	 • Cardiovascular	Dysfunction	
Score	>3	(includes	heart	rate,	
quality	of	peripheral	pulsation,	
degree	of	precordial	pulsation,	
duration	of	murmur	and	
cardiothoracic	ratio)	
• LA:Ao	>1.3:1	
Sadeghi-Moghaddam	et	al	
(2017)	(109)	
80	 Oral	IBU	vs	Oral	INDO	 N/A	 • LA:Ao	>1.4:1	
• Duct	Diameter	>1.5mm	
Demir	et	al	(2017)	(110)	 72	 Oral	IBU	vs	Rectal	IBU	 • Tachycardia	
• Apnoea	
• Thrill	
• Active,	heaving	precodium	
• Bounding	peripheral	pulses	
• Wide	pulse	pressure	
• Murmur	
• Increasing	oxygen	dependence	
• Duct	Diameter	>1.5mm	
• LA:Ao	>1.5:1	
• Evidence	of	left-to-right	shunting	
• Evidence	of	reverse	end-diastolic	
flow	
Harkin	et	al	(2016)	(111)		 48	 IV	PARA	vs	Placebo	 • Increased	need	for	respiratory	
support	
• Decreased	systolic/	mean	BP	
• Increased	pulse	pressure	
• Pulmonary	congestion	
• Cardiomegaly	
• Hepatomegaly	
• Murmur	
• LA:Ao	>1.4:1	
• PDA	Diameter	>50%	wider	than	
LPA	
• Flow	pattern	evidence	of	left-to-
right	shunting	
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• Hyperdynamic	precordium	
• Bounding	pulses	
Dani	et	al	(2016)	(112)		 110	 IV	PARA	vs	IV	IBU	 N/A	 • Evidence	of	left-to-right	shunting	
• LA:Ao	>1.3:1	
• Duct	Diameter	>1.5mm	
Yang	et	al	(2016)	(113)	 87	 Oral	PARA	vs	Oral	IBU	 • Systolic	or	consecutive	murmur	
in	the	left	border	of	sternum;	
• Strengthened	beat	of	anterior	
thorax;	
• Locomotive	pulse;	
• Tachycardia	in	quiet	state;	
• Unexplainable	deterioration	of	
respiratory	condition;	
• Increased	pulmonary	vasculature	
shadows	and	enlarged	heart	or	
signs	of	pulmonary	oedema	
under	CXR	examination	
• LA:Ao	>1.4:1	
• Pulmonary	Artery	Diastolic	
Backflow;	
• PDA	Diameter	>1.4mm	
Dash	et	al	(2015)	(114)		 77	 Oral	PARA	vs	IV	INDO	 N/A	 • Duct	Diameter	>1.5mm	
• Evidence	of	left-to-right	shunting	
• LA:Ao	>1.5:1	
Yadav	et	al	(2014)	(115)		 83	 Oral	IBU	vs	Oral	INDO	 N/A	
	
• Duct	Diameter	>1.5mm	
• Systolic	and	diastolic	pressure	
gradients	
• LA:Ao	>1.4:1	
• Evidence	of	PDA	flow	
(hypertensive,	growing	or	
pulsatile	pattern)	
Oncel	et	al	(2014)	(116)		 90	 Oral	PARA	vs	Oral	IBU	 • Clinical	signs	of	PDA	not	
outlined.	
• Duct	Diameter	>1.5mm	
• LA:Ao	>1.5:1mm	
• End	diastolic	reversal	of	blood	
flow	in	the	aorta	
• “Poor	cardiac	function	in	
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additional	to	clinical	signs	of	
PDA”	
Kluckow	et	al	(2014)	(117)		 92	 Early	IV	INDO	vs	Placebo	 N/A	 • Duct	Diameter	>1.5mm	
Lago	et	al	(2014)	(118)		 112	 Bolus	IV	IBU	vs	Continuous	IV	IBU	 N/A	 • Duct	Diameter	>1.4mm/kg	
• Unrestrictive	pulsatile	
transductal	flow	(PDA	maximum	
velocity	<2.0m/s)	
• LA:Ao	>1.4:1	
• Mean	and	end	diastolic	flow	
velocity	in	the	LPA	>0.42	and	
>0.20	m/s	respectively	
• LVO/SVC	flow	ratio	>4	
Bagnoli	et	al	(2013)	(119)	 134	 IV	IBU	vs	Placebo	 N/A	 • LA:Ao	>1.4:1	
• LV:Ao	>2.1:1	
• Duct	Diameter	>1.5mm	
• Evidence	of	left-to-right	shunting	
• Diastolic	reversal	of	flow	in	the	
aorta	
Sosenko	et	al	(2012)	(120)	 105	 Early	IV	IBU	vs	Placebo	 • Signs	of	PDA	(not	specified)	plus	
evidence	of	pulmonary	
haemorrhage	(bloody	secretions	
from	ETT)	
• Signs	of	PDA	(not	specified)	plus	
cardiomegaly	and	pulmonary	
oedema	on	CXR	plus	
hypotension	requiring	inotropes	
or	respiratory	failure	(defined	as	
at	least	two	of:	FIO2	>0.5,	
intermittent	mandatory	
ventilation	>40	breaths/min,	
peak	inspiratory	pressure	>20cm	
H2O,	high	frequency	ventilation	
N/A	
[55]	
	
with	Paw	>13	and	FIO2	>0.5	[for	
>8h])	
Erdeve	et	al	(2012)	(121)	 80	 Oral	IBU	vs	IV	IBU	 • Clinical	signs	of	PDA	not	
outlined.	
• Duct	Diameter	>1.5mm	
• LA:Ao	>1.5:1	
• Left-to-right	Shunting	
• End-diastolic	reversal	of	aortic	
blood	flow	
• “Poor	cardiac	function	in	
addition	to	the	signs	of	PDA”	
Dani	et	al	(2012)	(122)	 70	 High-dose	IV	IBU	vs	Standard-dose	IV	
IBU	
N/A	 • Evidence	of	left-to-right	shunting	
• LA:Ao	>1.3:1	
• Duct	Diameter	>1.5mm	
Cheng	et	al	(2012)	(123)	 30	 IV	INDO	vs	Oral	IBU	 N/A	 • LA:Ao	>1.4:1	
• Duct	Diameter	>1.5mm	
Gokmen	et	al	(2011)	(124)	 102	 IV	IBU	vs	Oral	IBU	 • Clinical	signs	of	PDA	not	
outlined.	
• Duct	Diameter	>1.5mm	
• Evidence	of	left-to-right	shunting	
• LA:Ao	>1.5:1	
• End-Diastolic	reversal	of	aortic	
blood	flow	
• “Poor	cardiac	function	in	
addition	to	signs	of	PDA”	
Aranda	et	al	(2009)	(125)	 136	 IV	IBU	vs	Placebo	 N/A	 • LA:Ao	>1.4:1	
• LV:Ao	>2.1:1	
• Duct	Diameter	>1.5mm	
Sangtawesin	et	al	(2008)	
(126)	
62	 Oral	IBU	vs	Placebo	 • Bounding	pulses	
• Pulse	pressure	>35mmHg	
• Hyperactive	precordium	
• Tachycardia	(HR	>170bpm)	
• Hepatomegaly	
• Cardiomegaly	
• Increased	pulmonary	vasculature	
on	CXR	
• Left-to-right/bidirectional	
shunting	of	blood	
• LA:Ao	>1.4:1	
• Duct	Diameter	>1.5mm	
[56]	
	
Cherif	et	al	(2008)	(127)	 64	 Oral	IBU	vs	IV	IBU	 N/A	 • Disturbed	diastolic	flow	in	PA/PT	
• Diastolic	backflow	in	aorta	
• Diastolic	backflow	in	medium	
cerebral	artery/superior	
mesenteric	artery/renal	arteries	
• LA:Ao	>1.6:1	
Su	et	al	(2008)	(128)	 119	 IV	IBU	vs	IV	INDO	 N/A	 • Evidence	of	left-to-right	shunting	
(pulsatile/growing	pattern	only)	
Salama	et	al	(2008)	(129)	 41	 IV	INDO	vs	Oral	IBU	 N/A	 • Duct	Diameter	>1.5mm	
Jegatheesan	et	al	
(2008)(130)	
105	 Low	dose	INDO	vs	High	dose	INDO	 N/A	 • Evidence	of	Left-to-Right	flow	
Fakhraee	et	al	(2007)	(131)	 36	 Oral	INDO	vs	Oral	IBU	 N/A	
	
• Evidence	of	left-to-right	shunting	
• Duct	Diameter	>1.5mm	
• LA:Ao	>1.6:1	
• Severe	diastolic	backflow	in	
PT/Aorta	
Sangtawesin	et	al	(2006)	
(132)	
42	 Oral	IBU	vs	Placebo	 N/A	 • LA:Ao	>1.4:1	
• Duct	Diameter	>1.5mm	
Gimeno	Navarro	et	al	(2005)	
(133)	
47	 IV	INDO	vs	IV	IBU	 N/A	 • Presence	of	a	dominant	
aortopulmonary	shunt	
• Pulmonary	Trunk/DAP	ratio	>0.3	
• Inversion	of	the	Diastolic	Flow	in	
the	Abdominal	Aorta	
Gournay	et	al	(2004)	(134)	 131	 IV	IBU	vs	Placebo	 N/A	 • LA:Ao	>1.48:1	
• Retrograde/Absent	diastolic	flow	
in	the	cerebral	anterior	
artery/descending	thoracic	aorta	
• Pulsatile	flow	in	the	DA	
• Diastolic	flow	velocity	in	PA	
>20m/s	
Su	et	al	(2003)	(135)	 63	 IV	IBU	vs	IV	INDO	 N/A	 • Evidence	of	left-to-right	shunting	
• LA:Ao	>1.3:1	
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• Duct	Diameter	>1.5mm	
Lee	et	al	(2003)	(136)	 140	 Conventional-dose	IV	INDO	vs	
Prolonged	low-dose	IV	INDO	
• Systolic	Murmur	
• Hyperactive	precordium	
• Wide	Pulse	pressure	(diastolic	
pressure	less	than	half	systolic)	
• Hypotension	
• Apnoea	
• Rising	CO2	
• Duct	Diameter	>1.5mm	
Lago	et	al	(2002)	(137)	 175	 IV	INDO	vs	IV	IBU	 N/A	 • Disturbed	diastolic	flow	in	main	
PA	with	diastolic	backflow	in	the	
aorta	immediately	below	the	DA	
and	a	forward	flow	above	the	
ductal	insertion	
Supapannachart	et	al	
(2002)(138)	
18	 Oral	IBU	vs	Oral/IV	INDO	 • Systolic	murmur	at	left	upper	
parasternal	border;	
• Continuous	murmur	at	left	
upper	parasternal	border;	
• Active	precordium;	
• Bounding	pulse;	
• Wide	Pulse	Pressure	
(>35mmHg);	
• Tachycardia	(>170bpm);	
• Hepatomegaly;	
• CXR	showing	cardiomegaly	(CT	
ratio	>0.6)	or	increased	
pulmonary	vasculature	
N/A	
Dani	et	al	(2000)	(139)	 80	 Prophylactic	IV	IBU	vs	Post-
Echocardiography	IV	IBU	
N/A	 • LA:Ao	>1.3:1	
• Evidence	of	left-to-right	shunting	
• Duct	Diameter	>1.5mm	
Tammela	et	al	(1999)	(140)	 61	 Short-course	IV	INDO	vs	Long-course	
IV	INDO	
• Systolic	or	continuous	murmur	
at	LSE	
• Increased	precordial	impulse	
• Continuous	left-to-right	shunting	
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• Bounding	peripheral	pulses	
• Resting	tachycardia	
• Unexplained	deterioration	of	
respiratory	status	
• Increased	pulmonary	
markings/cardiomegaly/pulmon
ary	oedema	on	CXR	
Lai	et	al	(1990)(141)	 32	 Oral	INDO	vs	Placebo	 • Systolic	or	continuous	cardiac	
murmur;	
• Hyperactive	precordium;	
• Bounding	pulses;	
• Tachycardia;	
• Tachypnoea;	
• Hepatomegaly;	
• Cardiomegaly	with	pulmonary	
plethora	on	CXR	
• Used	echocardiography,	but	did	
not	outline	their	specific	criteria.	
Vogtmann	et	al	(1988)(142)	 41	 Oral	INDO	vs	Non-Treatment	 • Murmur;	
• Active	Precordium;	
• Bounding	Pulses;	
• Hypotension;	
• Tachycardia;	
• Evidence	of	Respiratory	
Decompensation;	
• Systolic	Time	Intervals	(PEP/LVET	
<0.3)	
Gersony	et	al	(1983)	(143)	 421	 UMT	+	IV	INDO	vs	UMT	+	IV	INDO	as	
Rescue	Therapy	vs	UMT	+	R	
escue	Surgery	
• Continuous	murmur	
• Need	for	ventilator	support	at	at	
least	48h	
• Hyperactive	precordium	
• Increased	pulse	pressure	
• Bounding	pulses	
• Tachycardia	(HR	>170bpm)	
• Tachypnoea	(RR	>70)	
• Hepatomegaly	
• LA:Ao	>1.15:1	
[59]	
	
Rudd	et	al	(1983)(144)	 30	 Oral	INDO	vs	Placebo	 • Full	pulses	in	the	absence	of	
anaemia;	
• Active	cardiac	impulse;	
• Loud	Pulmonary	component	of	
2nd	Heart	Sound;	
• Cardiomegaly	on	CXR;	
• Pleonaemia	
• LA:Ao	>1.2:1	
Monset-Couchard	et	al	
(1983)	(145)	
24	 IV	INDO	vs	Non-Treatment	 • Precordial	Shock;	
• Increased	Peripheral	Pulsatility;	
• Systolic	Murmur;	
• Evaluation	of	Heart	Rate;	
• Assessment	of	hepatic	volume;	
• Assessment	of	pulmonary	
vascularisation;	
• Cardiac	Volume;	
• Electrocardiogram	(evidence	of	
pressure	overload);	
• LA:Ao	(significant	value	not	
stated)	
Yanagi	et	al	(1981)(146)	 39	 Oral	INDO	vs	Placebo	 • Continuous	Ventilator	Support	 • LA:Ao	>1.3:1	
Table	3	Summary	of	Trials	included	for	Review:	IV	=	intravenous;	PARA	=	Paracetamol;	IBU	=	Ibuprofen;	INDO	=	Indomethacin;	LA:Ao	=	Left	Atrium:Aortic	Root	Ratio;	LPA	=	Left	
Pulmonary	Artery;	BP	=	Blood	Pressure;	PDA	=	Patent	Ductus	Arteriosus;	LVO/SVC	=	Left	Ventricular	Output/Superior	Vena	Cava;	LV:Ao	=	Left	Ventricle:Aortic	Root	Ratio;	ETT	=	
Endotracheal	Tube;	CXR	=	Chest	X-ray;	FiO2	=	Fraction	of	Inspired	Oxygen;	HR	=	Heart	Rate;	PA	=	Pulmonary	Artery;	PT	=	Pulmonary	Trunk;	DAP	=	Diameter	of	Pulmonary	Trunk;	DA	=	
Ductus	Arteriosus;	CT	ratio	=	cardiothoracic	ratio;	LSE	=	Left	Sternal	Edge;	PEP	=	pre-ejection	period;	LVET	=	Left	Ventricular	Ejection	Time;	UMT	=	Usual	Medical	Therapy	(in	the	case	
of	Gersony	et	al(143),	UMT	=	fluid	restriction,	diuretics	and	digoxin);	RR	=	Respiratory	Rate
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Clinical	Markers	of	Haemodynamic	Significance:	
Of	the	40	trials	reviewed,	eighteen	(45.0%)	used	clinical	signs	as	part	of	their	definition	for	hs-
PDA	(number	of	participants	=	1596	[42.9%]).	Sixteen	trials	used	a	combination	of	clinical	and	
echocardiographic	markers	to	define	haemodynamic	significance	(number	of	participants	=	1473	
[39.6%])	and	two	used	clinical	features	alone	(number	of	participants	=	123	[3.3%]).	The	three	
most	common	clinical	markers	were	hyperdynamic	precordium,	bounding	peripheral	pulses	and	
heart	murmur.	
Four	of	the	trials	that	used	clinical	markers	as	part	of	their	definition	did	not	provide	specific	
details	of	the	clinical	signs	used	for	diagnosis	of	hs-PDA.	Three	of	the	four	studies	(116,	121,	124)	
used	unspecified	clinical	features	of	PDA	in	conjunction	with	“poor	cardiac	function”	as	part	of	
their	definition	for	haemodynamic	significance.	Another	(120)	used	unspecified	clinical	signs	of	
PDA	along	with	a	number	of	clinical	findings	indicative	of	haemodynamic	compromise	and	
pulmonary	haemorrhage	to	define	hs-PDA.		
The	most	commonly	used	clinical	markers	of	haemodynamic	significance	used	by	the	remaining	
14	studies,	plus	the	signs	of	haemodynamic	compromise	used	by	(120),	are	summarised	in	Table	
4	(total	number	of	participants	across	15	trials	specifically	outlining	clinical	features	of	
haemodynamic	significance	=	1324).	One	study	(108)	used	a	previously	described	cardiovascular	
dysfunction	score	as	clinical	markers	of	haemodynamic	significance.	This	scoring	system	includes	
evaluation	of	heart	rate,	quality	of	peripheral	pulsation,	degree	of	precordial	pulsation,	duration	
of	murmur	and	cardiothoracic	ratio	(147).	These	values	will	thus	be	considered	individually	as	
part	of	Table	4.	
Echocardiographic	Markers	of	Haemodynamic	Significance:	
Of	the	40	trials	reviewed,	38	(95.0%)	used	echocardiographic	markers	as	part	of	their	definition	
for	hs-PDA	(number	of	participants	=	3600	[96.7%]).	Sixteen	trials	used	a	combination	of	
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echocardiographic	and	clinical	biomarkers	to	define	haemodynamic	significance	(number	of	
participants	=	1473	[39.2%]),	whereas	22	used	echocardiographic	markers	alone	(number	of	
participants	=	2127	[57.5%]).	The	echocardiographic	parameters	used	in	the	assessment	of	
haemodynamic	significance	can	be	seen	in	Table	4.	The	echocardiographic	parameters	of	“poor	
cardiac	function”	(116,	121,	124)	or	“evidence	of	reverse	diastolic	flow”		(110)	are	not	included	
due	to	lack	of	specificity.	Lai	TH	et	al	(141)	used	echocardiography	to	confirm	the	presence	of	
symptomatic	PDA	but	did	not	specify	the	individual	parameters	and	hence	is	not	included	in	the	
echocardiographic	markers	section	of	Table	4	(number	of	studies	included	=	37;	number	of	
participants	=	3568).	
Left	Atrium:Aortic	Root	Ratio	as	an	Echocardiographic	Marker	of	Haemodynamic	Significance:	
LA:Ao	was	the	single	most	commonly	used	marker	of	haemodynamic	significance	(Table	3),	with	
studies	including	2723	neonates	utilising	it.	There	was	wide	variation	in	the	threshold	used	to	
define	a	hs-PDA	(>1.15:1	-	>1.6:1).	Table	5	outlines	the	frequency	of	each	LA:Ao	threshold	value	
used,	and	the	proportion	of	neonates	from	the	entire	study	population	this	would	have	
captured.	
Relationship	between	Echocardiographic	Markers	of	Haemodynamic	Significance:	
LA:Ao,	duct	diameter,	and	evidence	of	shunting	were	the	three	most	commonly	used	
echocardiographic	parameters.	At	least	one	of	the	three	was	used	in	35	out	of	37	[94.6%;	
number	of	participants	=	3352	(93.9%)]	studies	which	used	echocardiography	for	the	definition	
of	hs-PDA	(Figure	6).	Despite	almost	95%	of	all	patients	having	one	of	these	parameters	used	in	
the	determination	of	hs-PDA,	only	1129/3352	(33.7%)	had	all	of	them	measured	simultaneously.	
Repeatability	of	Echocardiographic	Markers	of	Haemodynamic	Significance:	
An	overview	of	the	literature	reviewing	repeatability	of	echocardiographic	parameters	is	
presented	in	Table	2.	
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Clinical	Marker:	 Number	of	
Studies	(%):	
Number	of	
Participants	(%)	
Echocardiographic	Marker:	 Number	of	Studies	
(%):	
Number	of	
Participants	(%):	
Hyperdynamic	Precordium	 11	(73.3%)	 1115	(84.2%)	 LA:Ao	 28	(75.7%)	 2747	(77.0%)	
Bounding	Peripheral	Pulses	 10	(66.7%)	 975	(73.6%)	 Duct	Diameter	 24	(64.9%)	 2167	(60.7%)	
Murmur	 9	(60.0%)	 1023	(77.2%)	 Evidence	of	Left-to-
Right/Bidirectional	Shunting**	
19	(51.4%)	 1592	(44.6%)	
Cardiomegaly	 9	(60.0%)	 587	(44.3%)	 Reverse	End-Diastolic	Flow	in	the	
Aorta	
10	(27.0%)	 1159	(32.5%)	
Deterioration	of	Respiratory	Status*	 8	(53.3%)	 973	(73.5%)	 Disturbed	PA/PT	Flow	***	 7	(18.9%)	 905	(25.4%)	
Tachycardia	 8	(53.3%)	 897	(67.7%)	 Reverse	End-Diastolic	Flow	in	the	
Mesenteric	Artery	
2	(5.4%)	 364	(10.2%)	
Wide	Pulse	Pressure	 6	(40.0%)	 761	(57.5%)	 LV:Ao	 2	(5.4%)	 270	(7.6%)	
Increased	Pulmonary	Vasculature	on	
Chest	Radiograph	
6	(40.0%)	 290	(21.9%)	 Diastolic	Backflow	in	Cerebral	
Arteries	
2	(5.4%)	 195	(5.5%)	
Hepatomegaly	 5	(33.3%)	 581	(43.9%)	 LVO/SVC	Flow	Ratio	 1	(2.7%)	 112	(3.1%)	
Pulmonary	Oedema/Congestion	 4	(26.7%)	 301	(22.7%)	 Systolic	and	Diastolic	Pressure	
Gradients	
1	(2.7%)	 83	(2.3%)	
Tachypnoea	 2	(13.3%)	 453	(34.2%)	 Diastolic	Backflow	in	Renal	
Arteries	
1	(2.7%)	 64	(1.8%)	
Hypotension	 2	(13.3%)	 245	(18.5%)	 Pulmonary	Trunk/DAP	Ratio	 1	(2.7%)	 47	(1.3%)	
Apnoea	 2	(13.3%)	 212	(16.0%)	 PEP/LVET	 1	(2.7%)	 41	(1.1%)	
Evidence	of	Pulmonary	Haemorrhage	 1	(6.7%)	 105	(7.9%)	 	 	 	
Thrill	 1	(6.7%)	 72	(5.4%)	 	 	 	
Decreased	Systolic/Mean	Blood	
Pressure	
1	(6.7%)	 48	(3.6%)	 	 	 	
Loud	Pulmonary	Component	of	2nd	
Heart	Sound	
1	(6.7%)	 30	(2.3%)	 	 	 	
Table	4	Summary	of	clinical	and	echocardiographic	markers	of	haemodynamic	significance.	*Deterioration	of	Respiratory	Status	includes	rising	CO2,	increased	ventilator/oxygen	
dependence	and	respiratory	failure.	LA:Ao	=	Left	Atrium:Aortic	Root	Ratio;	PA	=	Pulmonary	artery;	PT	=	Pulmonary	Trunk;	LV:Ao	=	Left	Ventricle:Aortic	Root	Ratio;	LVO/SVC	=	Left	
Ventricular	Output/Superior	Vena	Cava;	DAP	=	Diameter	of	Pulmonary	Trunk;	PEP/LVET	=	pre-ejection	period/left	ventricular	ejection	time.	**includes	flow	patterns	(e.g.	
hypertensive,	pulsatile,	growing.	***includes	PA	backflow,	mean/end	diastolic	flow	velocity	in	LPA	and	disturbed	diastolic	backflow	in	PA
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LA:Ao	
Value:	
Frequency:	 Studies:	 Number	deemed	to	have	hs-PDA	
(%):	
>1.6:1	 3	 (107,	127,	131)	 400/2723	(14.7%)	
>1.5:1	 5	 (110,	114,	116,	121,	124)	 821/2723	(30.2%)	
>1.48:1	 1	 (148)	 952/2723	(35.0%)	
>1.4:1	 10	 (109,	111,	113,	115,	118,	119,	
123,	125,	126,	132)	
1766/2723	(64.9%)	
>1.3:1	 6	 (108,	112,	122,	135,	139,	146)	 2272/2723	(83.4%)	
>1.2:1	 1	 (144)	 2302/2723	(84.5%)	
>1.15:1	 1	 (143)	 2723/2723	(100%)	
Table	5	LA:Ao	as	an	echocardigraphic	marker;	one	study	(145)	used	LA:Ao	as	a	marker	of	hs-PDA	without	defining	a	
threshold	and	therefore	is	excluded	from	table	4.	
	
Figure	6	The	relationship	between	the	three	most	common	echocardiographic	markers	of	haemodynamic	
significance;	evidence	of	shunting	incorporates	evidence	of	left	to	right	shunting,	
flow/growing/pulsatile/hypertensive	patterns	and	presence	of	a	dominant	aortopulmonary	shunt.	
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3.4	Discussion	
Ideally	the	decision	to	intervene	in	a	neonate	with	a	PDA	should	be	based	on	the	
echocardiographic	documentation	of	a	significant	left-to-right	transductal	shunt,	with	
measurable	haemodynamic	effects,	leading	to	clinical	instability	(81).	This	approach	ensures	
those	with	haemodynamic	compromise	are	treated,	without	exposing	those	in	whom	
intervention	may	be	unnecessary	to	the	potentially	harmful	side	effects	of	treatment.	However,	
it	is	clear	from	this	systematic	review	that	RCTs	tend	to	use	inclusion	criteria	based	on	
echocardiographic	biomarkers	to	define	hs-PDA.	Less	than	half	of	studies	used	any	clinical	
markers	as	part	of	their	definition	for	a	haemodynamically	significant	PDA,	and	only	5%	used	
clinical	markers	alone.	The	use	of	clinical	markers	was	particularly	infrequent	in	studies	
published	from	2003-2015	(73.9%	[17/23]	used	echocardiography	alone).	However,	more	recent	
studies	(2016-date)	have	re-incorporated	clinical	markers	(42.9%	[3/7]	used	echocardiography	
alone).	
There	are	advantages	to	using	echocardiography,	including	the	non-invasive	nature	of	the	
investigation	as	well	as	its	reported	accuracy	in	diagnosing	PDA	compared	to	clinical	signs	(87,	
89).	However,	issues	surrounding	repeatability	remain	a	potential	shortcoming	for	
echocardiography.	Our	review	can	only	identify	assessment	of	inter-observer	variability	for	two	
of	the	most	commonly-used	echocardiographic	parameters	(LA:Ao	and	duct	diameter	–Table	2).	
Moreover,	the	use	of	LA:Ao	as	an	inclusion	criterion	in	RCTs	and	its	ideal	threshold	depends	on	
the	timing	of	the	echocardiography	as	PDA	shunting	causes	several	neuro-hormonal	adaptations	
which	result	in	progressively	increased	preload	and	stretching	of	the	LA	during	postnatal	
maturation	(37,	38).	It	is	thought	the	development	of	a	standardised	and	structured	neonatal	
echocardiography	training	curriculum	might	help	reduce	inter-	and	intra-observer	variation	in	
echocardiographic	measurements.		
The	range	of	criteria	used	and	cut	off	points	in	PDA	RCTs	has	previously	been	noted	in	2011	
(149).	The	current	review	contains	additional	details	about	the	specific	criteria	used,	the	
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combinations	chosen,	and	repeatability	of	echocardiographic	makers.	In	addition,	since	the	2011	
review	an	additional	18	RCTs	have	been	published	containing	1816	babies,	which	are	included	in	
our	systematic	review.	We	believe	there	is	an	ethical	requirement	to	determine	the	most	
clinically-useful	markers	of	hsPDA	to	ensure	neonates	in	these	studies	are	optimally	managed.		
While	there	is	no	consensus	for	either	the	definition	of	hs-PDA	or	the	strength	of	the	association	
between	hs-PDA	and	the	associated	adverse	outcomes	(IVH,	NEC,	BPD)	(150,	151),	
improvements	could	be	made	through	the	formation	of	a	core	data	set	for	PDA	research.	The	
formation	of	a	core	data	set	would	reduce	the	wide	variation	of	parameters	reported	in	
literature.	Ensuring	research	reports	on	the	same	parameters	would	have	significant	benefits	for	
future	meta-analyses,	allowing	more	rigorous	comparisons	between	markers	of	haemodynamic	
significance.	If	agreement	on	how	to	utilise	the	current	selection	of	clinical	and	
echocardiographic	criteria	cannot	be	reached,	it	may	be	that	novel	biomarkers	need	to	be	
developed	and	validated.	
A	limitation	of	this	review	is	that	several	studies	conducted	by	the	same	authors	used	the	same	
or	similar	definitions	of	haemodynamic	significance.	Individual	parameters	may	therefore	be	
over-represented	in	our	review	due	to	the	volume	of	published	material	from	individual	groups.	
Furthermore,	when	comparing	the	number	of	participants	who	were	subject	to	measurement	of	
each	parameter,	the	presence	of	large	studies	may	have	skewed	our	results.	
4.4	Conclusion	
There	 is	 wide	 variation	 in	 clinical	 and	 echocardiographic	 parameters	 used	 to	 define	
haemodynamic	 significance	 in	 published	 literature.	 Development	 of	 a	 core	 data	 set	 for	 PDA	
would	help	improve	the	quality	of	future	PDA	research.		
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Chapter	4:	Factors	affecting	the	measurement	of	Pulse	Wave	
Velocity	and	Phase	Difference	in	the	first	three	days	of	Neonatal	
Life	
4.1	Introduction	
The	early	postnatal	period	is	a	particularly	challenging	time	for	any	newborn.	In	both	term	and	
preterm	 neonates,	 a	 number	 of	 changes	 occur	 to	 help	 them	 adapt	 to	 life	 outside	 the	womb.	
These	 include	 cardiorespiratory	 adaptations	 as	 well	 as	 alterations	 to	 energy	 metabolism	 and	
temperature	control.	Those	born	prematurely	may	struggle	to	adapt	to	life	outside	of	the	womb	
due	 to	underdevelopment	of	organ	 systems,	 traumatic	birth	 conditions	or	 illnesses	 associated	
with	 prematurity	 such	 as	 PDA,	 sepsis	 and	 RDS.	 Furthermore,	 neonates	 born	 prematurely	 are	
more	likely	to	be	treated	with	medications	such	as	inotropes	or	vasopressors	in	early	life	to	help	
them	 survive.	 It	 is	 therefore	 believed	 that	 there	 are	 a	 number	 of	 variables	 which	 should	 be	
assessed	 when	 investigating	 a	 potential	 haemodynamic	 biomarker	 to	 be	 used	 in	 the	 early	
neonatal	period.	
PWV	has	long	been	validated	as	a	useful	method	of	measuring	haemodynamic	function	in	adults,	
however,	investigations	into	its	use	in	paediatric	populations	is	limited	and	research	into	its	use	
in	neonatal	populations	 is	even	more	uncommon.	There	is	also	limited	literature	reviewing	the	
expression	 of	 PWV	 in	 terms	 of	 phase	 difference.	 As	 a	 result,	 in	 order	 for	 PWV	 or	 phase	
difference	 to	be	 considered	as	potential	 novel	 biomarkers,	 it	 is	 crucial	 that	descriptive	data	 is	
collected	to	help	 identify	what	can	be	considered	as	a	“normal”	value,	as	well	as	any	potential	
variables	which	may	affect	its	measurement.			
Since	PWV	and	phase	difference	are	measurements	of	haemodynamic	function,	we	believe	it	is	
important	 to	assess	 the	 impact	of	 factors	which	may	affect	vascular	 tone	or	cardiac	output	on	
their	measurement.	Furthermore,	due	to	the	rapid	development	of	the	neonate	in	early	life,	it	is	
also	important	to	consider	factors	such	as	age	(days),	postnatal	age	(hours),	birth	weight	(BW),	
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GA	and	multiple	pregnancies	on	their	measurement.	 It	has	already	been	shown	that	 there	are	
significant	differences	 in	 the	measurements	of	PWV	 in	different	paediatric	age	groups	 ranging	
from	6	 to	18	years	 (152),	 so	we	hypothesise	 that	 their	measurement	 in	neonates	may	also	be	
affected	by	age.	Obtaining	baseline	information	on	values	measured	in	this	population	and	the	
variables	causing	alterations	in	their	measurement	is	a	key	first	step	in	their	validation	as	clinical	
biomarkers	 to	 be	 used	 in	 neonatology.	 As	 outlined	 by	Kearns	 et	 al,	 	 it	 is	 crucial	 to	 assess	 the	
impact	of	 the	growth	and	development	of	 the	child	before	a	biomarker	can	be	considered	 for	
implementation	 in	 clinical	 practice	 (58).	 The	 aim	 of	 this	 chapter	 is	 therefore	 to	 improve	 our	
understanding	 of	 the	 demographic	 and	 post-natal	 factors	 affecting	 the	measurement	 of	 PWV	
and	 phase	 difference	 in	 the	 first	 three	 days	 of	 life,	 in	 the	 hope	 of	 beginning	 a	 process	 of	
validation	for	these	biomarkers.	
4.2	Methods	
4.2.1	Study	Design	
A	prospective	observational	study	was	conducted	at	Liverpool	Women’s	Hospital.	All	neonates	
who	had	a	UAC	fitted	within	the	first	three	days	of	life	were	eligible	for	recruitment	in	the	study.	
A	demographic	profile	 (consisting	of	 routinely	 collected	data	only)	was	 collected	 from	existing	
clinical	 records.	 This	 included	 maternal	 data	 as	 well	 as	 neonatal	 data	 relating	 to	 age	 (days),	
postnatal	age	(hours),	GA,	BW	and	whether	the	participant	was	a	twin	or	higher	order	multiple	
pregnancy.	Data	was	also	collected	on	vital	signs	and	arterial	waveforms	(allowing	calculation	of	
PWV	 and	 phase	 difference),	 dose	 and	 rate	 of	 infusion	 of	 inotropes,	 and	 additional	
comorbidities/medications	 that	 were	 deemed	 to	 affect	 the	 patient’s	 haemodynamics	 (sepsis,	
IVH	and	NSAID,	caffeine	or	surfactant	administration).		
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All	 clinical	 data	 collected	 as	 part	 of	 this	 study	was	 in	 line	with	 standard	 care	 at	 the	 Liverpool	
Women’s	 Hospital.	 No	 investigations/procedures	were	 performed	 in	 addition	 to	 the	 standard	
care	patients	receive	whilst	placed	in	the	NICU.	
4.2.2	Inclusion	and	Exclusion	Criteria	
Inclusion	Criteria:	
Ø Neonate	admitted	to	Liverpool	Women’s	Hospital	Neonatal	Unit;	
Ø Age	1-3	days;	
Ø UAC	placed	in	situ	for	clinical	care	within	3	days	of	birth;	
Ø Transducer	capable	of	being	fitted	to	UAC	without	additional	intervention/disruption	to	
the	patient.	
Exclusion	criteria:	
Ø Age	>3	days;	
Ø UAC	not	sited	or	not	capable	of	being	fitted	to	transducer;	
Ø Survival	of	baby	expected	to	be	<24	hours;	
Ø Additional	 congenital	 heart	 disease	 or	 conditions	 expected	 to	 alter	 cardiovascular	
function	 (ventricular	 septal	 defect,	 atrioventricular	 septal	 defect,	 tetralogy	 of	 Fallot,	
transposition	 of	 great	 vessels,	 truncus	 arteriosus,	 coarctation	 of	 the	 aorta,	 congenital	
valvular	disease,	and	congenital	hydrops).	
Ø Chromosomal	abnormalities.	
Ø Considered	unsuitable	for	recruitment	by	nursing	staff	and	Consultant	Neonatologist	at	
Liverpool	Women’s	Hospital.	
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4.2.3	Study	Outcomes	
The	 primary	 outcome	 of	 this	 study	 was	 to	 collect	 descriptive	 data	 about	 PWV	 and	 phase	
difference	in	the	neonatal	period.	
The	 secondary	 outcome	 of	 this	 study	was	 to	 examine	 relationships	 between	 PWV	 and	 phase	
difference	 in	 relation	 to	demographic	data	 (age,	postnatal	 age,	GA,	BW,	multiple	pregnancies)	
and	 other	 post-natal	 events	 deemed	 likely	 to	 have	 an	 impact	 on	 neonatal	 haemodynamics	
(sepsis,	 intraventricular	 haemorrhage	 and	 inotrope,	 NSAID,	 caffeine	 or	 surfactant	
administration).	
4.2.4	Study	Procedures	
Ethical	Approval:	
Proportionate	 review	was	 sought	 for	 this	 research	 project	 due	 to	 the	 non-interventional	 and	
pseudo-anonymised	nature	of	data	collection.	HRA	approval	and	a	favourable	opinion	from	the	
North-East	 Tyne	 and	 Wear	 Research	 Ethics	 Committee	 was	 obtained	 before	 initiation	 of	 the	
study	(REC	Reference:	18/NE/0058).	
Recruitment:	
All	patients	admitted	to	the	unit	who	had	a	UAC	 in	situ	within	the	first	 three	days	of	 life	were	
included	 in	this	study	provided	no	exclusion	criteria	were	met.	Clinical	data	that	 is	collected	 in	
accordance	to	the	standard	care	protocol	was	anonymised	and	analysed	in	accordance	with	the	
aims	 of	 the	 study.	 Based	 on	 the	 typical	 patient	 population	 that	 is	 observed	 at	 the	 Liverpool	
Women’s	Hospital,	we	 believed	 it	was	 reasonable	 to	 recruit	 approximately	 30	 patients	 in	 this	
study.	Posters	were	placed	in	the	neonatal	unit	to	make	staff	aware	of	eligible	participants	in	the	
hope	this	would	improve	participant	recruitment.	Parents	were	able	to	opt	out	of	the	study.	
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Consent:	
All	 clinical	 data	 used	 as	 part	 of	 this	 prospective	 observational	 study	 is	 data	 that	 was	 already	
collected	 as	 part	 of	 each	 patient’s	 routine	 clinical	 care	 at	 the	 Liverpool	 Women’s	 Hospital.	
Additional	 information	 on	 PWV	 and	 phase	 difference	 was	 synthesised	 without	 further	
intervention	 to	 the	 patient.	 These	 values	 were	 calculated	 based	 on	 the	 routine	 clinical	 data	
collected.	 Each	 participant	was	 assigned	 a	 study	 number	 and	 no	 identifiable	 information	was	
linked	to	 the	data	 that	 is	collected.	Based	on	the	 fact	 this	study	was	performed	using	pseudo-
anonymised	data	that	requires	no	alteration	to	patient	care,	parental	consent	was	not	sought	for	
this	study.	
If	parents	who	became	aware	of	 the	 study	 (e.g.	 seeing	equipment	being	added	 to	 the	patient	
monitors	or	seeing	study	posters	erected	on	the	ward)	wanted	more	information	on	the	details	
of	the	study,	an	information	leaflet	would	be	made	available	on	request.	The	leaflet,	along	with	
the	 aforementioned	 ward	 posters	 and	 verbal	 explanations	 provided	 by	 clinical	 staff	 and	 the	
research	team,	would	give	parents	the	ability	to	opt	out	of	the	study.	
Data	Collection:	
Demographic	 data	 on	maternal	 and	 neonatal	 characteristics,	 as	 well	 as	 data	 on	management	
whilst	 in	 the	 NICU	 was	 collected	 from	 patient	 records	 via	 the	 Liverpool	 Women’s	 Hospital	
MediTech	and	Badger	systems.	
PWV	data	collection	would	occur	on	days	1-3	of	life	where	an	infant	has	a	UAC	in	situ	as	part	of	
the	routine	pathway	of	clinical	care.	Days	of	life	were	calculated	according	to	the	ward	policy	on	
the	beginning	of	day	1	of	life.	Neonates	are	considered	day	1	of	life	for	the	first	24	hours,	day	2	
of	 life	 from	24-48	hours	etc.	 If	 a	baby	had	a	UAC	 fitted	on	day	2	 (or	3),	 a	 reduced	number	of	
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day’s	data	was	collected.	Also,	 if	 a	UAC	was	 removed	or	 stopped	 functioning	prior	 to	day	3,	a	
reduced	number	of	day’s	data	was	collected.	
The	data	was	collected	from	the	routine	monitoring	undertaken	on	the	baby	and	will	be	stored	
on	the	Liverpool	Women’s	Trust	system.	Access	 to	 raw	data	on	this	system	was	 limited	to	 the	
named	 study	 team.	The	 collection	and	 storage	of	 this	 information	was	password	protected	 to	
ensure	security	of	identifiable	information.	Prior	to	statistical	analysis,	all	data	was	anonymised	
and	transferred	to	a	University	of	Liverpool	computer	based	shared	drive	to	allow	all	members	
of	the	research	team	to	have	access	to	the	relevant	information	without	compromising	patient	
confidentiality.	
Invasive	Blood	Pressure	Monitoring:	
Continuous	invasive	BP	was	monitored	via	a	UAC	(3.5	Fr)	that	was	inserted	soon	after	birth.	The	
catheters	are	typically	positioned	between	the	sixth	and	ninth	thoracic	vertebra.	The	catheter	is	
connected	to	the	electronic	transducer	via	a	38	cm	extension	made	from	rigid	plastic.		
Catheter	position	is	confirmed	with	radiography.	The	aortic	valve	is	radio-translucent	and	there	
is	no	clear	 landmark	to	 identify	 it.	The	relation	of	 the	aortic	valve	to	vertebral	 level	varies	and	
the	 average	position,	 according	 to	 Eycleshymer	 and	 Schoemaker,	 is	 at	 the	 level	 of	 the	middle	
third	of	the	seventh	thoracic	vertebra	(153).	There	are	no	data	for	preterm	babies	and	for	this	
reason	 we	 reviewed	 CT	 scans	 from	 term	 infants	 with	 cardiac	 conditions	 and	 found	 that	 the	
relation	of	the	aortic	valve	to	the	vertebral	level	varied	greatly,	but	the	average	was	found	to	be	
around	 the	 6th	 thoracic	 vertebra.	 The	 distance	 of	 the	 catheter	 tip	 from	 the	 aortic	 valve	 was	
estimated	using	PACS	software.	The	location	of	the	aortic	valve	was	assumed	to	be	at	the	level	
of	 T6.	 Anatomical	 landmarks	 such	 as	 the	 carina	were	 used	where	 possible	 to	 account	 for	 the	
arch	of	the	aorta.	
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All	 possible	 steps	were	 taken	 to	 ensure	 the	 collection	of	 quality	 data.	 The	UACs	 and	 the	data	
being	displayed	on	the	monitor	were	assessed	by	a	member	of	the	research	team	prior	to	data	
collection.	Ultimately,	 the	decision	 to	 collect	data	was	at	 the	discretion	of	 the	member	of	 the	
clinical	 care/research	 team	who	was	 collecting	 it.	 The	 assessment	 of	 the	 data	was	 qualitative	
and	included	assessment	of	the	following:	
Ø Pulse	pressure:	normal	pulse	pressure	for	preterm	infants	is	approximately	15-25mmHg	
(154).	A	narrow	pulse	pressure	may	be	seen	if	the	UAC	is	blocked;	
Ø Arterial	 waveform:	 the	 arterial	 trace	 was	 assessed	 for	 the	 presence	 of	 a	 normal	
waveform	 and	 the	 absence	 of	 dampening	 (the	 absorption	 of	 energy	 within	 the	
oscillating	 system	 resulting	 in	 artificial	 reduction	 in	 the	 amplitude	 of	 the	 arterial	
waveform)	 (155).	 Although	 the	 presence	 of	 a	 dichrotic	 notch	 is	 deemed	 normal,	 the	
absence	of	a	clearly	defined	single	peak	in	such	waveforms	eliminates	the	possibility	for	
PWV/phase	difference	analysis.	Arterial	waveforms	were	also	therefore	assessed	for	the	
presence	of	a	dichrotic	notch;	
Ø Appearance	of	UAC:	visual	assessment	of	 the	UAC	 (e.g.	checking	 for	air	bubbles	 in	 the	
tubing	between	the	UAC	and	the	blood	pressure	transducer);	
Ø Transducer	 location:	ensuring	 the	blood	pressure	 transducer	 is	 situated	at	 the	 level	of	
the	patient’s	heart.	
The	data	collection	software	allowed	review	of	the	waveform	data	that	had	been	collected.	This	
acted	as	an	aid	in	the	identification	of	“dampened”	signals	which	occur	when	the	UAC	becomes	
blocked.	This	was	used	to	ensure	the	collection	of	quality	data.	Based	on	the	data	collected	we	
can	 therefore	 classify	 the	 quality	 and	 usefulness	 of	 the	 arterial	 waveforms	 as	 “adequate”,	
“suboptimal”	 (inadequate	 for	 analysis	but	 adequate	 for	patient	monitoring,	 e.g.	 presence	of	 a	
significant	dichrotic	notch),	or	“inadequate”	(e.g.	significantly	dampened	signal).	
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Pulse	Wave	Velocity	and	Phase	Difference:	
The	PWV	and	phase	difference	were	calculated	by	combining	 the	ECG	and	peak	systolic	blood	
pressure	waveform	collected	by	the	IxTrend	software®	(Ixellence	GmbH,	Wildau,	Germany).	The	
time	difference	between	 the	R	wave	of	 the	ECG	waveform	and	 the	peak	of	 the	 systolic	blood	
pressure	 waveform	 was	 calculated	 using	 the	 MATLAB	 software	 and	 expressed	 as	 PWV	 and	
phase,	i.e.	the	proportion	of	one	cardiac	cycle	(Figure	7).	This	data	was	collected	by	connecting	
the	patient’s	monitor	(which	is	already	receiving	information	via	the	transducer	attached	to	the	
patient’s	UAC)	to	a	computer	with	the	appropriate	software	installed.	This	was	achieved	by	the	
insertion	 of	 a	 Bluetooth	 device	 into	 the	 back	 of	 the	 patient’s	monitor	 and	 the	 insertion	 of	 a	
paired	 dongle	 into	 the	 researcher’s	 computer.	 Data	 was	 therefore	 collected	 without	 any	
additional	disruption	to	the	infant.	We	aimed	to	collect	data	for	a	minimum	of	30	minutes	a	day	
for	the	first	three	days	of	life	for	those	included	in	the	study.	This	provided	baseline	information	
on	the	variation	of	PWV/phase	difference	in	early	life.	This	is	the	data	that	would	be	compared	
to	the	variables	stated	above	to	better	understand	the	characteristics	of	these	biomarkers	in	the	
neonate.		
4.3	Results	
A	 total	 of	 32	 UACs	 were	 inserted	 during	 the	 data	 collection	 period	 with	 14	 patients	 being	
recruited	for	inclusion	in	the	study.	A	total	of	3	patients	were	subsequently	excluded	due	to	data	
being	 deemed	 unsuitable	 for	 analysis.	 A	 total	 of	 16	 days’	 worth	 of	 data	 collection	 across	 11	
participants	was	therefore	used	for	analysis.	The	reasons	for	exclusion	for	the	other	18	patients	
are	outlined	in	Figure	8.		
4.3.1	Analysis	of	Arterial	Waveform	Morphology	
A	 total	 of	 seven	 days’	 worth	 of	 data	 was	 deemed	 unsuitable	 for	 PWV/phase	 difference	
calculation	due	 to	 suboptimal	 arterial	blood	pressure	waveforms.	 In	order	 for	 the	appropriate	
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analysis	to	be	carried	out,	a	single	clear	peak	of	the	arterial	waveform	must	be	identified.	In	the	
excluded	cases,	the	arterial	waveform	was	considered	either	too	“damp”,	or	the	presence	of	a	
significant	dichrotic	notch	meant	that	analysis	could	not	be	conducted.	This	was	because	a	single	
clear	peak	could	not	be	identified.	Examples	of	both	are	illustrated	in	Figure	9.	
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Figure	7	ECG	and	Arterial	Waveform	Analysis	for	PWV	calculation
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Number	of	UACs	inserted	
during	study	period	=	
32	
Number	initially	recruited	
for	involvement	in	study	=	
14	
Number	not	recruited	into	
study	=	
18	
Reason	for	non-recruitment:	
Comorbid	condition	deemed	to	cause	
significant	cardiovascular/haemodynamic	
instability	=	5	
Died	within	24	hours	of	UAC	insertion	=	1	
UAC	removed	shortly	after	insertion	
before	data	collection	could	occur	=	3	
Outside	of	Day	1-3	recruitment	period	=	2	
Patient	transferred	to	DGH	with	UAC	in	
situ	before	data	collection	could	occur	=	1	
Study	awaiting	non-substantial	
amendment	to	extend	data	collection	
period	preventing	recruitment	=	1	
Admitted	during	period	when	researcher	
was	not	present	on	the	unit	=	5	
Figure	8	Recruitment	Flowchart;	UAC	=	Umbilical	Arterial	Catheter;	DGH	=	District	General	Hospital.	
Number	of	
Participants	included	
in	study	=	
11	
Data	collected	
unsuitable	for	
analysis	=		
3	
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(a)	
(b)	
(c)	
Figure	9	Examples	of	Arterial	Waveform	Morphology:	(a)	-	an	example	of	an	adequate	waveform	extracted	from	the	data	collected	on	Baby	10	Day	2;	(b)	–	an	example	of	a	suboptimal	
waveform	exhibiting	a	dominant	dichrotic	notch	resulting	in	a	“double-peak”	phenomenon	extracted	from	the	data	collected	on	Baby	11	Day	1;	(c)	–	an	example	of	an	unusable	“dampened”	
waveform	extracted	from	the	data	collected	on	Baby	12	Day	1.	
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4.3.2	Results	–	Preterm	Neonates	
Of	 the	 11	 participants	 recruited	 as	 part	 of	 the	 study,	 9	 were	 preterm	 (GA	 <37	 weeks).	 The	
demographic	data	of	the	preterm	neonates	included	in	this	study	is	shown	in	Table	6.	The	initial	
measurement	data	noted	in	this	population	is	illustrated	in	Table	7.	
Relationship	between	Pulse	Wave	Velocity/Phase	Difference	and	Demographic	Variables:	
The	following	demographic	variables	were	assessed	for	their	 impact	upon	the	measurement	of	
PWV	and	Phase	Difference:	
Ø Day	of	life	(Figure	10);	
Ø Sex	(Figure	11).	
Ø Birthweight	(Figure	12);	
Ø Gestational	Age	at	Birth	(Figure	13);	
Ø Corrected	Gestational	Age	(Figure	14);	
Ø Post-Natal	Age	(Figure	15);	
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Total	Participants	 9	
Days	of	Data	Collection:	
Total	
Day	1	
Day	2	
Day	3	
	
16	
4	
7	
5	
Sex:	
Male	
Female	
	
6	
3	
Birthweight	(g)*	 930	(820	–	1020)	
Gestational	Age	at	Birth	(weeks)*	 26.29	(25.43	–	27.00)	
Corrected	Gestational	Age	(weeks)*	 26.50	(24.86	–	26.78)	
Post-Natal	Age	(hours)*	 34.5	(22.75	–	49.75)	
Maternal	Age	(years)*	 25	(22	–	31)	
Antenatal	Steroid	Administration	
(complete	or	incomplete)	
5	
Maternal	Smoking	 4	(Data	not	recorded	for	Babies	3,	5	and	6)	
Surfactant	Administration	 6	
5-Minute	APGAR	Score*	 4	(2	–	6;	Data	not	recorded	for	Babies	2,	6	and	10)	
Mean	Arterial	Pressure	(mmHg)*	 32	(27.33	–	34.33)	
HeRO	Score*	 2.62	(0.96	–	3.39)	
Lactate	(mmol/L)*	 1.95	(1.37	–	2.17)	
Haemoglobin	(g/L)*	 139	(111.75	–	158.25)	
CRP	(mg/L)*	 7.6	(3.15	–	15.73)	
Fluid	Replacement	(ml/kg/day)*	 113.25	(89.05	–	144.13)	
SIMV:	
Days	
Mean	Airway	Pressure*	
Peak	Inspiratory	Pressure	(PIP)*	
Peak	Expiratory	End	Pressure	(PEEP)*	
	
5	
8	(6.5	–	12.5)	
18	(16	–	20)	
5	(4	–	5.5)	
CPAP:	
Days	
Peak	Expiratory	End	Pressure	(PEEP)*	
	
5	
4	(4	–	6)	
Caffeine	Administration	 5	
Inotrope	Administration	 1	
	 Pulse	Wave	Velocity	 Phase	Difference	
Median	(IQR)	 1.94	(1.74	–	2.27)	 180.66	(176.96	–	194.84)	
Range	 1.63	–	2.63	 158.66	–	203.08	
Table	7	Baselines	values	of	PWV	and	Phase	Difference	observed	in	the	preterm	population	
	
	
	
	
	
Table	6	Demographic	Data	of	Study	Participants;	*expressed	as	median	with	interquartile	range	(IQR);	CRP	=	C-
Reactive	Protein;	SIMV	=	Synchronised	Intermittent	Mechanical	Ventilation;	CPAP	=	Continuous	Positive	Airway		
Pressure			
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Figure	10	The	Relationship	between	Mean	PWV/Phase	Difference	and	Day	of	Life	
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Figure	11	The	Relationship	between	PWV/Phase	Difference	and	Sex 
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Figure	12	The	Relationship	between	PWV/Phase	Difference	and	Birthweight 
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Figure	13	The	Relationship	between	PWV/Phase	Difference	and	Gestational	Age	at	Birth	
 
[84]	
	
 
 
Figure	14	The	Relationship	between	PWV/Phase	Difference	and	Corrected	Gestational	Age 
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Figure	15	The	Relationship	between	PWV/Phase	Difference	and	Post-Natal	Age 
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An	overview	of	 the	 relationships	 between	PWV/Phase	Difference	 and	 the	 above	demographic	
variables,	as	well	as	the	strength	of	their	associations,	is	exhibited	in	Table	8.	
PWV:	
Variable:	 Rho	(2	Significant	
Figures):	
Strength	of	
Correlation:	
P	value:	
Day	of	Life	 0.00	 Weak	 0.667	
Birthweight	 0.80	 Strong	 0.01*	
Gestational	Age	at	Birth	 0.95	 Strong	 0.01*	
Corrected	Gestational	
Age	
0.90	 Strong	 0.001*	
Post-Natal	Age	 0.04	 Weak	 0.987	
Phase	Difference:	
Day	of	Life	 -1.00	 Strong	 0.01*	
Birthweight	 0.10	 Weak	 0.797	
Gestational	Age	at	Birth	 0.15	 Weak	 0.699	
Corrected	Gestational	
Age	
-0.09	 Weak	 0.814	
Post-Natal	Age	 -0.29	 Weak	 0.283	
Table	8	Overview	of	the	relationship	between	PWV/Phase	Difference	and	Demographic	variables;	*indicates	
significance	at	the	0.05	level	(2-tailed).	
Relationship	between	Pulse	Wave	Velocity/Phase	Difference	and	Clinical	Variables:	
The	 following	clinical	variables	were	assessed	 for	 their	 impact	upon	the	measurement	of	PWV	
and	Phase	Difference:	
Ø Antenatal	Steroid	Administration	(Figure	16); 
Ø Surfactant	Administration	(Figure	17); 
Ø Mean	Arterial	Blood	Pressure	(Figure	18); 
Ø HeRO	Score	(Figure	19); 
Ø Lactate	(Figure	20); 
Ø Haemoglobin	(Figure	21); 
Ø CRP	(Figure	22); 
Ø Fluid	Replacement	(Figure	23); 
Ø Mean	Airway	Pressure	(Figure	24); 
Ø Caffeine	Administration	(Figure	25); 
Ø IVH	(Figure	26). 
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Figure	16	The	Relationship	between	PWV/Phase	Difference	and	Antenatal	Steroid	Administration 
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Figure	17	The	Relationship	between	PWV/Phase	Difference	and	Surfactant	Administration 
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Figure	18	The	Relationship	between	PWV/Phase	Difference	and	Mean	Arterial	Blood	Pressure 
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Figure	19	The	Relationship	between	PWV/Phase	Difference	and	HeRO	Score 
 
 
[91]	
	
 
 
Figure	20	The	relationship	between	PWV/Phase	Difference	and	Lactate 
 
 
[92]	
	
 
 
Figure	21	The	Relationship	between	PWV/Phase	Difference	and	Haemoglobin 
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Figure	22	The	Relationship	between	PWV/Phase	Difference	and	CRP 
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Figure	23	The	Relationship	between	PWV/Phase	Difference	and	Fluid	Replacement 
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Figure	24	The	Relationship	between	PWV/Phase	Difference	and	Mean	Airway	Pressure 
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Figure	25	The	Relationship	between	PWV/Phase	Difference	and	Caffeine	Administration 
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Figure	26	The	Relationship	between	PWV/Phase	Difference	and	IVH 
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An	 overview	 of	 the	 relationships	 between	 PWV/Phase	 Difference	 and	 the	 above	 clinical	
variables,	as	well	as	the	strength	of	their	associations,	is	exhibited	in	Table	9.	
PWV:	
Variable:	 Rho	(2	Significant	
Figures):	
Strength	of	Correlation:	 P	value:	
Mean	Arterial	Blood	
Pressure	
0.12	 Weak	 0.765	
HeRO	Score	 0.02	 Weak	 0.966	
Lactate	 0.20	 Weak	 0.606	
Haemoglobin	 0.69	 Moderate	 0.041*	
CRP	 -0.37	 Weak	 0.330	
Fluid	Replacement	 0.15	 Weak	 0.700	
Mean	Airway	Pressure	 -0.20	 Weak	 0.800	
Phase	Difference:	
Mean	Arterial	Blood	
Pressure	
-0.40	 Weak	 0.286	
HeRO	Score	 0.27	 Weak	 0.488	
Lactate	 0.15	 Weak	 0.700	
Haemoglobin	 0.18	 Weak	 0.651	
CRP	 0.26	 Weak	 0.500	
Rate	of	Fluid	Replacement	 -0.72	 Moderate	 0.030*	
Mean	Airway	Pressure	 0.60	 Moderate	 0.400	
Table	9	Overview	of	the	relationship	between	PWV/Phase	Difference	and	Clinical	Variables;	*indicates	significant	
value	at	the	0.05	level	(2-tailed). 
4.3.3	Results	–	Term	Neonates	
Of	 the	 11	 participants	 recruited	 as	 part	 of	 this	 study	 2	 were	 born	 at	 term.	 Both	 neonates	
however,	suffered	hypoxic-ischaemic	injury	at	birth	and	were	therefore	cooled	during	the	period	
of	 data	 collection.	 As	 well	 as	 this,	 they	 required	 significant	 haemodynamic	 support	 with	
administration	of	inotropes	and	vasopressors.	It	was	therefore	deemed	inappropriate	to	conduct	
analysis	on	their	data	due	to	the	number	of	potential	confounders	and	very	small	sample	size.	
It	 is	hoped	 that	 this	data	 could	be	used	 in	 the	 future	 if	 additional	data	was	 collected	on	 term	
infants	through	subsequent	studies.	
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Chapter	 5:	 Investigating	 the	 Relationship	 between	 Patent	 Ductus	
Arteriosus	and	the	Measurement	of	Pulse	Wave	Velocity	and	Phase	
Difference	
5.1	Introduction	
Collection	 and	 collation	of	 normative	data	 is	 an	 important	 first	 step	 in	 the	 validation	of	 novel	
biomarkers.	However,	in	order	to	justify	further	research,	it	is	important	to	identify	the	potential	
clinical	 impact	 of	 a	 proposed	 biomarker.	 As	 highlighted	 by	 Savage	 and	 Everett,	 in	 order	 for	 a	
biomarker	 to	 be	 considered	 for	 inclusion	 in	 clinical	 practice,	 it	 is	 crucial	 to	 highlight	 the	
relationship	between	it	and	the	current	gold	standard	investigation,	as	well	as	highlighting	areas	
where	its	use	could	improve	care	beyond	what	is	already	available	(59).		
As	demonstrated	in	previous	chapters,	the	use	of	PWV	and	Phase	Difference	has	the	potential	to	
improve	current	management	of	PDA.	Due	to	the	nature	of	 its	measurement,	the	formation	of	
an	 algorithm	 providing	 an	 hourly	 PWV/Phase	 Difference	 “score”	 predictive	 of	 PDA	 diameter	
could	 act	 as	 a	 useful	 screening	 method	 for	 those	 suffering	 from	 large,	 potentially	
haemodynamically	significant	PDAs.	Furthermore,	calculation	of	such	a	score	could	help	improve	
monitoring	 capabilities	 of	 those	 who	 are	 currently	 undergoing	 PDA	 treatment.	 The	 ability	 to	
review	trends	of	such	a	score	would	allow	clinicians	to	 identify	a	worsening	or	 improving	PDA.	
This	could	improve	neonatal	care	through	the	reduction	of	unnecessary	echocardiograms	being	
performed.	Such	scoring	systems	have	already	been	used	 to	great	effect	 in	 specialist	neonatal	
units.	The	HeRO	system	provides	an	hourly	score	for	patients	using	an	algorithm	based	on	heart	
rate	variability.	 It	 is	 thought	 that	alterations	 in	heart	 rate	variability	are	 linked	 to	 the	onset	of	
sepsis,	and	so	those	with	a	rising	HeRO	score	can	be	screened	for	infection	and	promptly	treated	
with	antibiotics	(156).	Implementation	of	a	similar	system	using	PWV/Phase	Difference	could	be	
a	valuable	supplement	to	echocardiography	in	the	investigation	and	management	of	PDA.	
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A	PDA	has	the	potential	ability	to	affect	the	measurement	of	PWV/Phase	Difference	in	a	number	
of	 ways.	 As	 illustrated	 in	 Figure	 4,	 the	 Moens-Korteweg	 equation	 exhibits	 the	 variables	 that	
affect	 the	measurement	of	PWV.	We	hypothesise	 that	 the	presence	of	a	PDA	will	have	a	 two-
fold	effect	on	the	measurement	of	PWV.	Firstly,	the	presence	of	a	PDA	will	 increase	the	vessel	
radius	(r)	aspect	of	the	equation.	An	increasingly	large	PDA	diameter	will	therefore	cause	a	larger	
r	 value,	 resulting	 in	 a	 hypothetically	 reduced	 pulse	 wave	 velocity.	 This	 effect	 may	 also	 be	
exacerbated	by	the	effect	of	the	PDA	on	the	functioning	of	the	ANS.	As	mentioned	previously,	a	
recent	 study	 by	 Goudjil	 et	 al	 highlighted	 an	 increase	 in	 parasympathetic	 activity	 in	 those	
suffering	from	PDA	(44).	This	parasympathetic	dominance	may	further	contribute	to	the	effect	
on	vessel	radius	through	vasodilatation.		
The	aim	of	this	chapter	is	to	investigate	the	relationship	between	measurements	of	PDA	severity	
(PDA	diameter,	LA:Ao)	and	PWV/phase	difference.	
5.2	Methods	
A	 prospective	 observational	 study	 was	 conducted	 on	 the	 neonatal	 intensive	 care	 unit	 of	 the	
Liverpool	Women’s	 Hospital	 following	 confirmation	 of	 ethical	 approval	 as	 outlined	 in	 section	
4.2.4.	 All	 neonates	 with	 a	 UAC	 in	 situ	 within	 the	 first	 three	 days	 of	 life	 were	 eligible	 for	
recruitment	provided	they	did	not	fulfil	any	of	the	exclusion	criteria.	Routine	clinical	data	(ECG	
and	arterial	waveform)	allowing	the	calculation	of	PWV/Phase	difference	was	to	be	collected,	as	
well	as	echocardiographic	parameters	related	to	PDA	severity	(PDA	Diameter,	LA:Ao,	Transductal	
velocity).		
All	inclusion	and	exclusion	criteria	and	data	collection	procedures	were	the	same	as	mentioned	
in	 Chapter	 4	 with	 one	 exception.	 During	 days	 3-10,	 additional	 data	 was	 collected	 when	
participants	were	undergoing	echocardiographic	evaluation.	Therefore,	PWV/	Phase	Difference	
data	was	compared	to	echocardiographic	data	within	the	first	10	days	of	life	for	those	recruited	
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in	the	study.	This	data	was	collected	within	a	4	hour	window	(between	2	hours	before	to	2	hours	
after)	of	the	echocardiogram.	
Graphical	 and	 non-parametric	 correlational	 analysis	 to	 assess	 the	 relationship	 between	 PWV,	
Phase	Difference	and	markers	of	PDA	severity	will	be	performed	in	accordance	with	the	methods	
outlined	in	Chapter	4.	
5.3	Results	
Of	 the	 11	 participants	 recruited	 as	 part	 of	 the	 study,	 a	 total	 of	 6	 neonates	 had	 an	
echocardiogram	performed	whilst	their	UAC	remained	in	situ.	One	participant	was	found	to	have	
bi-directional	blood	flow	through	their	PDA	and	thus	was	excluded	from	the	analysis.	This	was	to	
avoid	 the	 potentially	 confounding	 effects	 of	 the	 differing	 physiology	 between	 a	 bi-directional	
and	a	purely	left-to-right	shunt.	The	data	from	5	echocardiograms	was	therefore	used.	
The	 following	 echocardiographic	 parameters	were	 compared	 to	 PWV	and	Phase	Difference	 to	
assess	their	relationship:	
Ø PDA	Diameter	(Figure	27);	
Ø Left	Atrial:Aortic	Ratio	(Figure	28).	
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Figure	27	The	Relationship	between	PWV/Phase	Difference	and	PDA	Diameter 
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Figure	28	The	Relationship	between	PWV/Phase	Difference	and	LA:Ao 
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An	 overview	 of	 the	 relationships	 between	 PWV/Phase	 Difference	 and	 the	 above	
echocardiographic	variables,	as	well	as	the	strength	of	their	associations,	is	exhibited	in	Table	10.	
PWV:	
Variable:	 Rho:	 Strength:	 P	value:	
PDA	Diameter	 -0.10	 Weak	 0.873	
LA:Ao	 0.00	 Weak	 1.000	
Phase	Difference:	
PDA	Diameter	 0.30	 Weak	 0.624	
LA:Ao	 0.50	 Weak	 0.391	
Table	10	Overview	of	the	Relationship	between	PWV/Phase	Difference	and	Echocardiographic	Variables	
 
 
 
 
	
	 	
[105]	
	
Chapter	6:	Investigating	Novel	Biomarkers	in	Neonatal	
Haemodynamics	–	A	Discussion	
The	 analysis	 of	 the	 variation	 of	 measurement	 and	 the	 association	 between	 PWV/Phase	
difference	and	demographic	 variables	 is	 an	 important	 first	 step	 in	 their	 validation	as	potential	
biomarkers	 in	neonatology.	We	demonstrated	median	values	 for	PWV	and	phase	difference	 in	
our	 study	 population.	 We	 also	 outlined	 the	 variability	 of	 distribution	 and	 range	 of	 values	
observed.	 Although	 this	 is	 an	 important	 initial	 step	 in	 the	 estimation	 of	 “normal”	 values,	
conclusions	cannot	be	made	due	to	the	small	sample	size	of	 this	study.	 It	 is	hoped	that	 future	
research	can	build	on	this	data	to	help	identify	a	normal	range	of	values	for	this	population.	
There	was	a	strong	association	between	PWV	and	birthweight/gestational	age	at	birth	(r	=	0.8,	p	
=	 0.01	 and	 r	 =	 0.95,	 p	 =	 <0.01	 respectively,	 Table	 8).	 Furthermore,	 a	 strong	 association	 was	
observed	between	PWV	and	corrected	GA	(r	=	0.90,	p	=	0.001,	Table	8).	Phase	difference	showed	
weak,	 non-significant	 associations	 with	 all	 demographic	 variables	 except	 for	 the	 comparison	
between	 mean	 phase	 difference	 and	 day	 of	 life	 (r	 =	 -1.00,	 p	 =	 0.01,	 Table	 8).	 This	 strong	
relationship	exhibited	an	overall	decrease	in	phase	difference	across	the	first	three	days	of	life.	
This	 relationship	 differed	 from	 the	 comparison	 between	 phase	 difference	 and	 postnatal	 age.	
Based	on	the	relationship	between	mean	phase	difference	and	day	of	life,	we	would	expect	the	
relationship	between	phase	difference	and	postnatal	age	to	follow	a	similar	trend;	however,	no	
association	 was	 exhibited.	 The	 different	 associations	 between	 PWV	 and	 phase	 difference	
suggest	that	these	parameters	are	capturing	different	aspects	of	haemodynamic	physiology.	We	
can	speculate	that	a	biomarker	that	 is	strongly	associated	with	maturity	(indicated	by	GA)	may	
be	less	strongly	associated	with	the	state	of	a	PDA	than	a	biomarker	that	is	associated	with	day-
to-day	changes.		
We	note	a	potential	drawback	of	monitoring	systems	that	calculate	algorithmic	“scores”	based	
on	the	patient’s	condition	at	different	time	intervals.	Although	every	effort	was	made	to	collect	
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data	on	patients	after	cares	had	been	performed,	they	often	still	required	investigations	during	
periods	of	data	collection.	The	process	of	disrupting	the	patient	–	for	arterial	blood	gas	sampling	
for	example	–	may	cause	changes	to	their	physiological	state	or	the	functioning	of	the	UAC.	This	
may	temporarily	alter	measurements	during	that	period	of	time.	The	patient	may	also	undergo	
weaning	 of	 oxygen	 or	 medication	 causing	 a	 temporary	 alteration	 to	 their	 physiological	 state	
whilst	 they	 adapt	 to	 new	 levels	 of	 intervention.	 Furthermore,	 data	may	 be	 collected	 across	 a	
period	during	which	the	patient	suffers	a	significant	apnoea	or	bradycardia.	All	of	these	factors	
could	cause	substantial	hour-to-hour	variation,	possibly	explaining	the	lack	of	correlation	noted	
when	comparing	phase	difference	to	smaller	time	intervals.	It	may	be	useful	for	future	studies	to	
compare	PWV/phase	values	before	and	after	 alterations	 in	 care	or	 changes	 in	 clinical	 state	 to	
assess	their	impact	on	the	measurement	of	these	biomarkers.	
Analysis	of	clinical	variables	showed	some	potential	associations	with	PWV	and	phase	difference.	
A	 notable	 difference	 was	 observed	 between	 those	 who	 had	 and	 had	 not	 received	 treatment	
with	 surfactant.	 It	 has	 been	 suggested	 that	 sustained	 high	 pressure	 ventilation	 following	 the	
administration	of	 surfactant	 can	cause	 increased	 intrathoracic	pressure	 (157).	This	 subsequent	
raised	 intrathoracic	 pressure	 can	 impede	 venous	 return,	 thus	 reducing	 cardiac	 output	 and	
systolic	 blood	 pressure.	 Based	 on	 this	 observation,	 the	 reduction	 in	 PWV	 noted	 in	 patients	
administered	with	surfactant	may	be	explained	by	the	effect	of	a	reduced	blood	vessel	radius	on	
the	Moens-Korteweg	 equation.	However,	 increased	 intrathoracic	 pressure	may	 also	 affect	 the	
elasticity	 of	 arterial	 vessels.	 Based	 on	 the	 Moens-Korteweg	 equation,	 this	 would	 cause	 an	
increase	 in	 PWV.	 Although	 there	 was	 no	 evidence	 of	 an	 association	 between	 mean	 airway	
pressure	 and	 PWV,	 future	 research	 should	 aim	 to	 further	 analyse	 the	 effect	 of	 raised	
intrathoracic	pressure	on	 these	biomarkers.	One	aspect	of	our	 results	 that	was	not	 in	keeping	
with	 what	 we	 would	 expect	 based	 on	 the	 Moens-Korteweg	 equation	 was	 the	 relationship	
between	PWV	and	haemoglobin	 level.	An	 increase	 in	haemoglobin	causes	an	 increase	 in	blood	
viscosity	(158),	which	we	would	expect	to	cause	a	decrease	in	PWV.	This	was	not	the	case	as	a	
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moderate	 and	 significant	 association	 was	 noted	 with	 an	 increase	 in	 haemoglobin	 being	
associated	with	a	higher	PWV	value	 (r	=	0.69,	p	=	0.04,	Table	9).	Due	to	 the	small	 sample	size	
associated	with	this	study,	multivariate	analysis	to	assess	potential	confounding	effects	on	this	
relationship	could	not	be	performed.	Although	weak,	non-significant	correlational	analysis	was	
noted	 (r	 =	 0.27,	 p	 =	 0.488	 and	 r	 =	 0.26,	 p	 =	 0.500	 respectively,	 Table	 9),	 the	 trend	 on	 visual	
inspection	suggested	a	possible	positive	relationship	between	phase	difference	and	both	HeRO	
score	and	CRP	on	day	1	of	life.	HeRO	score	and	CRP	are	used	as	infection	markers.	HeRO	score	is	
used	as	an	early	warning	scoring	system	on	the	Liverpool	Women’s	Hospital	NICU.	 It	works	by	
detecting	 alterations	 to	 heart	 rate	 variability,	 thought	 to	 be	 caused	 by	 the	 release	 of	
inflammatory	 cytokines	 during	 a	 period	 of	 infection.	 An	 algorithm	 subsequently	 produces	 a	
score	 for	 the	patient	 every	 hour.	 Identification	of	 an	 increasing	HeRO	 score	 is	 suggestive	 of	 a	
progressing	infection;	a	septic	screen	is	therefore	performed	and	the	patient	will	be	started	on	a	
course	 of	 empirical	 antibiotic	 therapy	 whilst	 awaiting	 results	 from	 the	 screen.	 We	 would	
therefore	expect	to	see	a	negative	correlation	between	them	and	PWV	due	to	the	vasodilatory	
effects	of	infection.	However,	no	participant	recruited	as	part	of	this	study	was	diagnosed	with	
blood	 culture	 confirmed	 sepsis	 and	 no	 significant	 correlation	 was	 noted	 between	 PWV	 and	
markers	 of	 infection.	 Although	 the	 mechanism	 is	 unclear,	 the	 association	 between	 phase	
difference	and	HeRO/CRP	may	be	explained	by	other	factors	affecting	the	normal	physiological	
functioning	of	 the	neonate.	 It	has	been	noted	 that	preterm	neonates	have	 reduced	heart	 rate	
variability	compared	to	term	neonates	(159).	It	is	thought	that	this	may	be	due	to	an	immature	
autonomic	nervous	 system.	One	explanation	 for	 this	 could	be	a	potential	association	between	
autonomic	function/heart	rate	variability	and	phase	difference,	exhibiting	as	a	positive	trend	in	
relation	 to	 HeRO	 score	 in	 this	 study.	 Future	 research	 could	 benefit	 from	 assessing	 this	
relationship.	Neonates	can	exhibit	an	inflammatory	response	for	a	number	of	reasons	apart	from	
infection,	including	hypoxia	or	poor	tissue	perfusion	(160).	The	trend	observed	between	CRP	and	
phase	difference	may	therefore	be	due	to	an	unrelated	inflammatory	response	that	happened	to	
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coexist	 at	 the	 time	 of	 data	 collection.	 A	 moderate	 and	 statistically	 significant	 negative	
correlation	was	observed	between	phase	difference	and	fluid	replacement	(r	=	-0.72,	p	=	0.03,	
Table	9).	A	possible	explanation	for	this	phenomenon	may	be	the	effect	of	circulating	volume	on	
the	mass	flow	of	blood	in	the	aorta.	For	example,	a	reduced	rate	of	fluid	replacement	may	result	
in	lower	circulating	volume	which	will	minimise	the	effect	of	mass	flow	of	blood	thus	prolonging	
the	pulse	transit	 time.	A	moderate	but	non-significant	positive	association	was	noted	between	
phase	 difference	 and	 mean	 airway	 pressure.	 This	 is	 in	 keeping	 with	 the	 negative	 association	
between	 PWV	 and	 mean	 airway	 pressure,	 as	 it	 would	 be	 expected	 for	 phase	 difference	 to	
increase	as	PWV	decreases.	
The	 comparison	 of	 PWV	 in	 male	 and	 female	 populations	 showed	 a	 considerable	 difference	
between	sexes,	however,	the	overlap	in	error	bars	suggests	that	this	difference	is	not	statistically	
significant.	 One	 possible	 reason	 for	 this	 possible	 discrepancy	 is	 the	 differences	 in	 male	 and	
female	populations	included	in	this	study	(6	males,	3	females).	Another	possible	reason	for	the	
observed	 difference	 is	 the	 difference	 in	 average	 gestational	 age	 of	 the	 two	 populations.	 The	
mean	gestational	age	at	birth	in	the	male	population	was	25.88	weeks	compared	to	a	mean	of	
27.57	 weeks	 in	 the	 female	 population.	 PWV	 is	 dependent	 on	 the	 measurement	 of	 the	
approximate	 distance	 for	 blood	 to	 travel	 between	 the	 aortic	 valve	 and	 the	 tip	 of	 the	 UAC	
catheter.	We	speculate	that	infants	with	increased	gestation	age	in	the	absence	of	intrauterine	
growth	restriction	will	have	increased	length	and	weight,	thus	increasing	the	distance	aspect	of	
the	PWV	calculation	leading	to	a	greater	overall	value.	
There	were	a	number	of	demographic	and	clinical	variables	that	the	authors	wanted	to	compare	
to	the	proposed	biomarkers	but	could	not	due	to	their	absence	 in	the	study	population.	There	
was	 only	 one	 set	 of	 twins	 included	 as	 part	 of	 this	 study.	 It	 was	 therefore	 not	 possible	 to	
investigate	 the	 effects	 of	 multiple	 pregnancies	 on	 the	 measurement	 of	 PWV	 and	 phase	
difference.	 Inotropes	were	 administered	 for	 one	 day	 in	 one	 participant	 and	 so	 the	 impact	 of	
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their	 use	 could	 not	 be	 assessed.	 Furthermore,	 at	 no	 point	 was	 any	 neonate	 treated	 with	
ibuprofen	or	diagnosed	with	blood	culture	confirmed	sepsis.	Future	research	should	endeavour	
to	analyse	the	effects	of	these	variables	on	PWV	and	phase	difference	as	they	have	the	potential	
to	cause	significant	effects	on	their	measurement.	
Comparison	of	PWV	and	phase	difference	with	echocardiographic	variables	showed	no	strong	or	
statistically	significant	correlations.	This	has	somewhat	disproved	the	authors’	hypothesis	of	the	
presence	 of	 a	 PDA	 causing	 a	 measurable	 effect	 on	 the	 measurement	 of	 PWV	 and	 phase	
difference.	However,	 the	 trend	on	visual	analysis	 suggestion	suggests	a	possible	positive	 trend	
between	 phase	 difference	 and	 both	 PDA	 diameter	 and	 LA:Ao.	 Notably,	 the	 correlation	
coefficient	for	phase	difference	and	LA:Ao	was	0.5.	Furthermore,	there	was	a	potential	outlier	in	
the	 comparison	 of	 PDA	 diameter	 and	 PWV.	 This	 participant	 exhibited	 a	 high	 PWV	 (2.03	m/s)	
despite	a	relatively	small	PDA	diameter	(1.79mm).	This	did	not	appear	to	be	in	keeping	with	the	
trend	exhibited	by	the	other	four	readings.	On	review	of	the	patient’s	history	and	management,	
no	identifiable	cause	for	this	discrepancy	could	be	identified.	Since	this	data	is	based	on	only	5	
echocardiographic	 readings,	a	possible	association	cannot	be	excluded.	 It	 is	 therefore	believed	
that	further	research	is	needed	into	the	association	between	echocardiographic	markers	of	PDA	
and	 PWV/phase	 difference	 in	 order	 to	 make	 more	 conclusive	 comments	 regarding	 their	
relationship.	
This	 study	was	 informed	by	 the	evidence	outlined	 in	 chapters	 2	 and	3.	 The	 continuing	 lack	of	
consensus	regarding	the	clinical	importance,	investigation	and	management	of	PDA	in	neonatal	
care	 highlights	 the	 need	 for	 continued	 research.	We	 identified	 the	 potential	 benefit	 of	 novel	
biomarkers	to	supplement	the	use	of	echocardiography	in	the	diagnosis	and	prognostication	of	
PDA	disease.	 The	non-invasive	nature	of	 the	measurement	of	 PWV	 in	 those	with	UACs	 in	 situ	
was	also	thought	 to	be	clinically	beneficial	by	providing	an	alternative	method	of	 investigation	
that	would	help	reduce	the	number	of	procedures	performed	on	patients	in	NICU.		
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The	 process	 of	 validation	 of	 a	 novel	 biomarker	 requires	 a	 rigorous	 process	 of	 validation.	
“Normal”	distribution	of	 its	measurement	across	the	proposed	population	of	benefit	must	first	
be	 conducted.	 Potential	 confounders	 and	 variables	 thought	 to	 significantly	 alter	 its	
measurement	must	also	be	sought.	This	provides	additional	data	 in	 relation	 to	 those	 in	whom	
using	the	biomarker	is	not	indicated.	Without	this,	comparison	of	a	biomarker	with	its	proposed	
diagnosis	 is	 irrelevant.	Throughout	biomarker	validation	the	appropriateness,	acceptability	and	
accessibility	of	 its	use	 in	clinical	practice	should	be	 reviewed.	We	believe	 that	 the	aims	of	 this	
study	were	appropriate	for	beginning	the	process	of	validation	for	a	novel	biomarker.	Chapter	4	
reviewed	the	variation	in	measurement	of	PWV	in	a	population	where	there	is	limited	evidence.	
It	 also	 assessed	 the	 association	 between	 a	 number	 of	 potential	 clinical	 confounders	with	 the	
proposed	 biomarker.	 Chapter	 5	 then	 illustrated	 its	 potential	 impact	 on	 current	 practice	 by	
comparing	its	measurement	to	a	clinical	condition.		
Our	study	sought	to	add	additional	information	to	what	had	already	been	published	in	literature.		
Previous	studies	reviewing	pulse	phase	difference	as	a	method	of	evaluating	PDA	(Goudjil	et	al,	
Kotidis	et	al)	conducted	their	studies	exclusively	in	preterm	neonates	(<32	weeks	and	<29	weeks,	
respectively).	Our	 study	 aimed	 to	 include	 babies	 of	 all	 gestations	 provided	 they	 had	 a	UAC	 in	
situ.	This	would	have	allowed	us	to	compare	PWV	and	phase	difference	measurements	in	both	
term	 and	 preterm	populations.	 Although	 our	 sample	 size	 for	 term	neonates	was	 deemed	 too	
small	 to	assess	as	a	 separate	population,	we	hope	 this	data	can	be	used	 in	 future	 research	 to	
assess	the	variation	in	measurements	in	term	neonates.	We	also	sought	to	investigate	additional	
clinical	 parameters	 to	 evaluate	 their	 effect	 on	 PWV/Phase	 Difference	 measurement.	 These	
include	 variables	 such	 as	mean	 airway	pressure	 that	were	not	 assessed	 in	 previous	 literature.	
This	study	was	also	conducted	using	a	UAC	and	arterial	waveform	rather	than	a	pulse	oximeter	
and	 arterial	 photoplethysmography.	 This	 was	 in	 the	 hope	 of	 identifying	 a	 new	 and	 more	
accurate	method	of	measuring	the	proposed	biomarkers.	
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We	believe	that	our	methodology	was	appropriate	to	answer	our	proposed	questions.	The	non-
interventional	nature	of	such	a	study	was	favourable	with	regards	to	study	uptake.	No	parents	
opted-out	 of	 study	 participation.	 Every	 effort	 was	made	 to	 provide	 parents	 with	 information	
about	the	study.	This	was	via	ward	posters	and	discussions	at	the	bedside	with	researcher	BR.	At	
no	point	was	additional	 information	 in	 the	 form	of	 information	 leaflets	 required.	 It	 is	 thought	
that	 this	 was	 due	 to	 the	 non-interventional	 nature	 of	 the	 study	 with	 zero	 physical	 patient	
contact.	 Furthermore,	 the	0%	opt-out	 rate	noted	 in	 this	 study	will	 have	eliminated	 the	 risk	of	
volunteer	bias.	Our	inclusion	criteria	ensured	that	there	was	a	clearly	outlined	study	population	
that	 would	 be	 studied	 within	 a	 set	 period	 of	 time	 in	 early	 neonatal	 life.	 Furthermore,	 our	
exclusion	criteria	helped	minimise	 the	effect	of	potential	 clinical	 confounders	which	may	have	
skewed	our	 results.	 Removal	 of	 patients	with	 conditions	 such	 as	 significant	 congenital	 cardiac	
disease	 or	 hydrops	 fetalis	 helped	 reduce	 the	 risk	 of	 anomalous	 results	 due	 to	 abnormal	
physiology.	 Although	 future	 studies	 reviewing	 the	 use	 of	 PWV	 in	 neonatal	 populations	 may	
benefit	from	reviewing	its	measurement	in	patients	with	physiological	or	anatomical	anomalies	
causing	 alterations	 in	 haemodynamic	 function,	 this	 was	 deemed	 inappropriate	 for	 the	 early	
stages	of	biomarker	validation.	For	those	recruited	as	part	of	the	study,	all	appropriate	routinely	
collected	 clinical	 data	 was	 documented.	 This	 allowed	 the	 comparison	 of	 a	 number	 of	 factors	
thought	 to	 potentially	 effect	 the	measurement	 of	 PWV.	 Examples	 include	 ventilation	 settings	
(effects	 of	 intrathoracic	 pressure),	 fluid	 replacement	 (effects	 of	 circulating	 volume)	 and	
haemoglobin	level	(viscosity	of	blood).	The	use	of	arterial	waveforms	provided	by	the	presence	
of	a	UAC	helped	reduce	variation	in	readings.	UACs	are	placed	between	T6-T9	and	confirmed	by	
radiography,	 providing	 consistent	 placement	 between	 participants.	 As	 well	 as	 this,	 the	 close	
proximity	of	the	catheter	tip	to	the	site	of	the	PDA	improves	the	accuracy	of	the	measurement	
of	its	effect	on	PWV.	
Every	 attempt	 was	 made	 to	 ensure	 consistency	 and	 validity	 of	 data	 collected.	 Researchers	
ensured	data	collection	occurred	while	the	patient	was	not	being	disturbed	to	avoid	any	external	
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influence	on	the	results	recorded.	Data	collection	was	almost	always	conducted	between	cares	
and	 after	 any	 scans	 had	been	performed.	 The	only	 exception	 to	 this	was	when	patients	were	
having	 echocardiograms	 performed	 as	 this	 allowed	 us	 to	 collect	 data	 relative	 to	 the	 patient’s	
disease	state	at	that	particular	time.	Prior	to	data	collection,	arterial	and	ECG	waveforms	were	
subject	 to	quality	assessment	by	 researcher	BR.	Arterial	waveforms	were	optimally	 scaled	and	
the	 ECG	 lead	 (I,	 II	 or	 III)	 that	 was	 producing	 the	 largest	 and	 most	 consistent	 R	 waves	 was	
selected.	This	ensured	clarity	of	the	peaks	of	both	the	R	wave	and	arterial	wave,	minimising	the	
potential	 for	error	 in	data	analysis.	All	echocardiograms	were	reviewed	by	one	member	of	 the	
research	team	(CK	–	paediatric	cardiology	registrar).	Measurements	of	PDA	diameter	and	LA:Ao	
were	determined	by	CK	using	pre-recorded	images.	
There	were	a	number	of	 limitations	associated	with	our	study	design.	Although	the	aim	of	one	
aspect	of	 the	study	was	 to	collect	normative	data	 to	evaluate	 the	biomarker	 in	early	neonatal	
life,	 the	ability	to	only	recruit	participants	 for	the	study	within	the	first	3	days	of	 life	 impacted	
echocardiogram	data	collection.	In	a	number	of	instances,	a	patient	may	have	been	>3	days	old	
with	 a	 UAC	 in	 situ	 and	 having	 an	 echocardiogram	 performed,	 however,	 if	 they	 had	 not	 been	
recruited	 in	 the	 first	 3	 days	 of	 life,	 their	 data	 could	 not	 be	 included	 in	 the	 study.	 Although	 a	
functional	UAC	was	deemed	to	be	an	accurate	method	of	measuring	the	arterial	waveform,	 in	
many	cases	they	proved	problematic.	Often	the	UAC	was	left	in	situ	despite	not	tracing	as	it	still	
provided	access	for	arterial	blood	sampling.	This	was	the	case	for	one	study	participant	on	day	
10	of	 life,	meaning	 that	no	data	collection	could	occur	during	an	echocardiogram.	There	were	
times	where,	despite	UAC	quality	assurance	checks	and	optimisation	of	scale,	the	trace	was	still	
considered	 poor.	 This	 inconsistency	 of	 readings	 highlights	 a	 potential	 drawback	 in	 the	 use	 of	
UACs	 for	 determining	 PWV.	 Furthermore,	 the	 distance	 aspect	 of	 the	 PWV	 equation	 was	
determined	by	a	 researcher	measuring	 the	approximate	route	of	 the	aorta	based	on	the	most	
recent	 chest	 radiograph	 performed	 at	 the	 time	 of	 data	 collection.	 Although	 anatomical	
landmarks	 such	 as	 the	 carina	 were	 used	 to	 maintain	 consistency	 in	 the	 tracing	 of	 the	
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approximate	route	of	the	aorta,	this	measurement	was	subject	to	a	number	of	potential	limiting	
factors.	A	chest	 radiograph	does	not	 take	 into	account	posterior-to-anterior	orientation	of	 the	
aorta;	the	aortic	valve	 is	radiolucent	and	thus	 its	approximate	 location	was	used;	clarity	of	the	
catheter	 tip	 and	 location	of	 the	 carina	were	occasionally	 difficult	 to	 precisely	measure	 due	 to	
suboptimal	radiograph	exposure;	and	finally,	radiographs	performed	on	NICU	patients	are	often	
rotated.	Despite	the	same	method	being	used	by	the	same	researcher	for	all	measurements,	all	
of	these	factors	may	have	resulted	in	inaccuracies	in	the	calculation	of	PWV.	For	this	reason	it	is	
believed	 that	phase	difference	may	be	a	more	appropriate	method	of	expressing	pulse	 transit	
time	as	it	is	not	dependent	on	aortic	measurements.	Certain	aspects	of	data	collection	were	also	
dependent	on	other	members	of	the	clinical	care	team.	Collection	of	demographic,	perinatal	and	
clinical	data	was	dependent	on	proper	documentation	on	the	Trust’s	“Badger”	system.	Although	
documentation	was	usually	of	a	high	standard,	 there	were	a	number	of	areas	where	data	was	
often	missing.	Maternal	details	such	as	smoking	history	or	steroid	exposure	was	often	missing.	
This	was	possibly	due	to	the	fact	many	participants	in	the	trial	were	born	preterm	and	this	data	
had	 not	 been	 recorded,	 or	 there	was	 not	 time	 to	 provide	 steroids.	 This	may	 have	 potentially	
skewed	our	analysis	of	the	study	demographic,	as	well	as	under-	or	overestimated	the	impact	of	
surfactant	 administration	 on	 the	 measurement	 of	 PWV	 in	 early	 neonatal	 life.	 Furthermore,	
echocardiograms	were	performed	by	whichever	neonatologist	was	working	on	NICU	 that	 day.	
This	may	have	introduced	some	degree	of	between-user	variability	within	the	echocardiographic	
data	recorded.		
The	Baby	OSCAR	early	intervention	in	PDA	trial	was	running	concurrently	with	this	research.	This	
is	a	multi-centre	randomised	placebo	controlled	trial	of	ibuprofen	for	extremely	preterm	babies	
who	 had	 been	 diagnosed	with	 a	 large	 PDA.	 This	was	 both	 beneficial	 and	 detrimental	 to	 data	
collection.	Those	who	were	potentially	eligible	were	screened	by	Doppler	echocardiogram	in	the	
first	 72	 hours	 of	 life.	 This	 allowed	 researchers	 to	 collect	 time-specific	 data	 that	 could	 be	
accurately	compared	to	the	current	PDA	status	of	a	study	participant.	However,	those	deemed	
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eligible	 for	 participation	 in	 the	OSCAR	 trial	 do	 not	 have	 another	 echocardiogram	 for	 3	weeks	
unless	 there	 is	 a	 decline	 in	 clinical	 condition.	 This	 may	 have	 reduced	 the	 number	 of	 babies	
having	echocardiograms	in	our	3-10	day	window	as	it	may	have	affected	the	threshold	at	which	
a	clinician	deemed	echocardiography	was	appropriate	in	study	participants.	Furthermore,	babies	
recruited	 into	 the	 Baby	OSCAR	 trial	 are	 treated	with	 either	 ibuprofen	 or	 a	 placebo.	 Although	
there	 was	 no	 open-label	 use	 of	 ibuprofen	 in	 our	 study	 population,	 we	 cannot	 exclude	 the	
possibility	 that	participants	may	have	been	potentially	administered	 ibuprofen	as	part	of	 their	
inclusion	 in	the	Baby	OSCAR	trial.	The	blinded	nature	of	this	concurrent	study	meant	we	could	
not	assess	whether	there	was	not	any	association	between	PWV/phase	difference	and	ibuprofen	
administration	 in	those	recruited	 in	our	study	that	were	also	part	of	 the	treatment	arm	of	 the	
Baby	OSCAR	trial.	The	results	of	our	study	are	also	likely	to	be	subject	to	an	element	of	sample	
size	bias	due	to	 the	small	number	of	participants	 recruited	as	part	of	 the	study.	UAC	 insertion	
rates	in	the	three	months	prior	to	protocol	submission	were	reviewed	in	an	attempt	to	provide	
an	 estimate	 of	 the	 number	 of	 participants	 we	 expected	 to	 recruit	 to	 this	 study.	 This	 review	
projected	that	we	could	expect	to	recruit	approximately	30	participants	over	a	period	of	three	
months.	During	this	sample	size	estimate,	we	failed	to	take	into	account	patients	in	this	period	
that	 would	 not	 have	 been	 suitable	 for	 recruitment.	 UACs	 are	 often	 inserted	 to	 critically	 ill	
neonates	who	require	 inotropes	or	 regular	arterial	blood	gas	monitoring.	Often	 these	patients	
are	 suffering	 from	 serious	 conditions	 that	 would	 have	 excluded	 them	 from	 our	 study.	 Our	
inability	 to	 take	 this	 into	 account	 during	 our	 sample	 size	 estimate	may	 have	 led	 to	 an	 over-
ambitious	 prospective	 number	 of	 recruits.	 As	 highlighted	 by	 Figure	 8,	 32	 UACs	were	 inserted	
during	 a	 3	month	 data	 collection	 period	 but	 6	were	 unable	 to	 be	 recruited	 due	 to	 significant	
comorbidity	or	death	within	24	hours.	Exposure	to	potential	participants	was	also	hindered	by	
issues	surrounding	ethical	approval	for	the	study.	Initial	delay	in	beginning	data	collection	due	to	
incomplete	 IRAS	 documentation	meant	 data	 collection	 was	 started	 almost	 seven	 weeks	 later	
than	anticipated.	Between	the	proposed	study	start	date	(02/01/18)	and	the	actual	study	start	
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date	(18/02/18)	there	were	24	UACs	inserted	on	the	unit,	16	of	whom	would	have	been	deemed	
suitable	for	recruitment	in	this	study.	In	addition	to	this,	a	non-substantial	amendment	form	had	
to	be	submitted	to	extend	the	period	of	data	collection	initially	suggested	in	the	protocol.	Delay	
in	the	issue	of	extension	resulted	in	an	additional	potential	participant	not	being	included	in	the	
study.	There	is,	however,	potential	for	the	data	of	this	study	to	be	combined	with	that	collected	
by	 Kotidis	 et	 al	 as	 part	 of	 the	 pilot	 study	 that	 informed	 this	 research	 project.	 Of	 the	 nine	
participants	in	this	study,	8	were	below	the	gestational	age	cut-off	point	(29	weeks)	for	inclusion	
in	the	pilot	study.	This	would	provide	a	larger	sample	size	from	which	more	reliable	data	could	
be	extracted	in	the	hope	of	improving	the	likelihood	of	future	publication.		
Our	 study	 exemplifies	 a	 number	 of	 the	 drawbacks	 of	 biomarker	 research	 in	 paediatric	
populations	highlighted	by	Savage	and	Everett	(59).	Our	study	was	subject	to	a	small	sample	size	
meaning	that	firm	conclusions	cannot	be	made	from	our	data	set	alone.	As	well	as	this,	our	study	
lacked	a	true	control	group.	Although	we	were	able	to	demonstrate	baseline	values	of	PWV	and	
phase	difference	in	our	study	population,	there	were	no	truly	“healthy”	participants	in	the	study	
as	 they	 were	 all	 premature.	 Furthermore,	 a	 control	 group	 to	 compare	 to	 the	 term	 infants	
included	in	our	study	in	future	studies	would	not	be	plausible	as	UAC	insertion	in	healthy	term	
neonates	 would	 be	 unethical.	 Therefore	 assessment	 of	 “normal”	 PWV	 and	 phase	 difference	
values	cannot	be	truly	estimated	using	this	method.	Use	of	a	method	of	calculating	PWV/phase	
difference	without	the	insertion	of	an	arterial	line	may	therefore	be	indicated	in	the	estimation	
of	“normal”	thresholds.	For	example,	further	research	regarding	the	use	of	peripheral	saturation	
probes	and	photoplethysmography	as	exhibited	in	a	recent	study	(68)	may	be	beneficial.	
Although	a	number	of	the	drawbacks	of	this	study	were	outside	of	the	control	of	the	research	
team,	there	are	a	number	of	ways	the	study	could	be	improved	if	it	was	repeated.	Expanding	the	
inclusion	 criteria	 to	 allow	 recruitment	 outside	 of	 the	 first	 three	 days	 of	 life	may	 have	 helped	
increase	the	amount	of	data	collected	between	days	3-10	of	 life.	Furthermore,	conducting	the	
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study	in	a	centre	that	was	not	part	of	the	Baby	OSCAR	trial	may	have	increased	the	number	of	
echocardiograms	performed	during	this	period.	All	data	collection	was	performed	by	researcher	
BR.	Although	this	ensured	consistency	 in	data	collection	methods,	the	 lack	of	a	 larger	research	
team	 contributed	 to	 reduced	 participant	 recruitment.	 A	 number	 of	 potential	 candidates	were	
missed	during	periods	when	BR	was	not	on	the	unit.	It	would	be	unfeasible	for	one	researcher	to	
be	present	on	the	unit	at	all	times	to	ensure	all	potential	candidates	were	recruited.	If	this	study	
was	 to	be	 repeated	on	 a	 larger	 scale,	 it	would	be	beneficial	 to	 have	 a	 number	of	 researchers	
trained	in	the	method	of	data	collection.	This	would	ensure	that	neonates	admitted	to	the	unit	
overnight	 or	 during	weekends	 had	 a	 better	 rate	 of	 recruitment.	 This	 would	 also	 improve	 the	
power	of	the	study,	and	allow	additional	statistical	analysis	to	be	performed	on	a	larger	cohort.	
Conducting	the	research	across	a	number	of	centres	and	across	a	greater	period	of	time	would	
further	 improve	 the	 sample	 size	 of	 subsequent	 research.	 This	 would	 remove	 any	 potential	
sample	size	bias	that	this	study	may	have	been	subject	to.	
6.1	Conclusion	
This	 study	 aimed	 to	 review	 the	 use	 of	 PWV	 and	 phase	 difference	 as	 potential	 biomarkers	 for	
implementation	in	clinical	practice.	Based	on	our	comparisons	between	demographic	and	clinical	
variables,	 it	 is	 thought	 that	 there	 are	 few	 variables	 that	 have	 significant	 impact	 on	 their	
measurement.	All	variables	which	were	shown	to	have	a	strong	correlation	with	the	biomarkers	
(birthweight,	gestational	age	at	birth,	corrected	gestational	age	and	day	of	 life)	could	be	easily	
accounted	for	if	these	biomarkers	were	to	be	introduced	into	clinical	practice.	Although	no	firm	
associations	were	noted	between	these	biomarkers	and	echocardiographic	markers	of	PDA,	the	
overall	 trend	 exhibited	 by	 visual	 analysis	 suggested	 a	 potential	 positive	 association	 between	
phase	difference	and	PDA	diameter/LA:Ao.		
Overall,	 the	 sample	 size	 for	 this	 study	 is	 too	 small	 to	 make	 conclusions	 about	 the	 effect	 of	
demographic,	clinical	and	echocardiographic	variables	on	the	measurement	of	PWV	and	phase	
[117]	
	
difference;	however,	we	believe	this	study	warrants	further	research	in	the	field	of	PWV/phase	
difference	validation	and	the	use	of	novel	biomarkers	in	the	management	of	PDA.	
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Appendix	1	–	Systematic	Review	Literature	Search	Results	
PubMed	Literature	Search	Results:	
Search	Term(s):	 Results:	
“Patent	Ductus	Arteriosus”	 11,365	
“Patent	Ductus	Arteriosus”	OR	“PDA”	 18,747	
“Patent	Ductus	Arteriosus”	OR	“PDA”	OR	
“Persistent	Ductus	Arteriosus”	
19,088	
“Patent	Ductus	Arteriosus”	OR	“PDA”	OR	
“Persistent	Ductus	Arteriosus”	AND	“Neonate”	
5461	
“Patent	Ductus	Arteriosus”	OR	“PDA”	OR	
“Persistent	Ductus	Arteriosus”	AND	“Neonate”	
OR	“Neonatal”	
5754	
“Patent	Ductus	Arteriosus”	OR	“PDA”	OR	
“Persistent	Ductus	Arteriosus”	AND	“Neonate”	
OR	“Neonatal”	OR	“Newborn”	
5895	
“Patent	Ductus	Arteriosus”	OR	“PDA”	OR	
“Persistent	Ductus	Arteriosus”	AND	“Neonate”	
OR	“Neonatal”	OR	“Newborn”	OR	“Preterm”	
5987	
“Patent	Ductus	Arteriosus”	OR	“PDA”	OR	
“Persistent	Ductus	Arteriosus”	AND	“Neonate”	
OR	“Neonatal”	OR	“Newborn”	OR	“Preterm”	
OR	“Premature”	
6098	
“Patent	Ductus	Arteriosus”	OR	“PDA”	OR	
“Persistent	Ductus	Arteriosus”	AND	“Neonate”	
OR	“Neonatal”	OR	“Newborn”	OR	“Preterm”	
OR	“Premature”	OR	“Prematurity”	
6104	
“Patent	Ductus	Arteriosus”	OR	“PDA”	OR	
“Persistent	Ductus	Arteriosus”	AND	“Neonate”	
OR	“Neonatal”	OR	“Newborn”	OR	“Preterm”	
OR	“Premature”	OR	“Prematurity”	AND	
“Ibuprofen”	
378	
“Patent	Ductus	Arteriosus”	OR	“PDA”	OR	
“Persistent	Ductus	Arteriosus”	AND	“Neonate”	
OR	“Neonatal”	OR	“Newborn”	OR	“Preterm”	
OR	“Premature”	OR	“Prematurity”	AND	
“Ibuprofen”	OR	“Indomethacin”	
1211	
“Patent	Ductus	Arteriosus”	OR	“PDA”	OR	
“Persistent	Ductus	Arteriosus”	AND	“Neonate”	
OR	“Neonatal”	OR	“Newborn”	OR	“Preterm”	
OR	“Premature”	OR	“Prematurity”	AND	
“Ibuprofen”	OR	“Indomethacin”	OR	
“Indometacin”	
1214	
“Patent	Ductus	Arteriosus”	OR	“PDA”	OR	
“Persistent	Ductus	Arteriosus”	AND	“Neonate”	
OR	“Neonatal”	OR	“Newborn”	OR	“Preterm”	
OR	“Premature”	OR	“Prematurity”	AND	
“Ibuprofen”	OR	“Indomethacin”	OR	
“Indometacin”	OR	“Paracetamol”	
1238	
Limited	to	Randomized	Controlled	Trials	 126	
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Scopus	Literature	Results:	
Search	Term(s):	 Results:	
“Patent	Ductus	Arteriosus”	 16,386	
“Patent	Ductus	Arteriosus”	OR	“PDA”	 37,179	
“Patent	Ductus	Arteriosus”	OR	“PDA”	OR	
“Persistent	Ductus	Arteriosus”	
37,330	
“Patent	Ductus	Arteriosus”	OR	“PDA”	OR	
“Persistent	Ductus	Arteriosus”	AND	“Neonate”	
2069	
“Patent	Ductus	Arteriosus”	OR	“PDA”	OR	
“Persistent	Ductus	Arteriosus”	AND	“Neonate”	
OR	“Neonatal”	
3877	
“Patent	Ductus	Arteriosus”	OR	“PDA”	OR	
“Persistent	Ductus	Arteriosus”	AND	“Neonate”	
OR	“Neonatal”	OR	“Newborn”	
8221	
“Patent	Ductus	Arteriosus”	OR	“PDA”	OR	
“Persistent	Ductus	Arteriosus”	AND	“Neonate”	
OR	“Neonatal”	OR	“Newborn”	OR	“Preterm”	
8399	
“Patent	Ductus	Arteriosus”	OR	“PDA”	OR	
“Persistent	Ductus	Arteriosus”	AND	“Neonate”	
OR	“Neonatal”	OR	“Newborn”	OR	“Preterm”	
OR	“Premature”	
8645	
“Patent	Ductus	Arteriosus”	OR	“PDA”	OR	
“Persistent	Ductus	Arteriosus”	AND	“Neonate”	
OR	“Neonatal”	OR	“Newborn”	OR	“Preterm”	
OR	“Premature”	OR	“Prematurity”	
8741	
“Patent	Ductus	Arteriosus”	OR	“PDA”	OR	
“Persistent	Ductus	Arteriosus”	AND	“Neonate”	
OR	“Neonatal”	OR	“Newborn”	OR	“Preterm”	
OR	“Premature”	OR	“Prematurity”	AND	
“Ibuprofen”	
701	
“Patent	Ductus	Arteriosus”	OR	“PDA”	OR	
“Persistent	Ductus	Arteriosus”	AND	“Neonate”	
OR	“Neonatal”	OR	“Newborn”	OR	“Preterm”	
OR	“Premature”	OR	“Prematurity”	AND	
“Ibuprofen”	OR	“Indomethacin”	
1610	
“Patent	Ductus	Arteriosus”	OR	“PDA”	OR	
“Persistent	Ductus	Arteriosus”	AND	“Neonate”	
OR	“Neonatal”	OR	“Newborn”	OR	“Preterm”	
OR	“Premature”	OR	“Prematurity”	AND	
“Ibuprofen”	OR	“Indomethacin”	OR	
“Indometacin”	
1983	
“Patent	Ductus	Arteriosus”	OR	“PDA”	OR	
“Persistent	Ductus	Arteriosus”	AND	“Neonate”	
OR	“Neonatal”	OR	“Newborn”	OR	“Preterm”	
OR	“Premature”	OR	“Prematurity”	AND	
“Ibuprofen”	OR	“Indomethacin”	OR	
“Indometacin”	OR	“Paracetamol”	
2018	
“Patent	Ductus	Arteriosus”	OR	“PDA”	OR	
“Persistent	Ductus	Arteriosus”	AND	“Neonate”	
OR	“Neonatal”	OR	“Newborn”	OR	“Preterm”	
245	
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OR	“Premature”	OR	“Prematurity”	AND	
“Ibuprofen”	OR	“Indomethacin”	OR	
“Indometacin”	OR	“Paracetamol”	AND	
“randomi*ed	controlled	trial”	
Minus	duplications	from	PubMed	Search	 171	
	
Web	of	Science	Literature	Search	Results:	
Search	Term(s):	 Results:	
“Patent	Ductus	Arteriosus”	 6951	
“Patent	Ductus	Arteriosus”	OR	“PDA”	 21,527	
“Patent	Ductus	Arteriosus”	OR	“PDA”	OR	
“Persistent	Ductus	Arteriosus”	
21,	739	
“Patent	Ductus	Arteriosus”	OR	“PDA”	OR	
“Persistent	Ductus	Arteriosus”	AND	“Neonate”	
1132	
“Patent	Ductus	Arteriosus”	OR	“PDA”	OR	
“Persistent	Ductus	Arteriosus”	AND	“Neonate”	
OR	“Neonatal”	
1908	
	
“Patent	Ductus	Arteriosus”	OR	“PDA”	OR	
“Persistent	Ductus	Arteriosus”	AND	“Neonate”	
OR	“Neonatal”	OR	“Newborn”	
2393	
“Patent	Ductus	Arteriosus”	OR	“PDA”	OR	
“Persistent	Ductus	Arteriosus”	AND	“Neonate”	
OR	“Neonatal”	OR	“Newborn”	OR	“Preterm”	
3102	
“Patent	Ductus	Arteriosus”	OR	“PDA”	OR	
“Persistent	Ductus	Arteriosus”	AND	“Neonate”	
OR	“Neonatal”	OR	“Newborn”	OR	“Preterm”	
OR	“Premature”	
3448	
“Patent	Ductus	Arteriosus”	OR	“PDA”	OR	
“Persistent	Ductus	Arteriosus”	AND	“Neonate”	
OR	“Neonatal”	OR	“Newborn”	OR	“Preterm”	
OR	“Premature”	OR	“Prematurity”	
3477	
“Patent	Ductus	Arteriosus”	OR	“PDA”	OR	
“Persistent	Ductus	Arteriosus”	AND	“Neonate”	
OR	“Neonatal”	OR	“Newborn”	OR	“Preterm”	
OR	“Premature”	OR	“Prematurity”	AND	
“Ibuprofen”	
421	
“Patent	Ductus	Arteriosus”	OR	“PDA”	OR	
“Persistent	Ductus	Arteriosus”	AND	“Neonate”	
OR	“Neonatal”	OR	“Newborn”	OR	“Preterm”	
OR	“Premature”	OR	“Prematurity”	AND	
“Ibuprofen”	OR	“Indomethacin”	
1082	
“Patent	Ductus	Arteriosus”	OR	“PDA”	OR	
“Persistent	Ductus	Arteriosus”	AND	“Neonate”	
OR	“Neonatal”	OR	“Newborn”	OR	“Preterm”	
OR	“Premature”	OR	“Prematurity”	AND	
“Ibuprofen”	OR	“Indomethacin”	OR	
“Indometacin”	
1087	
“Patent	Ductus	Arteriosus”	OR	“PDA”	OR	
“Persistent	Ductus	Arteriosus”	AND	“Neonate”	
1105	
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OR	“Neonatal”	OR	“Newborn”	OR	“Preterm”	
OR	“Premature”	OR	“Prematurity”	AND	
“Ibuprofen”	OR	“Indomethacin”	OR	
“Indometacin”	OR	“Paracetamol”	
“Patent	Ductus	Arteriosus”	OR	“PDA”	OR	
“Persistent	Ductus	Arteriosus”	AND	“Neonate”	
OR	“Neonatal”	OR	“Newborn”	OR	“Preterm”	
OR	“Premature”	OR	“Prematurity”	AND	
“Ibuprofen”	OR	“Indomethacin”	OR	
“Indometacin”	OR	“Paracetamol”	AND	
“Randomi*ed	Controlled	Trial”	
53	
Minus	Duplications	from	PubMed/Scopus	
Searches	
21	
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Appendix	2	–	Systematic	Review:	Excluded	Papers	
	
Author	(Year):	 Reason	for	Exclusion:	
Adamska	et	al	(2005)	(161)	 Unable	to	attain	translation.	
Aly	et	al	(2007)	(162)	 Did	not	outline	criteria	for	haemodynamic	
significance.	
Asbagh	et	al	(2015)	(163)	 Did	not	outline	criteria	for	haemodynamic	
significance.	
Bagheri	et	al	(2016)	(164)	 Did	not	outline	criteria	for	haemodynamic	
significance.	
Bravo	et	al	(2014)	(165)	 Did	not	outline	criteria	for	haemodynamic	
significance.	
Chotigeat	et	al	(2003)	(166)	 Did	not	outline	criteria	for	haemodynamic	
significance.	
Couser	et	al	(1996)	(167)	 Did	not	outline	criteria	for	haemodynamic	
significance.	
Dang	et	al	(2013)	(168)	 Did	not	outline	criteria	for	haemodynamic	
significance.	
DeMauro	et	al	(2013)	(169)	 Did	not	outline	criteria	for	haemodynamic	
significance.	
Hammerman	et	al	(2005)	(170)	 Not	an	RCT.	
Hammerman	et	al	(2008)	(171)	 Did	not	outline	criteria	for	haemodynamic	
significance.	
Kaapa	et	al	(1982)	(172)	 Used	aortograms,	not	echocardiograms.	
Krueger	et	al	(1987)	(173)	 Did	not	outline	criteria	for	haemodynamic	
significance.	
Lin	et	al	(2012)	(174)	 Did	not	outline	criteria	for	haemodynamic	
significance.	
Merritt	et	al	(1981)	(175)	 Did	not	outline	criteria	for	haemodynamic	
significance.	
Nestrud	et	al	(1980)	(176)	 Did	not	outline	criteria	for	haemodynamic	
significance.	
Peckham	et	al	(1984)	(177)	 One-year	follow-up	of	another	paper	included	
in	study.	
Pourarian	et	al	(2008)	(178)	 Did	not	outline	criteria	for	haemodynamic	
significance.	
Pourarian	et	al	(2015)	(179)	 Did	not	outline	criteria	for	haemodynamic	
significance.	
Rhodes	et	al	(1988)	(180)	 Did	not	outline	criteria	for	haemodynamic	
significance.	
Van	Overmeire	et	al	(2000)	(181)	 Did	not	outline	criteria	for	haemodynamic	
significance.	
Van	Overmeire	et	al	(2001)	(182)	 Did	not	outline	criteria	for	haemodynamic	
significance.	
Van	Overmeire	et	al	(2003)	(183)	 Not	an	RCT.	
Van	Overmeire	et	al	(2004)	(184)	 Did	not	outline	criteria	for	haemodynamic	
significance.	
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Appendix	3	–	Research	Protocol	
	
Investigating	Pulse	Wave	Velocity	as	a	Novel	
Biomarker	in	Neonatal	Haemodynamics	
Version	2.0	
06/11/18	
	
Main	Sponsor:	University	of	Liverpool	
Funders:	Student	project	and	Liverpool	Women’s	NHS	Foundation	Trust	
Study	Coordination	Centre:	Liverpool	Women’s	Hospital	NHS	Trust	
NRES	Reference:	18/NE/0058	
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Study	Team:	
Chief	Investigator:	Dr	Mark	Turner	
Co-	Investigators:	Dr	Charalampos	Kotidis,	Dr	Daniel	Hawcutt,	Ben	Rodgers	
Statistician:	Antonio	Eleuteri.	
Study	Manager:	Not	applicable.		
Study	Coordination	Centre:	
For	general	queries,	supply	of	study	documentation,	and	collection	of	data,	please	contact	Ben	
Rodgers	who	will	discuss	with	the	appropriate	clinician:	
Tel:	07714002504	
Email:	hlbrodge@student.liverpool.ac.uk	
Clinical	Queries:	
Clinical	queries	should	be	directed	at	Ben	Rodgers	(see	details	above).	
Sponsorship:	
The	University	of	Liverpool	is	the	main	sponsor	for	this	Study.	For	further	information	regarding	
the	sponsorship	conditions,	please	contact:	
Alex	Astor	
Head	of	Research	Support	–	Health	and	Life	Sciences	
University	of	Liverpool	
Research	Support	Office	
2nd	Floor	Block	D	Waterhouse	Building	
3	Brownlow	Street	
Liverpool	L69	3GL	
sponsor@liv.ac.uk	
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Study	Summary:	
This	protocol	describes	 the	“Pulse	Wave	Velocity	and	Phase	Difference	as	Novel	Biomarkers	 in	
Neonatal	 Haemodynamics”	 study	 and	 provides	 information	 about	 procedures	 for	 entering	
participants.	 Every	 care	 was	 taken	 in	 its	 drafting,	 but	 corrections	 or	 amendments	 may	 be	
necessary.	These	will	be	circulated	to	investigators	in	the	study.	Problems	relating	to	this	study	
should	be	referred,	in	the	first	instance,	to	the	primary	investigator	(Ben	Rodgers).	
This	study	will	adhere	to	the	principles	outlines	in	the	NHS	Research	Governance	Framework	for	
Health	and	Social	Care	(2nd	Edition).	 It	will	be	conducted	in	compliance	with	the	protocol,	Data	
Protection	Act	and	other	regulatory	requirements	as	appropriate.	
Glossary	of	Abbreviations:	
ANP	 Atrial	Natriuretic	Peptide	
ANS	 Autonomic	Nervous	System	
BNP	 Brain	Natriuretic	Peptide	
BPD	 Bronchopulmonary	Dysplasia	
BW	 Birth	Weight	
DA	 Ductus	Arteriosus	
ECG	 Electrocardiogram	
GA	 Gestational	Age	
GI	 Gastrointestinal	
HRV	 Heart	Rate	Variability	
hsPDA	 Haemodynamically	significant	Patent	Ductus	Arteriosus	
IVH	 Intraventricular	Haemorrhage	
NEC	 Necrotizing	Enterocolitis	
NICU	 Neonatal	Intensive	Care	Unit	
NO	 Nitric	Oxide	
NPV	 Negative	Predictive	Value	
NSAID	 Non-Steroidal	Anti-Inflammatory	Drug	
NT-proBNP	 Amino-terminal	pro-B-type	Natriuretic	Peptide	
PDA	 Patent	Ductus	Arteriosus	
PNS	 Parasympathetic	Nervous	System	
PPV	 Positive	Predictive	Value	
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PWV	 Pulse	Wave	Velocity	
RAAS	 Renin-Angiotensin-Aldosterone	System	
RDS	 Respiratory	Distress	Syndrome	
REC	 Research	Ethics	Committee	
SNS	 Sympathetic	Nervous	System	
SSA	 Site	Specific	Assessment	
UAC	 Umbilical	Arterial	Catheter	
	
Keywords:	
Pulse	Wave	Velocity,	Patent	Ductus	Arteriosus	(PDA),	Neonatology	
Title:	
Investigating	Pulse	Wave	Velocity	as	a	Novel	Biomarker	in	Neonatal	Haemodynamics.	
Design:	
Prospective	Observational	Study	
Aims:	
To	better	understand	the	effects	of	a	number	of	continuous	and	dichotomous	variables	on	the	
measurement	of	pulse	wave	velocity	in	neonates.	
Outcome	Measures:	
The	 relationship	 between	 pulse	 wave	 velocity	 and	 a	 number	 of	 variables	 affecting	 neonatal	
haemodynamics	in	the	first	three	days	of	life.	
Population	Eligibility:	
Inclusion	Criteria:	
Ø Neonate	admitted	to	Liverpool	Women’s	Hospital	Neonatal	Unit;	
Ø Age	0-3	days;	
Ø Umbilical	Arterial	Catheter	(UAC)	placed	in	situ	for	clinical	care	within	3	days	of	birth;	
Ø Transducer	capable	of	being	fitted	to	UAC	without	additional	intervention/disruption	to	
the	patient.	
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Exclusion	Criteria:	
Ø Age	>3	days;	
Ø UAC	not	sited	or	not	capable	of	being	fitted	to	transducer;	
Ø Survival	of	baby	expected	to	be	<72	hours;	
Ø Additional	 congenital	 heart	 disease	 or	 conditions	 expected	 to	 alter	 cardiovascular	
function	 (ventricular	 septal	 defect,	 atrioventricular	 septal	 defect,	 tetralogy	 of	 Fallot,	
transposition	 of	 great	 vessels,	 truncus	 arteriosus,	 coarctation	 of	 the	 aorta,	 congenital	
valvular	disease,	and	congenital	hydrops).	
Ø Chromosomal	abnormalities;	
Ø Considered	unsuitable	for	recruitment	by	nursing	staff	and	Consultant	Neonatologist	at	
Liverpool	Women’s	Hospital.	
Duration:	
Data	collection	will	occur	on	site	by	the	primary	investigator	(Ben	Rodgers)	from	February	18th	to	
1st	June	2018.	Statistical	analysis	and	write	up	will	be	performed	in	June	2018.	
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1.	Introduction:	
1.1.	Background:	
Preterm	birth,	defined	as	birth	at	less	than	37	weeks	gestational	age(1),	occurs	in	5-10%	of	births	
in	resource-rich	countries	such	as	the	UK	and	USA(2).	Preterm	neonates	are	a	population	with	a	
unique	 set	 of	 potential	 pathologies	 associated	 with	 high	 rates	 of	 mortality	 and	 long-term	
morbidity.	 From	 the	 development	 of	 antepartum	 steroid	 and	 surfactant	 therapy	 for	 neonatal	
respiratory	 distress	 syndrome	 (RDS)	 (4,	 5),	 to	 the	 use	 of	 probiotics	 in	 the	 prevention	 of	
necrotising	 enterocolitis	 (NEC)	 (185),	 survival	 rates	 in	 both	 term	 and	 preterm	 neonates	 have	
improved	 drastically	 across	 the	 globe(7,	 8).	 However,	 Lawn	 et	 al	 reported	 in	 2014	 that	 there	
were	still	2.9	million	neonatal	deaths	worldwide(9)	and	the	Office	for	National	Statistics	reported	
that	between	2014	and	2015,	immaturity-related	conditions	were	responsible	for	between	49.3-
50.3%	of	neonatal	deaths	in	England	and	Wales(10).	This	demonstrates	that	there	is	still	a	clear	
need	for	improved	care	within	the	field	of	neonatology	to	help	improve	outcomes.	
Biomarkers	in	Neonatology:	
Biomarkers	 are	 defined	 as	 “a	 characteristic	 that	 is	 objectively	measured	 and	 evaluated	 as	 an	
indicator	of	normal	biological	processes,	pathogenic	processes,	or	pharmacological	response	to	a	
therapeutic	 intervention”(53).	Neonatology	has	seen	an	increase	in	biomarker	research	to	help	
improve	 the	 diagnosis	 and	 management	 of	 life-threatening	 conditions.	 For	 example,	
conventional	 biomarkers	 such	 as	 interleukins	 and	 cytokines	 involved	 in	 the	 immune	 cascade	
have	 been	 extensively	 researched	 in	 relation	 to	 neonatal	 sepsis	 (54-56).	 However,	 these	
biomarkers	are	not	specific	to	a	particular	disease	or	organ	system.	There	has	thus	been	a	call	
for	 further	 investigation	 into	 “novel”	 biomarkers	 to	 help	 improve	 diagnostic	 capabilities	 and	
drug	 development	 in	 neonatology	 and	 paediatrics	 (57,	 58).	 Savage	 and	 Everett	 outlined	 the	
desirable	 traits	 of	 biomarkers	 (59).	 Ultimately,	 a	 biomarker	 should	 consist	 of	 a	 sample	 that	 is	
acceptable	 and	 accessible	 combined	with	 an	 appropriate	 and	 accurate	 assay.	 However,	when	
investigating	a	novel	biomarker	for	its	association	with	a	specific	clinical	outcome,	they	suggest	it	
is	important	to	consider	the	following:	
IV. Assay	performance	–	is	the	assay	accurate,	reliable	and	responsive	to	the	condition	
they	are	investigating?	
V. Qualification	–	does	the	biomarker	have	a	robust	relationship	with	the	current	gold	
standard	investigation	for	the	proposed	clinical	outcome?	
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VI. Utility	–	can	the	biomarker	improve	care	beyond	what	is	already	available?	(59)	
Kearns	 has	 also	 outlined	 the	 importance	 of	 considering	 the	 effects	 of	 normal	 growth	 and	
development	before	a	biomarker	is	implemented	in	clinical	practice	(58).	In	order	for	biomarkers	
to	be	considered	useful,	there	therefore	needs	to	be	a	rigorous	process	of	validation	before	they	
can	be	considered	for	implication	in	clinical	practice	(60-62).		
Pulse	 Wave	 Velocity	 and	 Phase	 Difference:	 Novel	 Biomarkers	 in	 the	
Assessment	of	Neonatal	Haemodynamics?	
Pulse	wave	 velocity	 (PWV)	 is	 a	method	 of	measuring	 arterial	 stiffness	 that	 is	 calculated	 from	
measurements	 of	 the	 time	 it	 takes	 the	 impulse	 arising	 from	 a	 contraction	 of	 the	 heart’s	
ventricles	 to	 travel	 between	 two	 recording	 sites	 –	 the	 so-called	 “pulse	 transit	 time”	 (70).	 The	
measurement	of	arterial	stiffness,	which	is	 inversely	proportional	to	PWV,	helps	us	understand	
the	mechanics	 of	 large	 vessels	 and	 thus	 circulatory	 physiology	 and	 disease	 (70).	 	 It	 has	 been	
suggested	 that	 the	 concurrent	 analysis	 of	 heart	 rate	 variability	 and	 PWV	 can	 also	 be	 used	 to	
assess	peripheral	vascular	sympathetic	functions	in	adults	which	reflect	a	number	of	pathologies	
(77).	 Furthermore,	 although	 it	 has	 typically	 been	 used	 in	 adult	 populations	 in	 the	 past,	 it	 has	
been	 shown	 that	PWV	can	be	accurately	measured	and	easily	 reproduced	when	assessing	 the	
vasculature	 of	 the	 neonate	 (78).	 The	 factors	 affecting	 PWV	 can	 be	 shown	 by	 the	 Moens-
Korteweg	equation	(figure	1):	
	 	
PWV	=								
	
Any	 factors	 that	 affect	 the	 components	 of	 this	 equation	 can	 cause	 variations	 to	 the	
measurement	of	PWV.	Although	predominantly	a	disease	of	older	populations,	arterial	stiffening	
has	been	noted	in	paediatric	populations	with	conditions	associated	with	cardiovascular	disease	
such	as	diabetes	mellitus	and	chronic	kidney	disease	(79,	80).	Hypotension	is	a	common	problem	
for	patients	admitted	to	NICU	and	the	resulting	increased	diameter	of	blood	vessels	will	result	in	
a	lower	pulse	wave	velocity.		
Figure	4	Moens-Korteweg	equation;	E	=	incremental	modulus	of	stiffness	of	the	vessel;	h	=	vessel	wall	thickness;	p	=	
density	of	blood;	R	=	radius	of	blood	vessel	
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Further	 insight	 into	the	stiffness	of	blood	vessels	can	be	gained	by	measuring	the	difference	in	
time	 between	 the	 R	 wave	 of	 an	 electrocardiogram	 (ECG)	 wave	 (corresponding	 to	 ventricular	
contraction)	and	the	peak	of	the	systolic	blood	pressure	wave	measured	at	a	known	point.	This	
value	is	known	as	the	phase	difference.	This	helps	measure	the	differences	in	mass	flow	of	blood	
compared	to	that	of	the	transmission	of	the	pulse	waves	within	the	vessels.		
In	 neonates,	 the	 recording	 of	 the	 systolic	 blood	 pressure	 wave	 requires	 the	 insertion	 of	 an	
umbilical	arterial	catheter	(UAC).	UAC’s	are	standard	practice	in	neonates	who	require	invasive	
haemodynamic	 monitoring	 or	 frequent	 blood	 tests	 in	 the	 days	 after	 birth	 (74).	 The	 UAC	 is	
connected	 to	 a	 transducer	 which	 provides	 real-time	 information	 to	 the	 patients	 monitor,	
allowing	 the	 arterial	 waveform	 to	 be	 observed.	 The	 use	 of	 appropriate	 software	 allows	 the	
information	on	the	arterial	waveform	of	the	neonate	to	be	collected	and	compared	to	the	ECG	R	
waves	to	calculate	the	phase	difference.	
PWV	is	an	established	biomarker	 in	adult	populations	and	has	shown	potential	with	regards	to	
its	 use	 in	 paediatrics	 (152).	However,	 the	 transitional	 circulation	 is	 extremely	 complex,	with	 a	
number	of	variables	affecting	the	haemodynamics	of	the	neonate.	These	include	gestational	age,	
weight,	 the	 open	 fetal	 channels	 (patent	 foramen	 ovale	 (PFO)	 and	 PDA),	 inotropic	 support,	 or	
comorbidities	such	as	IVH	and	lung	disease.	Further	research	into	the	effects	of	these	potential	
variables	 is	 necessary	 to	 further	 validate	 PWV	 and	 phase	 difference	 as	 novel	 biomarkers	 in	
neonatology	before	their	use	in	clinical	practice	is	further	assessed.	
The	Patent	Ductus	Arteriosus:	
Although	 essential	 for	 fetal	 life	 whilst	 in	 utero,	 persistence	 of	 the	 DA	 into	 infancy	 can	 have	
significant	 haemodynamic	 consequences,	 notably	 disruption	 to	 cerebral	 and	 systemic	
circulation.	
A	persistent	patent	ductus	arteriosus	(PDA)	is	a	common	condition	within	neonatology.	It	occurs	
in	 approximately	 1	 in	 2000	 neonates	 born	 at	 term	 (38)	 and	 is	 inversely	 proportional	 to	
birthweight	 in	premature	neonates,	with	the	incidence	ranging	from	30-50%	(14).	Clyman	et	al	
reported	that	combined	data	from	five	other	studies	showed	that	spontaneous	closure	of	a	PDA	
after	7	days	of	life	occurred	in	only	36%	of	patients	born	at	27-28	weeks	gestational	age	(GA),	in	
32%	of	those	born	at	25-26	weeks	GA,	and	in	just	13%	of	those	born	at	24	weeks	GA	(15).	There	
are	a	number	of	 factors	 that	contribute	 to	 the	persistence	of	a	PDA	 in	preterm	neonates.	 It	 is	
thought	that	as	term	babies	approach	birth,	there	is	a	decrease	in	the	sensitivity	of	ductal	cells	
to	the	vasodilatory	prostaglandins	that	help	keep	the	DA	patent	(39).	Ductal	cells	in	the	preterm	
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infant	are	thought	to	be	more	sensitive	to	vasodilatory	prostaglandins,	and	this	in	combination	
with	 the	 immature	 fetal	 lungs’	 reduced	 ability	 to	metabolise	 prostaglandins	 contribute	 to	 the	
failure	of	the	DA	to	close	(40,	41).		
PDA	 is	 associated	with	 a	number	of	 adverse	outcomes	 in	 infancy.	 It	 has	been	associated	with	
life-threatening	 conditions	 such	 as	 IVH,	 NEC	 and	 bronchopulmonary	 dysplasia	 (BPD)	 (15-18).	
Adverse	outcomes	secondary	to	PDA,	particularly	BPD,	can	be	attributed	to	the	so	called	“steal	
phenomenon”.	A	 left-to-right	 shunt	 caused	by	 the	 lower	 vascular	 resistance	of	 the	pulmonary	
vessels	 results	 in	 pulmonary	 hyperperfusion	 and	 systemic	 hypoperfusion	 (42).	 This	 has	 a	
particularly	significant	effect	on	the	cerebral,	renal	and	mesenteric	systems	(15,	43).		
Current	 Practices	 in	 the	 Detection	 and	 Monitoring	 of	 the	 Patent	 Ductus	
Arteriosus:	
Although	 investigations	 such	as	ECG	and	chest	 radiographs	 can	provide	additional	 information	
when	assessing	an	infant	with	a	PDA,	the	gold	standard	investigation	is	the	echocardiogram	(43).	
This	allows	direct	visualisation	and	measurement	of	the	severity	of	the	PDA.	However,	accurate	
use	 of	 echocardiography	 requires	 specialist	 training	 and	 exhibits	 approximately	 a	 10%	 intra-
observer	variability	and	a	15-20%	inter-observer	variability	(186).	Furthermore,	investigations	in	
neonatal	 intensive	 care	 (NICU)	 can	 be	 detrimental	 to	 the	 health	 and	 the	 development	 of	 the	
preterm	 infant.	 Disruption	 of	 sleep,	 increased	 noise	 around	 the	 incubator	 and	 temperature	
changes	 associated	 with	 interventions	 can	 all	 have	 adverse	 effects	 on	 the	 neonate	 (11-13).	
Echocardiography	 provides	 only	 a	 one-off	 measurement	 and	 therefore	 requires	 multiple	
readings	 to	 monitor	 PDA	 closure,	 or	 to	 assess	 patients	 with	 possible	 PDA	 reopening.	 It	 is	
therefore	believed	that	a	reduction	in	unnecessary	echocardiography	in	neonates	suspected	of	
suffering	from	PDA	would	be	beneficial	to	the	overall	care	of	neonates.	We	postulate	that	novel	
biomarkers	that	allow	continuous	non-invasive	monitoring	of	PDA	in	preterm	neonates	will	help	
improve	diagnostic	and	monitoring	practices	in	NICU.		
A	 recent	 pilot	 study	 performed	 at	 the	 Liverpool	Women’s	Hospital	 assessed	 the	 use	 of	 phase	
difference	 and	 pulse	 wave	 velocity	 as	 potential	 novel	 biomarkers	 in	 the	 haemodynamic	
assessment	of	extremely	preterm	neonates.	Although	it	was	a	small	pilot	study	consisting	of	just	
14	patients,	it	showed	promising	results	with	phase	difference	showing	significant	correlation	to	
the	PDA	diameter	(P	=	<0.001,	r	=	0.820).	The	pilot	study	also	suggested	that	PWV	was	related	to	
PDA	size	in	preterm	neonates	as	it	alters	the	parameters	of	the	Moens-Korteweg	equation.	We	
postulate	that	changes	to	the	ANS	affecting	vascular	tone	will	alter	the	measurement	of	PWV	in	
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newborn	babies	due	to	changes	in	vessel	diameter.	Although	PWV	and	phase	difference	require	
further	research	into	the	effect	of	common	variables	found	in	neonatology	on	their	validity,	it	is	
believed	that	the	results	of	this	pilot	study	warrant	further	research.	
1.2.	Rationale	for	Study:	
Novel	 biomarkers	 used	 in	 the	 monitoring	 of	 neonatal	 haemodynamics	 could	 significantly	
improve	neonatal	outcomes.	PWV	is	a	useful	biomarker	in	the	investigation	of	haemodynamics	
in	 adult	 and	 paediatric	 populations;	 however,	 there	 is	 limited	 evidence	 in	 the	 neonatal	
population.	The	continuously	changing	nature	of	neonatal	haemodynamics	during	the	first	days	
of	life	possess	a	significant	challenge	for	the	validation	of	haemodynamic	biomarkers	due	to	the	
multiple	 simultaneously	 changing	 parameters	 (cardiac,	 vascular,	 pulmonary	 and	 autonomic	
adaptation	to	extrauterine	life).	Disease	and	prolonged	patency	of	the	fetal	channels	can	further	
complicate	 the	 above	 interactions.	 Assessing	 the	 impact	 of	 potential	 variables	 affecting	 the	
measurement	of	PWV	and	phase	difference	is	crucial	for	their	validation	as	potential	biomarkers	
in	neonatology.	
PDA	is	extremely	prevalent	 in	preterm	neonates.	 It	often	requires	serial	monitoring	in	order	to	
both	 diagnose	 the	 condition	 and	 assess	 its	 response	 to	 treatment.	 It	 is	 believed	 that	 further	
research	 into	 other	 non-invasive	methods	 of	 investigation	 is	warranted	 to	 improve	 its	 overall	
management	 in	secondary	care.	Reducing	 the	number	of	potentially	unnecessary	 investigation	
may	 also	 help	 reduce	 the	 distress	 experienced	 by	 the	 patient	 and	 their	 family.	 Based	 on	 the	
results	of	the	recent	pilot	study	performed	at	the	Liverpool	Women’s	Hospital,	we	hypothesise	
that	a	PDA	is	associated	with	alterations	in	the	PWV	and	phase	difference.	We	postulate	that	this	
is	 likely	 to	be	due	 to	 the	effect	of	vasodilatation	associated	with	PDA	on	 the	Moens-Korteweg	
equation.	We	anticipate	that	the	larger	the	PDA	diameter,	the	lower	the	PWV	and	the	larger	the	
phase	difference.	
2.	Study	Objectives:	
The	aim	of	the	study	is	to	improve	our	understanding	of	the	factors	affecting	the	measurement	
of	PWV	and	phase	difference	in	neonates.	A	prospective	cohort	study	of	neonates	admitted	to	
the	NICU	with	a	UAC	in	situ	will	be	performed	in	the	Liverpool	Women’s	Hospital.		
The	primary	objective	of	this	study	is	to	investigate	the	associations	of	a	number	of	demographic	
variables	with	PWV	and	phase	difference.	These	are:		
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I. Gestational	Age;	
II. Birth	Weight;	
III. Postnatal	Age.	
IV. Twin	or	higher	multiple	pregnancies.	
The	 rationale	 for	 the	 investigation	 of	 the	 link	 between	 PWV,	 phase	 difference	 and	 these	
variables	is	to	better	understand	patient	factors	that	may	affect	the	measurement	of	these	novel	
biomarkers.	 In	 order	 to	 validate	 their	 measurement	 as	 potential	 biomarkers,	 it	 is	 crucial	 to	
identify	 any	 features	 that	 may	 cause	 anomalous	 results	 or	 that	 may	 need	 to	 be	 taken	 into	
account	when	calculating	 their	value	and	applying	 it	 to	a	clinical	picture.	Features	 such	as	GA,	
weight,	 age	 and	 HRV	 are	 greatly	 variable	 in	 neonatal	 populations	 and	 have	 the	 potential	 to	
affect	the	overall	haemodynamics	of	the	patient.	Twin	or	higher	multiple	pregnancies	can	result	
in	disturbances	to	fetoplacental	haemodynamics.	
The	secondary	objective	is	to	investigate	the	associations	of	variables	that	vary	after	birth	on	the	
PWV	and	phase	difference.	These	include:	
I. Inotropic	support;	
II. Infection	–	suspected	or	blood	culture	confirmed;	
III. Intraventricular	Haemorrhage	(IVH)	–	presence	yes/no	+/-	grade	(1-4);	
IV. Autonomic	Function	(as	measured	by	heart	rate	variability	(HRV));	
V. Oxygen	saturation;	
VI. The	 tertiary	objective	 is	 to	assess	 the	 relationship	between	 the	measurement	of	PWV,	
phase	difference	and	PDA	diameter.	
The	 rationale	 for	 investigating	 these	 dichotomous	 variables	 is	 their	 effect	 on	 patient	
haemodynamics.	 Inotropic	support	has	a	direct	effect	on	the	blood	flow	due	to	their	effect	on	
heart	contractility.	Sepsis	causes	widespread	vasodilatation	with	a	reduction	in	systemic	vascular	
resistance	 and	 changes	 to	 cardiac	 output.	 Intraventricular	 haemorrhage	 is	 linked	 to	 pressure	
passive	 cerebral	 circulation	 and	 changes	 to	 cerebral	 autoregulation	 which	 are	 particularly	
common	 in	 preterm	 infants(187).	 As	 previously	mentioned,	 it	 has	 been	hypothesised	 that	 the	
presence	 of	 a	 PDA	 leads	 to	 a	 predominance	 of	 the	 PNS,	 resulting	 in	 vasodilatation	 and	 thus	
alterations	 to	 the	PWV.	However,	 the	development	of	 the	autonomic	nervous	system	has	also	
been	 shown	 to	be	altered	 in	 those	born	prematurely	who	do	not	necessarily	 suffer	 from	PDA	
(188).	Data	on	HRV	 is	 to	be	collected	 to	better	understand	 the	 relationship	between	 the	ANS,	
PDA	 and	 PWV.	 The	 pilot	 study	 previously	 conducted	 at	 Liverpool	Women’s	Hospital	 assessing	
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the	correlation	between	PDA	and	phase	difference	also	 found	a	potential	association	between	
the	 arterial	waveform	 produced	 as	 part	 of	 the	measurement	 of	 oxygen	 saturation	 and	 phase	
difference.	 A	 recent	 study	 by	Goudjil	 et	 al	 assessed	 the	 measurement	 of	 PWV	 expressed	 as	
phase	difference	as	a	non-invasive	method	for	the	detection	of	a	PDA	(68).	They	collected	data	
on	 those	aged	<32	weeks	GA	and	using	arterial	photoplethysmography	collected	 from	a	pulse	
oximeter,	 they	 found	 that	 phase	 difference	 was	 strongly	 associated	 with	 PDA	 (optimal	 pulse	
phase	difference	(PPD)	cut-off	of	≥1.65	deg/cm,	with	an	area	under	the	ROC	curve	of	0.98	(95%	
confidence	interval,	0.96-1),	sensitivity	=	94.2%;	specificity	=	98.3%)	and	should	be	considered	as	
a	 non-invasive	method	 of	 detection	 (68).	 Since	 oxygen	 saturation	 is	 routinely	 collected	 on	 all	
babies	 on	 the	 unit,	 we	 hope	 to	 gather	 some	 additional	 data	 to	 further	 research	 into	 this	
relationship,	whilst	 also	 comparing	 it	 to	 the	 data	 collected	 from	 the	 arterial	waveform	of	 the	
UAC.	 This	 will	 enable	 us	 to	 further	 assess	 the	 validity	 of	 PWV/phase	 difference	 as	 a	 novel	
biomarker	 in	 the	 investigation	 of	 PDA	 whilst	 also	 identifying	 the	 optimal	 method	 of	
measurement.	
3.	Study	Design:	
This	 prospective	 observational	 study	 will	 be	 conducted	 at	 Liverpool	 Women’s	 Hospital.	 All	
neonates	 admitted	 who	 have	 a	 UAC	 within	 the	 first	 three	 days	 of	 life	 will	 be	 eligible	 for	
recruitment	in	the	study.		
A	demographic	profile	(consisting	of	routinely	collected	data	only)	will	be	collected	from	existing	
clinical	 records.	 Data	 will	 also	 be	 collected	 on	 PWV,	 phase	 difference,	 haemodynamic	
biomarkers	of	PDA	via	echocardiogram,	dose	and	 rate	of	 infusion	of	 inotropes,	 and	additional	
comorbidities	that	are	deemed	to	affect	the	patient’s	haemodynamics	(appendix	1).		
All	 clinical	 data	 to	 be	 collected	 as	 part	 of	 this	 study	will	 be	 in	 line	with	 the	 standard	 of	 care	
protocol	at	the	Liverpool	Women’s	Hospital.	No	investigations/procedures	will	be	performed	in	
addition	to	the	standard	care	patients	receive	whilst	placed	in	the	NICU.	
Inclusion	and	Exclusion	Criteria:	
Inclusion	Criteria:	
Ø Neonate	admitted	to	Liverpool	Women’s	Hospital	Neonatal	Unit;	
Ø Age	0-3	days;	
Ø UAC	placed	in	situ	for	clinical	care	within	3	days	of	birth;	
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Ø Transducer	capable	of	being	fitted	to	UAC	without	additional	intervention/disruption	to	
the	patient.	
Exclusion	criteria:	
Ø Age	>3	days;	
Ø UAC	not	sited	or	not	capable	of	being	fitted	to	transducer;	
Ø Survival	of	baby	expected	to	be	<24	hours;	
Ø Additional	 congenital	 heart	 disease	 or	 conditions	 expected	 to	 alter	 cardiovascular	
function	 (ventricular	 septal	 defect,	 atrioventricular	 septal	 defect,	 tetralogy	 of	 Fallot,	
transposition	 of	 great	 vessels,	 truncus	 arteriosus,	 coarctation	 of	 the	 aorta,	 congenital	
valvular	disease,	and	congenital	hydrops).	
Ø Chromosomal	abnormalities.	
Ø Considered	unsuitable	for	recruitment	by	nursing	staff	and	Consultant	Neonatologist	at	
Liverpool	Women’s	Hospital.	
Study	Outcomes:	
1. Descriptive	data	about	PWV	and	phase	difference	in	the	neonatal	period;	
2. Information	about	relationships	between	PWV	and	phase	difference	and:	
A. Demographic	data	
B. Variables	influences	by	postnatal	events	and	PDA	diameter.	
Study	Procedures:	
Recruitment:	
All	patients	admitted	to	the	unit	who	have	a	UAC	in	situ	within	the	first	three	days	of	life	will	be	
included	 in	 this	 study.	 Clinical	 data	 that	 is	 collected	 in	 accordance	 to	 the	 standard	 of	 care	
protocol	will	be	anonymised	and	analysed	 in	accordance	with	 the	aims	of	 the	study.	Based	on	
the	typical	patient	population	that	is	observed	at	the	Liverpool	Women’s	Hospital,	we	believe	it	
is	 reasonable	 to	 recruit	 a	minimum	of	30	patients	 in	 this	 study.	Posters	will	 be	erected	 in	 the	
neonatal	 unit	 to	 make	 staff	 aware	 of	 eligible	 participants	 in	 the	 hope	 this	 will	 improve	
participant	recruitment	(appendix	2).	Parents	will	be	able	to	opt	out	of	the	study.	
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Consent:	
All	 clinical	 data	used	as	part	of	 this	 prospective	observational	 trial	 is	 data	 that	will	 already	be	
collected	 as	 part	 of	 each	 patient’s	 routine	 clinical	 care	 at	 the	 Liverpool	 Women’s	 Hospital.	
Additional	 information	 on	 PWV	 and	 phase	 difference	 will	 be	 collected	 without	 further	
intervention	 to	 the	 patient.	 These	 values	will	 be	 calculated	 based	 on	 the	 routine	 clinical	 data	
collected	(see	“Pulse	Wave	Velocity	and	Phase	Difference”	section	below).	Each	participant	will	
be	 assigned	 a	 study	 number	 and	 no	 identifiable	 information	will	 be	 linked	 to	 the	 data	 that	 is	
collected.	Based	on	the	fact	this	study	will	be	performed	using	anonymised	data	that	requires	no	
alteration	to	patient	care,	we	will	not	be	seeking	parental	consent	for	this	study.	
The	parents	may	become	aware	of	the	study	procedures	(e.g.	adding	the	monitoring	equipment	
to	the	monitoring	procedures,	even	though	the	study	monitoring	equipment	has	no	 impact	on	
the	 baby).	 A	 study	 information	 leaflet	 will	 be	 made	 available	 for	 families	 (appendix	 3).	 The	
leaflet,	along	with	the	aforementioned	ward	posters	and	verbal	explanations	provided	by	clinical	
staff	and	the	research	team,	will	give	parents	the	ability	to	opt	out	of	the	study.	
Data	Collection:	
Data	 collection	will	 occur	 on	days	 0-3	 of	 life	where	 an	 infant	 has	 a	UAC	 in	 situ	 as	 part	 of	 the	
routine	pathway	of	clinical	care.	Days	of	 life	will	be	calculated	according	to	the	ward	policy	on	
the	beginning	of	day	1	of	life.	If	a	baby	has	a	UAC	fitted	on	day	2	(or	3)	a	reduced	number	of	days	
data	will	be	collected.	Also,	 if	a	UAC	 is	removed	or	stops	functioning	prior	to	day	3,	a	reduced	
number	of	days	data	will	be	collected.	
The	data	will	be	collected	from	the	routine	monitoring	undertaken	on	the	baby	(see	below)	and	
will	 be	 stored	 on	 the	 Liverpool	 Women’s	 Hospital	 Trust	 system.	 Access	 to	 raw	 data	 on	 this	
system	will	be	limited	to	the	named	study	team.	The	collection	and	storage	of	this	information	
will	 be	 password	 protected	 to	 ensure	 security	 of	 identifiable	 information.	 Prior	 to	 statistical	
analysis,	all	data	will	be	anonymised	and	transferred	to	a	University	of	Liverpool	computer	based	
shared	 drive	 to	 allow	 all	 members	 of	 the	 research	 team	 to	 have	 access	 to	 the	 relevant	
information	without	compromising	patient	confidentiality.	
Invasive	Blood	Pressure	Monitoring:	
Continuous	 invasive	 BP	 will	 be	 monitored	 via	 an	 umbilical	 artery	 catheter	 (3.5	 Fr)	 that	 was	
inserted	 soon	 after	 birth.	 The	 catheters	 are	 typically	 positioned	 between	 the	 sixth	 and	 tenth	
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thoracic	 vertebra.	 The	 catheter	 will	 be	 connected	 to	 the	 electronic	 transducer	 via	 a	 38	 cm	
extension	 made	 from	 rigid	 plastic.	 The	 distance	 from	 the	 blood	 pressure	 transducer	 will	 be	
calculated	based	on	UAC	and	extension	length.		
Catheter	position	is	confirmed	with	radiography.	The	aortic	valve	is	radio	translucent	and	there	
is	no	clear	landmark	to	identify	it.	The	relation	of	the	aortic	valve	to	vertebral	 level	varies	a	lot	
and	 the	 average	 position,	 according	 to	 Eycleshymer	 and	 Schoemaker,	 is	 at	 the	 level	 of	 the	
middle	third	of	the	seventh	thoracic	vertebra(153).	There	are	no	data	for	preterm	babies	and	for	
this	reason	we	reviewed	CT	scans	from	term	infants	with	cardiac	conditions	and	found	that	the	
relation	of	the	aortic	valve	to	the	vertebral	level	varied	greatly,	but	the	average	was	found	to	be	
around	the	6th	thoracic	vertebra.	The	distance	of	the	catheter	tip	from	the	aortic	valve	will	be	
traced	using	PACS	software.	
	All	possible	steps	will	be	taken	to	ensure	the	collection	of	quality	data.	The	UACs	and	the	data	
being	displayed	on	the	monitor	will	be	assessed	by	a	suitably	experienced	member	of	staff	prior	
to	data	collection.	Ultimately,	the	decision	to	collect	data	will	be	at	the	discretion	of	the	member	
of	 the	 clinical	 care/research	 team	 who	 is	 collecting	 it.	 The	 assessment	 of	 the	 data	 will	 be	
qualitative	and	will	include	assessment	of	the	following:	
Ø Pulse	 pressure:	 normal	 pulse	 pressure	 for	 preterm	 infants	 is	 approximately	 15-
25mmHg(154).	A	narrow	pulse	pressure	may	be	seen	if	the	UAC	is	blocked;	
Ø Arterial	waveform:	 the	 arterial	waveform	will	 be	 assessed	 for	 the	 presence	 of	 normal	
features	such	as	the	percussion	wave,	the	tidal	wave	and	the	dicrotic	notch	and	wave;	
Ø Appearance	of	UAC:	visual	assessment	of	 the	UAC	 (e.g.	checking	 for	air	bubbles	 in	 the	
tubing	between	the	UAC	and	the	blood	pressure	transducer);	
Ø Transducer	 location:	ensuring	 the	blood	pressure	 transducer	 is	 situated	at	 the	 level	of	
the	patient’s	heart.	
Photographs	 will	 be	 taken	 with	 the	 absence	 of	 identifiable	 information	 to	 aid	 in	 the	
identification	of	“dampened”	signals	which	occur	when	the	UAC	becomes	blocked.	This	will	be	
used	 to	 ensure	 the	 quality	 of	 data	 collection.	 We	 will	 also	 endeavour	 to	 grade	 the	 images	
depending	on	the	amount	of	dampening	(absent,	mild,	moderate,	severe)	to	assess	the	effect	of	
dampening	on	other	variables.	
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Pulse	Wave	Velocity	and	Phase	Difference:	
The	PWV	and	phase	difference	will	be	calculated	by	combining	the	ECG	and	peak	systolic	blood	
pressure	waveform	collected	by	the	IxTrend	software®	(Ixellence	GmbH,	Wildau,	Germany).	The	
time	difference	between	 the	R	wave	of	 the	ECG	waveform	and	 the	peak	of	 the	 systolic	blood	
pressure	waveform	will	be	calculated	and	expressed	as	phase,	i.e.	the	proportion	of	one	cardiac	
cycle.	 This	 data	 is	 collected	 by	 connecting	 the	 patient’s	 monitor	 (which	 is	 already	 receiving	
information	 via	 the	 transducer	 attached	 to	 the	 patient’s	 UAC)	 to	 a	 computer	 with	 the	
appropriate	 software	 installed	 (figure	 2).	 Data	 is	 therefore	 collected	 without	 any	 additional	
disruption	 to	 the	 infant.	We	 aim	 to	 collect	 data	 for	 between	 a	minimum	 of	 30	minutes	 to	 a	
maximum	of	2	hours	a	day	for	the	first	three	days	of	life	for	those	included	in	the	study.	This	will	
provide	baseline	 information	on	the	variation	of	PWV/phase	difference	 in	early	 life.	This	 is	 the	
data	 that	 will	 be	 compared	 to	 the	 variables	 stated	 above	 to	 better	 understand	 the	
characteristics	of	these	biomarkers	in	the	developing	neonate.	As	much	data	will	be	collected	as	
possible	for	the	first	three	days	of	life.	For	example,	if	a	neonate	is	fitted	with	a	UAC	on	day	2,	
they	will	still	be	eligible	for	inclusion	in	the	study	but	only	2	days’	worth	of	data	will	be	collected.		
	
Additional	 data	 collection	 will	 be	 performed	 for	 between	 a	 minimum	 of	 30	 minutes	 and	 a	
maximum	 of	 2	 hours	 before	 each	 echocardiogram.	 We	 aim		
to	 complete	 this	 data	 collection	 within	 a	 4	 hour	 window	 of	 the	 echocardiogram	 (i.e.	 from	 2	
Figure	2	the	proposed	method	of	collection	of	data	for	PWV	and	Phase	Difference 
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hours	before	to	2	hours	after	the	procedure).	This	will	provide	more	time-specific	data	that	can	
be	more	accurately	compared	to	PDA	diameter.		
Echocardiography:	
All	 echocardiography	 studies	 will	 be	 performed	 using	 a	 Vivid	 E9	 GE	machine	 and	 12	 or	 6-Hz	
probe.	Echocardiography	will	be	conducted	according	to	 the	standard	operating	procedures	of	
the	Liverpool	Women’s	Hospital	depending	on	clinical	need	for	each	individual	patient.	The	PDA	
diameter	 will	 be	 recorded	 during	 each	 echocardiogram	 that	 is	 performed.	 No	 additional	
echocardiograms	will	be	performed	than	 is	clinically	necessary	 in	order	to	minimise	distress	to	
the	patient	and	their	family.	We	anticipate	that	due	to	the	patient’s	admission	to	the	neonatal	
unit	 and	 their	 need	 for	 the	 insertion	 of	 a	 UAC,	 each	 patient	 will	 receive	 at	 least	 one	
echocardiogram	during	their	admission.	
Autonomic	Function:	
The	ECG	data	will	be	recorded	as	part	of	the	routine	neonatal	care,	from	three	lead	electrodes	
forming	the	Einthoven	triangle	 -	 two	electrodes	are	placed	onto	either	side	of	 the	chest	and	a	
third	on	 the	outer	aspect	of	one	 thigh.	 IxTrend	 software®	 (Ixellence	GmbH,	Wildau,	Germany)	
will	be	used	to	capture	ECG	raw	data.	The	signal	will	be	sampled	at	512	Hz	and	stored	on	trust	
shared	drive.	Recordings	will	be	performed	whilst	the	infants	are	asleep	and	where	they	will	not	
be	 disturbed	 throughout	 the	 duration	 of	 the	 recording.	 Recordings	 will	 precede	
echocardiography.	Sleep	state	will	be	justified	according	to	criteria	set	by	Sheldon	(189).	Of	note,	
this	procedure	does	not	cause	any	disturbance	to	the	participant	and	so	can	be	conducted	at	the	
same	 time	 as	 other	 assessments.	 Methods	 for	 HRV	 are	 described	 in	 the	 Task	 Force	 of	 the	
European	 Society	 of	 Cardiology	 report	 and	 the	 North	 American	 Society	 of	 Pacing	 and	
Electrophysiology	(1996)	(190).	Spectral	analysis	is	commonly	applied	to	a	series	of	cardiac	cycle	
RR	intervals	derived	from	an	ECG	signal	over	a	3-	to	15-minutes	period	(190,	191).	The	spectral	
analysis	 of	 the	 RR	 series	 will	 be	 performed	 by	 using	 an	 algorithm	 of	 Fourier	 Transform	
(MATLAB®)	(192).	The	goal	of	spectral	analysis	was	to	determine	the	repartition	of	power	(190)	
across	low	frequencies	(LFs,	0.04–0.15	Hz)	reflecting	both	the	sympathetic	and	parasympathetic	
stimulation	and	high	frequencies	(HFs,	0.15–1.5	Hz)	reflecting	parasympathetic	activity	in	the	RR	
series.	
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4.	Statistical	Analysis:	
All	data	collected	will	be	pseudoanonymised.	Data	without	personal	identifiers	will	be	passed	to	
shared	areas	 in	 the	University	of	Liverpool	 file	system.	Graphical	analysis	will	be	performed	to	
assess	gross	association	between	PWV,	phase	difference	and	days	of	life.	This	will	be	combined	
with	 data	 related	 to	 the	 variables	 anticipated	 to	 affect	 the	measurement	 of	 PWV	 and	 phase	
difference	to	assess	their	association.	Additional	data	collected	on	PWV	and	phase	difference	in	
correlation	with	echocardiography	and	measurement	of	 the	PDA	as	mentioned	above	will	also	
be	 included.	 Correlation	 coefficient	 will	 also	 be	 calculated.	 Intergroup	 comparisons	 will	 be	
conducted	on	demographic	variables	collected.	The	statistical	significance	will	be	set	depending	
on	 the	 sample	 size	 collected.	 Linear	 regression	 analysis	 will	 be	 performed	 to	 identify	 the	
correlation	between	multiple	variables.	Non-parametric	statistical	analysis	will	be	conducted	to	
assess	the	distribution	of	variables	measured	as	part	of	the	study.	The	number	of	variables	to	be	
included	in	multivariate	analysis	will	rely	on	the	number	of	participants	recruited	as	part	of	the	
study	(see	“Sample	Size”	below).	Any	additional	statistical	analysis	performed	will	be	according	
to	recommendation	by	the	statistician	for	this	study.	
Sample	Size:	
We	aim	to	recruit	as	many	patients	as	possible	to	the	study	within	the	time	available.	Based	on	
the	intake	of	patients	at	the	Liverpool	Women’s	Hospital	and	the	percentage	of	those	requiring	
the	insertion	of	UACs,	we	aim	to	complete	the	data	collection	for	this	study	over	approximately	
4	months	and	believe	 it	 is	reasonable	to	collect	data	on	a	minimum	of	40	patients.	 In	order	to	
conduct	multivariate	analysis,	we	aim	to	recruit	10	patients	per	variable	we	aim	to	compare	to	
PWV/phase	difference.	Since	we	cannot	accurately	predict	the	number	of	participants	that	will	
be	recruited	to	the	study,	we	acknowledge	the	possibility	that	the	number	of	variable	compared	
to	PWV	may	need	to	be	reduced	accordingly.	The	decision	based	on	what	variable(s)	to	exclude	
in	this	instance	would	be	based	on	the	clinical	judgement	of	the	research	team.	
5.	Regulatory	Issues:	
This	 Study	 will	 be	 conducted	 according	 to	 the	 National	 Institute	 of	 Health	 Research’s	 Good	
Clinical	Practice	guidelines.	The	Chief	Investigator	aims	to	gain	ethical	approval	from	the	relevant	
Research	Ethics	Committee	(REC).	The	study	will	be	submitted	for	Site	Specific	Assessment	(SSA)	
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at	each	participating	NHS	Trust.	The	Chief	Investigator	will	require	a	copy	of	the	Trust	research	
and	development	approval	letter	before	accepting	participants	into	the	study.	The	study	will	be	
conducted	 in	 accordance	 with	 the	 recommendations	 for	 physicians	 involved	 in	 research	 on	
human	subjects	adopted	by	the	18th	World	Medical	Assembly,	Helsinki	1964	and	later	revisions.		
6.	End	of	Study:	
The	end	of	study	will	be	defined	as	database	lock.	
7.	Archiving:	
Data	 and	 all	 appropriate	 information	 will	 be	 stored	 for	 a	 minimum	 of	 5	 years	 after	 the	
completion	of	the	study.	
8.	Publication	Policy:	
We	hope	that	this	study	will	produce	results	that	will	be	eligible	for	publication	in	peer-reviewed	
journals	and	for	presentation	at	scientific	conferences.		
9.	Intellectual	Property:	
We	will	be	in	contact	with	the	University	of	Liverpool	regarding	gaining	intellectual	property	for	
the	 potential	 use	 of	 this	 biomarker	 as	 a	 detection/monitoring	 tool	 in	 the	 management	 of	
neonates	with	PDA	in	the	future.		
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Appendix	4:	Sample	Data	Collection	Form	
Patient	ID	Number:																																																														Day	of	Life:	
Maternal	Demographics:	
Age:	 	
Antenatal	Steroid	Use	(Completed	Course):	 Yes	/	No	
Maternal	Hypertension:	 Yes	/	No	
Type	of	Delivery:	 Vaginal	/	Caesarean	/	Instrumental	
Past	Medical	History:	 	
	
	
Medication	History:	 	
	
	
Family	History:	 	
Social	History:	 	
	
Perinatal	Data:	
GA:	 	
BW	(kg):	 	
Small	for	Gestational	Age:	 	
Multiple	(Order):	 	
Sex:	 Male	/	Female	
Need	for	Advanced	Resuscitation	at	Birth	
(intubation	+/-	assisted	circulation):	
	
Placental	Transfusion	Procedures	(Delayed	
Cord	Clamping	(DCC)/Intact	Umbilical	Cord	
Milking	(IUCM)/Cut	Umbilical	Cord	Milking	
(CUCM):		
None	/	DCC	/	IUCM	/	CUCM	
5-minute	APGAR	Score:	 				/10	
Working	Weight	(kg):	 	
	
Vital	Signs:																								Date:																										Time:	
Heart	Rate	(bpm):	 	
Blood	Pressure:	 							mmHg/						mmHg	
SpO2:	 						%	
Respiratory	Rate:	 					/min	
HeRO	Score:	 	
																															
Biochemical	Data:																						Date:																					Time:	
pH:	 	
PaCO2:	 	
Lactate:	 	
Base	Excess:	 	
[144]	
	
Hb:	 	
White	Cell	Count:	 	
Blood	Culture:	 Positive	/	Negative	
CRP:	 	
	
Treatment	Data:																												Date:																						Time:	
Ventilator	Status:	 	
Fluid	Replacement:	 	
Inotrope	Dose:	 	
Inotrope	Rate:	 	
Other:	 	
	
Co-Morbidity	Data:																		Date:																										Time:	
Intraventricular	Haemorrhage	(Grade):	 N	/	1	/	2	/	3	/	4	
Sepsis	(Blood	Culture	Positive):	 Y	/	N	
Other:	 	
	
PWV/Phase	Difference/PDA	Data:																								Date:																											Time:	
Pulse	Wave	Velocity	(m/s):	 	
Phase	Difference	(°):	 	
PDA	Diameter	(mm):	 	
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Appendix	5	–	Sample	Ward	Posters	
	
[146]	
	
	
	
[147]	
	
	
	
[148]	
	
	
Appendix	6	–	Parent/Caregiver	Information	Leaflet	
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